S3-Leitlinie – Kolorektales Karzinom

Wolff Schmiegel; Barbara Buchberger; Markus Follmann; Ullrich Graeven; Volker Heinemann; Thomas Langer; Monika Nothacker; Rainer Porschen; Claus Rödel; Thomas Rösch; Wolfgang Schmitt; Simone Wesselmann; Christian Pox

doi:10.1055/s-0043-121106

Zeitschrift für Gastroenterologie, Inhaltsverzeichnis

Z Gastroenterol 2017; 55(12): 1344-1498
DOI: 10.1055/s-0043-121106

Leitlinie

S3-Leitlinie – Kolorektales Karzinom

Langversion 2.0 – November 2017–AWMF-Registernummer: 021/007OL

Wolff Schmiegel

¹Ruhr-Universität Bochum, Knappschaftskrankenhaus, Medizinische Universitätsklinik und Berufsgenossenschaftliches Universitätsklinikum Bergmannsheil, Gastroenterologie und Hepatologie, Bochum

,

Barbara Buchberger

²Essener Forschungsinstitut für Medizinmanagement GmbH, Essen

,

Markus Follmann

³Office des Leitlinienprogramms Onkologie, Berlin

,

Ullrich Graeven

⁴Kliniken Maria Hilf GmbH, Klinik für Hämatologie, Onkologie und Gastroenterologie, Mönchengladbach

,

Volker Heinemann

⁵Klinikum Großhadern, III. Medizinische Klinik Hämatologie und Onkologie, München

,

Thomas Langer

³Office des Leitlinienprogramms Onkologie, Berlin

,

Monika Nothacker

⁶AWMF Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften e.V., Berlin

,

Rainer Porschen

⁷Klinikum Bremen-Ost, Klinik für Innere Medizin, Bremen

,

Claus Rödel

⁸Universitätsklinikum Johann Wolfgang Goethe Universität, Klinik für Strahlentherapie und Onkologie, Frankfurt

,

Thomas Rösch

⁹Universitätsklinikum Hamburg-Eppendorf, Klinik und Poliklinik für interdisziplinäre Endoskopie, Hamburg

,

Wolfgang Schmitt

¹⁰Klinikum Neuperlach, Klinik für Gastroenterologie, München

,

Simone Wesselmann

¹¹Deutsche Krebsgesellschaft, Berlin

,

Christian Pox^*^**

¹²St. Joseph-Stift Bremen, Medizinische Klinik, Bremen

Literatur
1 Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften – Ständige Kommission. L. AWMF-Regelwerk „Leitlinien“. 2012 1. Auflage. cited 09.12.2013; Available from: http://www.awmf.org/leitlinien/awmf-regelwerk/awmf-regelwerk.html
2 Kirkegaard H. et al. Association of adherence to lifestyle recommendations and risk of colorectal cancer: a prospective Danish cohort study. BMJ 2010; 341: c5504
3 Halle M, Schoenberg MH. Physical activity in the prevention and treatment of colorectal carcinoma. Dtsch Arztebl Int 2009; 106 (44) 722-727
4 Wolin KY. et al. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer 2009; 100: 611-616
5 Wolin KY, Yan Y, Colditz GA. Physical activity and risk of colon adenoma: a meta-analysis. Br J Cancer 2011; 104: 882-885
6 Woli KY. et al. Leisure-time physical activity patterns and risk of colon cancer in women. Int J Cancer 2007; 121 (12) 2776-2781
7 Friedenreich C. et al. Physical activity and risk of colon and rectal cancers: the European prospective investigation into cancer and nutrition. Cancer Epidemiol Biomarkers Prev 2006; 15: 2398-2407
8 Lubin F. et al. Nutritional and lifestyle habits and water-fiber interaction in colorectal adenoma etiology. Cancer Epidemiol Biomarkers Prev 1997; 6: 79-85
9 Giacosa A. et al. Energy intake, overweight, physical exercise and colorectal cancer risk. Eur J Cancer Prev 1999; 8 (Suppl. 01) S53-S60
10 Friedenreich CM, Orenstein MR. Physical activity and cancer prevention: etiologic evidence and biological mechanisms. J Nutr 2002; 132 (Suppl. 11) 3456S-3464S
11 Terry MB. et al. Risk factors for advanced colorectal adenomas: a pooled analysis. Cancer Epidemiol Biomarkers Prev 2002; 11: 622-629
12 Lee IM. Physical activity and cancer prevention--data from epidemiologic studies. Med Sci Sports Exerc 2003; 35 (11) 1823-1827
13 Wei EK. et al. Comparison of risk factors for colon and rectal cancer. Int J Cancer 2004; 108: 433-442
14 Martinez ME. et al. Physical activity, body mass index, and prostaglandin E2 levels in rectal mucosa. J Natl Cancer Inst 1999; 91: 950-953
15 Giovannucci E. Modifiable risk factors for colon cancer. Gastroenterol Clin North Am 2002; 31: 925-943
16 Giovannucci E. Diet, body weight, and colorectal cancer: a summary of the epidemiologic evidence. J Womens Health (Larchmt) 2003; 12: 173-182
17 Renehan AG. et al. Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. Lancet 2008; 371: 569-578
18 Pischon T. et al. Body size and risk of colon and rectal cancer in the European Prospective Investigation Into Cancer and Nutrition (EPIC). J Natl Cancer Inst 2006; 98: 920-931
19 Ning Y, Wang L, Giovannucci EL. A quantitative analysis of body mass index and colorectal cancer: findings from 56 observational studies. Obes Rev 2010; 11: 19-30
20 Terry MB, Neugut AI. Cigarette smoking and the colorectal adenoma-carcinoma sequence: a hypothesis to explain the paradox. Am J Epidemiol 1998; 147: 903-910
21 Almendingen K. et al. Smoking and colorectal adenomas: a case-control study. Eur J Cancer Prev 2000; 9: 193-203
22 Chao A. et al. Cigarette smoking and colorectal cancer mortality in the cancer prevention study II. J Natl Cancer Inst 2000; 92: 1888-1896
23 Giovannucci E. An updated review of the epidemiological evidence that cigarette smoking increases risk of colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 725-731
24 Reid ME. et al. Smoking exposure as a risk factor for prevalent and recurrent colorectal adenomas. Cancer Epidemiol Biomarkers Prev 2003; 12: 1006-1011
25 Botteri E. et al. Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology 2008; 134: 388-395
26 Botteri E. et al. Smoking and colorectal cancer: a meta-analysis. JAMA 2008; 300: 2765-2778
27 Miller PE. et al. Dietary patterns and colorectal adenoma and cancer risk: a review of the epidemiological evidence. Nutr Cancer 2010; 62: 413-424
28 Cottet V. et al. Dietary patterns and the risk of colorectal adenoma recurrence in a European intervention trial. Eur J Cancer Prev 2005; 14: 21-29
29 Mai V. et al. Diet quality and subsequent cancer incidence and mortality in a prospective cohort of women. Int J Epidemiol 2005; 34: 54-60
30 Sansbury LB. et al. The effect of strict adherence to a high-fiber, high-fruit and -vegetable, and low-fat eating pattern on adenoma recurrence. Am J Epidemiol 2009; 170: 576-584
31 Wakai K. et al. Dietary risk factors for colon and rectal cancers: a comparative case-control study. J Epidemiol 2006; 16: 125-135
32 Beresford SA. et al. Low-fat dietary pattern and risk of colorectal cancer: the Women’s Health Initiative Randomized Controlled Dietary Modification Trial. JAMA 2006; 295: 643-654
33 Lanza E. et al. The polyp prevention trial continued follow-up study: no effect of a low-fat, high-fiber, high-fruit, and -vegetable diet on adenoma recurrence eight years after randomization. Cancer Epidemiol Biomarkers Prev 2007; 16: 1745-1752
34 Dahm CC. et al. Dietary fiber and colorectal cancer risk: a nested case-control study using food diaries. J Natl Cancer Inst 2010; 102: 614-626
35 Ishikawa H. et al. Randomized trial of dietary fiber and Lactobacillus casei administration for prevention of colorectal tumors. Int J Cancer 2005; 116: 762-767
36 Jacobs ET. et al. Fiber, sex, and colorectal adenoma: results of a pooled analysis. Am J Clin Nutr 2006; 83: 343-349
37 Park Y. et al. Dietary fiber intake and risk of colorectal cancer: a pooled analysis of prospective cohort studies. JAMA 2005; 294: 2849-2457
38 Robertson DJ. et al. Fat, fiber, meat and the risk of colorectal adenomas. Am J Gastroenterol 2005; 100: 2789-2795
39 Austin GL. et al. Moderate alcohol consumption protects against colorectal adenomas in smokers. Dig Dis Sci 2008; 53: 116-122
40 Cho E. et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med 2004; 140: 603-613
41 Mizoue T. et al. Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies. Am J Epidemiol 2008; 167: 1397-1406
42 Moskal A. et al. Alcohol intake and colorectal cancer risk: a dose-response meta-analysis of published cohort studies. Int J Cancer 2007; 120: 664-671
43 Chao A. et al. Meat consumption and risk of colorectal cancer. JAMA 2005; 293: 172-182
44 Larsson SC, Wolk A. Meat consumption and risk of colorectal cancer: a meta-analysis of prospective studies. Int J Cancer 2006; 119: 2657-2664
45 Mathew A. et al. Meat intake and the recurrence of colorectal adenomas. Eur J Cancer Prev 2004; 13: 159-164
46 Norat T. et al. Meat, fish, and colorectal cancer risk: the European Prospective Investigation into cancer and nutrition. J Natl Cancer Inst 2005; 97: 906-916
47 Sinha R. et al. Meat, meat cooking methods and preservation, and risk for colorectal adenoma. Cancer Res 2005; 65: 8034-8041
48 Geelen A. et al. Fish consumption, n-3 fatty acids, and colorectal cancer: a meta-analysis of prospective cohort studies. Am J Epidemiol 2007; 166: 1116-1125
49 Sugawara Y. et al. Fish consumption and the risk of colorectal cancer: the Ohsaki Cohort Study. Br J Cancer 2009; 101: 849-854
50 Pot GK. et al. Fish consumption and markers of colorectal cancer risk: a multicenter randomized controlled trial. Am J Clin Nutr 2009; 90: 354-361
51 Je Y, Liu W, Giovannucci E. Coffee consumption and risk of colorectal cancer: a systematic review and meta-analysis of prospective cohort studies. Int J Cancer 2009; 124: 1662-1668
52 Sun CL. et al. Green tea, black tea and colorectal cancer risk: a meta-analysis of epidemiologic studies. Carcinogenesis 2006; 27: 1301-1309
53 Zhang X. et al. Risk of colon cancer and coffee, tea, and sugar-sweetened soft drink intake: pooled analysis of prospective cohort studies. J Natl Cancer Inst 2010; 102: 771-783
54 Foschi R. et al. Citrus fruit and cancer risk in a network of case-control studies. Cancer Causes Control 2010; 21: 237-242
55 Millen AE. et al. Fruit and vegetable intake and prevalence of colorectal adenoma in a cancer screening trial. Am J Clin Nutr 2007; 86: 1754-1764
56 Koushik A. et al. Fruits, vegetables, and colon cancer risk in a pooled analysis of 14 cohort studies. J Natl Cancer Inst 2007; 99: 1471-1483
57 Limburg PJ. et al. Prospective evaluation of trans-fatty acid intake and colorectal cancer risk in the Iowa Women’s Health Study. Int J Cancer 2008; 123: 2717-2719
58 Alexander DD. et al. Meta-analysis of animal fat or animal protein intake and colorectal cancer. Am J Clin Nutr 2009; 89: 1402-1409
59 Galeone C. et al. Fried foods, olive oil and colorectal cancer. Ann Oncol 2007; 18: 36-39
60 Nakamura T. et al. Excessive fat restriction might promote the recurrence of colorectal tumors. Nutr Cancer 2010; 62: 154-163
61 Larsson SC. et al. Dietary acrylamide intake and risk of colorectal cancer in a prospective cohort of men. Eur J Cancer 2009; 45: 513-516
62 Hogervorst JG. et al. Dietary acrylamide intake is not associated with gastrointestinal cancer risk. J Nutr 2008; 138: 2229-2236
63 Mucci LA, Wilson KM. Acrylamide intake through diet and human cancer risk. J Agric Food Chem 2008; 56: 6013-6019
64 Mucci LA, Adami HÖ, Wolk A. Prospective study of dietary acrylamide and risk of colorectal cancer among women. Int J Cancer 2006; 118: 169-173
65 Bjelakovic G. et al. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 2007; 297: 842-857
66 Weingarten MA, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev 2008;
67 Wactawski-Wende J. et al. Calcium plus vitamin D supplementation and the risk of colorectal cancer. N Engl J Med 2006; 354: 684-696
68 Sanjoaquin MA. et al. Folate intake and colorectal cancer risk: a meta-analytical approach. Int J Cancer 2005; 113: 825-828
69 Wu K. et al. A randomized trial on folic acid supplementation and risk of recurrent colorectal adenoma. Am J Clin Nutr 2009; 90: 1623-1631
70 Jaszewski R. et al. Folic acid supplementation inhibits recurrence of colorectal adenomas: a randomized chemoprevention trial. World J Gastroenterol 2008; 14: 4492-4498
71 Cole BF. et al. Folic acid for the prevention of colorectal adenomas: a randomized clinical trial. JAMA 2007; 297: 2351-2359
72 Logan RF. et al. Aspirin and folic acid for the prevention of recurrent colorectal adenomas. Gastroenterology 2008; 134: 29-38
73 Grau MV. et al. Prolonged effect of calcium supplementation on risk of colorectal adenomas in a randomized trial. J Natl Cancer Inst 2007; 99: 129-136
74 Wallace K. et al. Effect of calcium supplementation on the risk of large bowel polyps. J Natl Cancer Inst 2004; 96: 921-925
75 Hartman TJ. et al. The association of calcium and vitamin D with risk of colorectal adenomas. J Nutr 2005; 135: 252-259
76 Lin J. et al. Total magnesium intake and colorectal cancer incidence in women. Cancer Epidemiol Biomarkers Prev 2006; 15: 2006-2009
77 Jacobs ET. et al. Selenium and colorectal adenoma: results of a pooled analysis. J Natl Cancer Inst 2004; 96: 1669-1675
78 Peters U. et al. High serum selenium and reduced risk of advanced colorectal adenoma in a colorectal cancer early detection program. Cancer Epidemiol Biomarkers Prev 2006; 15: 315-320
79 Vinogradova Y. et al. Risk of colorectal cancer in patients prescribed statins, nonsteroidal anti-inflammatory drugs, and cyclooxygenase-2 inhibitors: nested case-control study. Gastroenterology 2007; 133: 393-402
80 Bertagnolli MM. et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med 2006; 355: 873-884
81 Arber N. et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med 2006; 355: 885-895
82 Baron JA. et al. A randomized trial of rofecoxib for the chemoprevention of colorectal adenomas. Gastroenterology 2006; 131: 1674-1682
83 Bardou M, Barkun A, Martel M. Effect of statin therapy on colorectal cancer. Gut 2010; 59 (11) 1572-1585
84 Routine aspirin or nonsteroidal anti-inflammatory drugs for the primary prevention of colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med 2007; 146: 361-364
85 Flossmann E, Rothwell PM. Effect of aspirin on long-term risk of colorectal cancer: consistent evidence from randomised and observational studies. Lancet 2007; 369: 1603-1613
86 Rothwell PM. et al. Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trials. Lancet 2011; 377: 31-41
87 Chan AT. et al. Long-term use of aspirin and nonsteroidal anti-inflammatory drugs and risk of colorectal cancer. JAMA 2005; 294: 914-923
88 Hormone therapy for the prevention of chronic conditions in postmenopausal women: recommendations from the U.S. Preventive Services Task Force. Ann Intern Med 2005; 142: 855-860
89 Farquhar C. et al. Long term hormone therapy for perimenopausal and postmenopausal women. Cochrane Database Syst Rev 2009;
90 Alberts DS. et al. Phase III trial of ursodeoxycholic acid to prevent colorectal adenoma recurrence. J Natl Cancer Inst 2005; 97: 846-853
91 DGGG, Hormontherapie (HT) in der Peri- und Postmenopause. 2009
92 Birkner BR. Evidence-based prevention of colorectal carcinoma. Dtsch Med Wochenschr 2003; 128: 2598-2603
93 Winawer SJ. et al. Colorectal cancer screening: clinical guidelines and rationale. Gastroenterology 1997; 112: 594-642
94 Imperiale TF. et al. Results of screening colonoscopy among persons 40 to 49 years of age. N Engl J Med 2002; 346: 1781-1785
95 Whitlock EP. et al. Screening for colorectal cancer: a targeted, updated systematic review for the US Preventive Services Task Force. Ann Intern Med 2008; 149: 638-658
96 Stevens T, Burke CA. Colonoscopy screening in the elderly: when to stop?. Am J Gastroenterol 2003; 98: 1881-1885
97 Kirchgatterer A. et al. Colonoscopy and sigmoidoscopy in patients aged eighty years or older. Z Gastroenterol 2002; 40: 951-956
98 Pox CP. et al. Efficacy of a Nationwide Screening Colonoscopy Program for Colorectal Cancer. Gastroenterology 2012; 142: 1460-1467
99 Zhang B, Fattah A, Nakama H. Characteristics and survival rate of elderly patients with colorectal cancer detected by immunochemical occult blood screening. Hepatogastroenterology 2000; 47: 414-418
100 Winawer SJ. et al. Prevention of colorectal cancer by colonoscopic polypectomy. The National Polyp Study Workgroup. N Engl J Med 1993; 329: 1977-1981
101 Citarda F. et al. Efficacy in standard clinical practice of colonoscopic polypectomy in reducing colorectal cancer incidence. Gut 2001; 48: 812-815
102 Zauber AG. et al. Colonoscopic polypectomy and long-term prevention of colorectal-cancer deaths. N Engl J Med 2012; 366: 687-696
103 Hol L. et al. Screening for colorectal cancer: randomised trial comparing guaiac-based and immunochemical faecal occult blood testing and flexible sigmoidoscopy. Gut 2010; 59: 62-68
104 Quintero E. et al. Colonoscopy versus fecal immunochemical testing in colorectal-cancer screening. N Engl J Med 2012; 366: 697-706
105 Huppe D. et al. Effectiveness of screening colonoscopy in a community-based study. Z Gastroenterol 2008; 46: 193-200
106 Kahi CJ. et al. Effect of screening colonoscopy on colorectal cancer incidence and mortality. Clin Gastroenterol Hepatol 2009; 7: 770-775 ; quiz 711
107 Imperiale TF. et al. Risk of advanced proximal neoplasms in asymptomatic adults according to the distal colorectal findings. N Engl J Med 2000; 343: 169-174
108 Lieberman A. et al. Use of colonoscopy to screen asymptomatic adults for colorectal cancer. Veterans Affairs Cooperative Study Group 380. N Engl J Med 2000; 343: 162-168
109 Atkin W. et al. Single flexible sigmoidoscopy screening to prevent colorectal cancer: baseline findings of a UK multicentre randomised trial. Lancet 2002; 359: 1291-1300
110 Muller AD, Sonnenberg A. Protection by endoscopy against death from colorectal cancer. A case-control study among veterans. Arch Intern Med 1995; 155: 1741-1748
111 Newcomb PA. et al. Screening sigmoidoscopy and colorectal cancer mortality. J Natl Cancer Inst 1992; 84: 1572-1575
112 Selby JV. et al. A case-control study of screening sigmoidoscopy and mortality from colorectal cancer. N Engl J Med 1992; 326: 653-657
113 Singh H. et al. Predictors of colorectal cancer after negative colonoscopy: a population-based study. Am J Gastroenterol 2010; 105: 663-673 ; quiz 674
114 Brenner H. et al. Protection from right- and left-sided colorectal neoplasms after colonoscopy: population-based study. J Natl Cancer Inst 2010; 102: 89-95
115 Brenner H. et al. Protection from colorectal cancer after colonoscopy: a population-based, case-control study. Ann Intern Med 2011; 154: 22-30
116 Sieg A, Hachmoeller-Eisenbach U, Eisenbach T. Prospective evaluation of complications in outpatient GI endoscopy: a survey among German gastroenterologists. Gastrointest Endosc 2001; 53: 620-627
117 Rex DK. et al. Colonoscopic miss rates of adenomas determined by back-to-back colonoscopies. Gastroenterology 1997; 112: 24-28
118 Rex DK. et al. 5-year incidence of adenomas after negative colonoscopy in asymptomatic average-risk persons [see comment]. Gastroenterology 1996; 111: 1178-1181
119 Brenner H. et al. Long-term risk of colorectal cancer after negative colonoscopy. J Clin Oncol 2011; 29: 3761-3767
120 Bekanntmachungen der Bundesärztekammer: Richtlinien zur prädiktiven genetischen Diagnostik. Dt Ärztebl 2003; 100: A1297-A1305
121 Bekanntmachungen: Richtlinien des Bundesausschusses der Ärzte und Krankenkassen über die Früherkennung von Krebserkrankungen („Krebsfrüherkennungs-Richtlinien“). Dtsch Arztebl Int 2002; 1: 518
122 Atkin WS. et al. Once-only flexible sigmoidoscopy screening in prevention of colorectal cancer: a multicentre randomised controlled trial. Lancet 2010; 375: 1624-1633
123 Muller AD, Sonnenberg A. Prevention of colorectal cancer by flexible endoscopy and polypectomy. A case-control study of 32702 veterans. Ann Intern Med 1995; 123: 904-910
124 Newcomb PA. et al. Long-term efficacy of sigmoidoscopy in the reduction of colorectal cancer incidence. J Natl Cancer Inst 2003; 95: 622-625
125 Schoen RE. et al. Results of repeat sigmoidoscopy 3 years after a negative examination. Jama 2003; 290: 41-48
126 Burke CA, Elder K, Lopez R. Screening for colorectal cancer with flexible sigmoidoscopy: is a 5-yr interval appropriate? A comparison of the detection of neoplasia 3 yr versus 5 yr after a normal examination. Am J Gastroenterol 2006; 101: 1329-1332
127 Winawer SJ. et al. Screening for colorectal cancer with fecal occult blood testing and sigmoidoscopy. J Natl Cancer Inst 1993; 85: 1311-1318
128 Lieberman DA, Weiss DG. One-time screening for colorectal cancer with combined fecal occult-blood testing and examination of the distal colon. N Engl J Med 2001; 345: 555-560
129 Gondal G. et al. The Norwegian Colorectal Cancer Prevention (NORCCAP) screening study: baseline findings and implementations for clinical work-up in age groups 50–64 years. Scand J Gastroenterol 2003; 38: 635-642
130 Kato J. et al. Combination of sigmoidoscopy and a fecal immunochemical test to detect proximal colon neoplasia. Clin Gastroenterol Hepatol 2009; 7: 1341-1346
131 Eliakim R. et al. Evaluation of the PillCam Colon capsule in the detection of colonic pathology: results of the first multicenter, prospective, comparative study. Endoscopy 2006; 38: 963-970
132 Schoofs N, Deviere J, Van Gossum A. PillCam colon capsule endoscopy compared with colonoscopy for colorectal tumor diagnosis: a prospective pilot study. Endoscopy 2006; 38: 971-977
133 Van Gossum A. et al. Capsule endoscopy versus colonoscopy for the detection of polyps and cancer. N Engl J Med 2009; 361: 264-270
134 Spada C. et al. Meta-analysis shows colon capsule endoscopy is effective in detecting colorectal polyps. Clin Gastroenterol Hepatol 2010; 8: 516-522
135 Gay G. et al. Could the colonic capsule PillCam Colon be clinically useful for selecting patients who deserve a complete colonoscopy?: results of clinical comparison with colonoscopy in the perspective of colorectal cancer screening. Am J Gastroenterol 2010; 105: 1076-1086
136 Eliakim R. et al. Prospective multicenter performance evaluation of the second-generation colon capsule compared with colonoscopy. Endoscopy 2009; 41: 1026-1031
137 Spada C. et al. Second-generation colon capsule endoscopy compared with colonoscopy. Gastrointest Endosc 2011; 74: 581-589 e1
138 Mandel JS. et al. Reducing mortality from colorectal cancer by screening for fecal occult blood. Minnesota Colon Cancer Control Study. N Engl J Med 1993; 328: 1365-1371
139 Zhu MM. et al. Comparison of immunochemical and guaiac-based fecal occult blood test in screening and surveillance for advanced colorectal neoplasms: a meta-analysis. J Dig Dis 2010; 11: 148-160
140 van Rossum LG. et al. Colorectal cancer screening comparing no screening, immunochemical and guaiac fecal occult blood tests: a cost-effectiveness analysis. Int J Cancer 2011; 128: 1908-1917
141 Hundt S, Haug U, Brenner H. Comparative evaluation of immunochemical fecal occult blood tests for colorectal adenoma detection. Ann Intern Med 2009; 150: 162-169
142 Brenner H, Haug U, Hundt S. Inter-test agreement and quantitative cross-validation of immunochromatographical fecal occult blood tests. Int J Cancer 2010; 127: 1643-1649
143 Haug U. et al. Sensitivity of immunochemical faecal occult blood testing for detecting left- vs right-sided colorectal neoplasia. Br J Cancer 2011; 104: 1779-1785
144 Allison JE. et al. Screening for colorectal neoplasms with new fecal occult blood tests: update on performance characteristics. J Natl Cancer Inst 2007; 99: 1462-1470
145 Park DI. et al. Comparison of guaiac-based and quantitative immunochemical fecal occult blood testing in a population at average risk undergoing colorectal cancer screening. Am J Gastroenterol 2010; 105: 2017-2025
146 Launoy GD. et al. Evaluation of an immunochemical fecal occult blood test with automated reading in screening for colorectal cancer in a general average-risk population. Int J Cancer 2005; 115: 493-496
147 van Roon AH. et al. Diagnostic yield improves with collection of 2 samples in fecal immunochemical test screening without affecting attendance. Clin Gastroenterol Hepatol 2011; 9: 333-339
148 Haug U, Hundt S, Brenner H. Quantitative immunochemical fecal occult blood testing for colorectal adenoma detection: evaluation in the target population of screening and comparison with qualitative tests. Am J Gastroenterol 2010; 105: 682-690
149 Doran J, Hardcastle JD. Bleeding patterns in colorectal cancer: the effect of aspirin and the implications for faecal occult blood testing. Br J Surg 1982; 69: 711-713
150 Ahlquist DA. et al. Patterns of occult bleeding in asymptomatic colorectal cancer. Cancer 1989; 63: 1826-1830
151 Macrae FA, John DJ. Relationship between patterns of bleeding and hemoccult sensitivity in patients with colorectal cancers or adenomas. Gastroenterology 1982; 82: 891-898
152 Greegor DH. Occult blood testing for detection of asymptomatic colon cancer. Cancer 1971; 28: 131-134
153 Hardcastle JD. et al. Randomised controlled trial of faecal-occult-blood screening for colorectal cancer. Lancet 1996; 348: 1472-1477
154 Kronborg O. et al. Randomised study of screening for colorectal cancer with faecal-occult-blood test. Lancet 1996; 348: 1467-1471
155 Hewitson P. et al. Screening for colorectal cancer using the faecal occult blood test, Hemoccult. Cochrane Database Syst Rev 2007;
156 Levin B, Hess K, Johnson C. Screening for colorectal cancer. A comparison of 3 fecal occult blood tests. Arch Intern Med 1997; 157: 970-976
157 Gnauck R, Macrae FA, Fleisher M. How to perform the fecal occult blood test. CA Cancer J Clin 1984; 34: 134-147
158 Jaffe RM. et al. False-negative stool occult blood tests caused by ingestion of ascorbic acid (vitamin C). Ann Intern Med 1975; 83: 824-826
159 Macrae FA. et al. Optimal dietary conditions for hemoccult testing. Gastroenterology 1982; 82: 899-903
160 Rozen P, Knaani J, Samuel Z. Eliminating the need for dietary restrictions when using a sensitive guaiac fecal occult blood test. Dig Dis Sci 1999; 44: 756-760
161 Pignone M. et al. Meta-analysis of dietary restriction during fecal occult blood testing. Eff Clin Pract 2001; 4: 150-156
162 van Rossum LG. et al. Random comparison of guaiac and immunochemical fecal occult blood tests for colorectal cancer in a screening population. Gastroenterology 2008; 135: 82-90
163 Webendorfer S. et al. Precautions for intestinal cancer in the workplace. An initiative for secondary prevention in the BASF joint-stock company. Dtsch Med Wochenschr 2004; 129: 239-243
164 Mandel JS. et al. The effect of fecal occult-blood screening on the incidence of colorectal cancer. N Engl J Med 2000; 343: 1603-1607
165 Traverso G. et al. Detection of APC mutations in fecal DNA from patients with colorectal tumors. N Engl J Med 2002; 346: 311-320
166 Ahlquist DA. et al. Colorectal cancer screening by detection of altered human DNA in stool: feasibility of a multitarget assay panel. Gastroenterology 2000; 119: 1219-1227
167 Dong SM. et al. Detecting colorectal cancer in stool with the use of multiple genetic targets. J Natl Cancer Inst 2001; 93: 858-865
168 Tagore KS. et al. Sensitivity and specificity of a stool DNA multitarget assay panel for the detection of advanced colorectal neoplasia. Clin Colorectal Cancer 2003; 3: 47-53
169 Imperiale TF. et al. Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population. N Engl J Med 2004; 351: 2704-2714
170 Ahlquist DA. et al. Stool DNA and occult blood testing for screen detection of colorectal neoplasia. Ann Intern Med 2008; 149: 441-450, W81
171 Haug U, Hundt S, Brenner H. Sensitivity and specificity of faecal tumour M2 pyruvate kinase for detection of colorectal adenomas in a large screening study. Br J Cancer 2008; 99: 133-135
172 Moslein G. et al. Analysis of the statistical value of various commercially available stool tests – a comparison of one stool sample in correlation to colonoscopy. Dtsch Med Wochenschr 2010; 135: 557-562
173 de Haan MC. et al. Diagnostic value of CT-colonography as compared to colonoscopy in an asymptomatic screening population: a meta-analysis. Eur Radiol 2011; 21: 1747-1763
174 El-Maraghi RH, Kielar AZ. CT colonography versus optical colonoscopy for screening asymptomatic patients for colorectal cancer a patient, intervention, comparison, outcome (PICO) analysis. Acad Radiol 2009; 16: 564-571
175 Pox CP, Schmiegel W. Role of CT colonography in colorectal cancer screening: risks and benefits. Gut 2010; 59: 692-700
176 Frazier AL. et al. Cost-effectiveness of screening for colorectal cancer in the general population. Jama 2000; 284: 1954-1961
177 Geul KW. et al. Prevention of colorectal cancer. Costs and effectiveness of sigmoidoscopy. Scand J Gastroenterol Suppl 1997; 223: 79-87
178 Inadomi JM. Update on the cost-effectiveness of screening for colorectal neoplasia. Curr Opin Gastroenterol 2003; 29: 44-50
179 Khandker RK. et al. A decision model and cost-effectiveness analysis of colorectal cancer screening and surveillance guidelines for average-risk adults. Int J Technol Assess Health Care 2000; 16: 799-810
180 McGrath JS, Ponich TP, Gregor JC. Screening for colorectal cancer: the cost to find an advanced adenoma. Am J Gastroenterol 2002; 97: 2902-2907
181 Norum J. Prevention of colorectal cancer: a cost-effectiveness approach to a screening model employing sigmoidoscopy. Ann Oncol 1998; 9: 613-618
182 Pignone M. et al. Cost-effectiveness analyses of colorectal cancer screening: a systematic review for the US Preventive Services Task Force. Ann Intern Med 2002; 137: 96-104
183 Sonnenberg A, Delco F. Cost-effectiveness of a single colonoscopy in screening for colorectal cancer. Arch Intern Med 2002; 162: 163-168
184 Vijan S. et al. Which colon cancer screening test? A comparison of costs, effectiveness, and compliance. Am J Med 2001; 111: 593-601
185 Zauber AG. et al. Evaluating test strategies for colorectal cancer screening: a decision analysis for the US Preventive Services Task Force. Ann Intern Med 2008; 149: 659-669
186 Lansdorp-Vogelaar I, Knudsen AB, Brenner H. Cost-effectiveness of colorectal cancer screening. Epidemiol Rev 2011; 33: 88-100
187 Sung JJ. et al. Asia Pacific consensus recommendations for colorectal cancer screening. Gut 2008; 57: 1166-1176
188 Jasperson KW. et al. Hereditary and familial colon cancer. Gastroenterology 2010; 138: 2044-2058
189 Andrieu N. et al. Familial relative risk of colorectal cancer: a population-based study. Eur J Cancer 2003; 39: 1904-1911
190 Johns LE, Houlston RS. A systematic review and meta-analysis of familial colorectal cancer risk. Am J Gastroenterol 2001; 96: 2992-3003
191 Lichtenstein P. et al. Environmental and heritable factors in the causation of cancer--analyses of cohorts of twins from Sweden, Denmark, and Finland. N Engl J Med 2000; 343: 78-85
192 Slattery ML. et al. Family history and colorectal cancer: predictors of risk. Cancer Causes Control 2003; 14: 879-887
193 Winawer S. et al. Colorectal cancer screening and surveillance: clinical guidelines and rationale-Update based on new evidence. Gastroenterology 2003; 124: 544-560
194 Bonelli L. et al. Family history of colorectal cancer as a risk factor for benign and malignant tumours of the large bowel. A case-control study. Int J Cancer 1988; 41: 513-517
195 Fuchs CS. et al. A prospective study of family history and the risk of colorectal cancer. N Engl J Med 1994; 331: 1669-1674
196 Guillem JG. et al. Clustering of colorectal cancer in families of probands under 40 years of age. Dis Colon Rectum 1996; 39: 1004-1007
197 Guillem JG. et al. Colonoscopic screening for neoplasms in asymptomatic first-degree relatives of colon cancer patients. A controlled, prospective study. Dis Colon Rectum 1992; 35: 523-529
198 Kune GA, Kune S, Watson LF. The role of heredity in the etiology of large bowel cancer: data from the Melbourne Colorectal Cancer Study. World J Surg 1989; 13 (01) 124-129
199 Rozen P. et al. Family history of colorectal cancer as a marker of potential malignancy within a screening programm. Cancer 1987; 60: 248-254
200 Sondergaard JO, Bulow S, Lynge E. Cancer incidence among parents of patients with colorectal cancer. Int J Cancer 1991; 47: 202-206
201 St JohnDJ. et al. Cancer risk in relatives of patients with common colorectal cancer. Ann Int Med 1993; 118: 785-790
202 Butterworth AS, Higgins JP, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer 2006; 42: 216-227
203 Hall NR. et al. Hereditary susceptibility to colorectal cancer. Relatives of early onset cases are particularly at risk. Dis Colon Rectum 1996; 39: 739-743
204 Hunt LM. et al. Endoscopic screening of relatives of patients with colorectal cancer. Gut 1998; 42: 71-75
205 Winawer SJ. et al. Risk of colorectal cancer in the families of patients with adenomatous polyps. National Polyp Study Workgroup. N Engl J Med 1996; 334: 82-87
206 Ahsan H. et al. Family history of colorectal adenomatous polyps and increased risk for colorectal cancer. Ann Intern Med 1998; 128: 900-905
207 Nakama H. et al. Family history of colorectal adenomatous polyps as a risk factor for colorectal cancer. Eur J Cancer 2000; 36: 2111-2114
208 Almendingen K, Hofstad B, Vatn MH. Does a family history of cancer increase the risk of occurrence, growth, and recurrence of colorectal adenomas?. Gut 2003; 52: 747-751
209 Winawer SJ. et al. Risk and surveillance of individuals with colorectal polyps. WHO Collaborating Centre for the Prevention of Colorectal Cancer. Bull World Health Organ 1990; 68: 789-795
210 Atkin WS, Morson BC, Cuzick J. Long-term risk of colorectal cancer after excision of rectosigmoid adenomas. N Engl J Med 1992; 326: 658-662
211 Otchy DP. et al. Metachronous colon cancer in persons who have had a large adenomatous polyp. Am J Gastroenterol 1996; 91: 448-454
212 van Stolck RU. et al. Adenoma characteristics at first colonoscopy as predictors of adenoma recurrence and characteristics at follow-up. The Polyp Prevention Study Group. Gastroenterology 1998; 115: 13-18
213 Noshirwani KC. et al. Adenoma size and number are predictive of adenoma recurrence: implications for surveillance colonoscopy. Gastrointest Endosc 2000; 51: 433-437
214 Aldridge AJ, Simson JN. Histological assessment of colorectal adenomas by size. Are polyps less than 10 mm in size clinically important?. Eur J Surg 2001; 167: 777-781
215 Avidan B. et al. New occurrence and recurrence of neoplasms within 5 years of a screening colonoscopy. Am J Gastroenterol 2002; 97: 1524-1529
216 Bertario L. et al. Predictors of metachronous colorectal neoplasms in sporadic adenoma patients. Int J Cancer 2003; 105: 82-87
217 Chen CD. et al. A case-cohort study for the disease natural history of adenoma-carcinoma and de novo carcinoma and surveillance of colon and rectum after polypectomy: implication for efficacy of colonoscopy. Br J Cancer 2003; 88: 1866-1873
218 Bensen S. et al. The colonoscopic miss rate and true one-year recurrence of colorectal neoplastic polyps. Polyp Prevention Study Group. Am J Gastroenterol 1999; 94: 194-199
219 Katalinic A, Raspe H, Waldmann A. Positive family history of colorectal cancer--use of a questionnaire. Z Gastroenterol 2009; 47: 1125-1131
220 Baron JA. et al. Neoplastic and antineoplastic effects of beta-carotene on colorectal adenoma recurrence: results of a randomized trial. J Natl Cancer Inst 2003; 95: 717-722
221 Karnes WE. Epidemiology and etiology of sporadic colorectal adenocarcinoma. Current opinion in Gastroenterology 1994; 10: 19-26
222 Sandler RS. et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003; 348: 883-890
223 Rothwell PM. et al. Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trials. Lancet 2010; 376: 1741-1750
224 Burt RW. Screening of patients with a positive family history of colorectal cancer. Gastrointest Endosc Clin N Am 1997; 7: 65-79
225 Gilbert JM. et al. Feasibility study of colonoscopy as the primary screening investigation in relatives of patients with colorectal cancer. Ann R Coll Surg Engl 2001; 83: 415-419
226 Syrigos KN. et al. Colonoscopy in asymptomatic individuals with a family history of colorectal cancer. Ann Surg Oncol 2002; 9: 439-443
227 Bradshaw N. et al. Colonoscopy surveillance of individuals at risk of familial colorectal cancer. Gut 2003; 52: 1748-1751
228 Brenner H, Hoffmeister M, Haug U. Family history and age at initiation of colorectal cancer screening. Am J Gastroenterol 2008; 103: 2326-2331
229 Waldmann A, Raspe H, Katalinic A. Colon cancer risk in persons at familial or hereditary risk aged < 55 years. Z Gastroenterol 2009; 47: 1052-1058
230 Levin B. et al. Screening and surveillance for the early detection of colorectal cancer and adenomatous polyps, 2008: a joint guideline from the American Cancer Society, the US Multi-Society Task Force on Colorectal Cancer, and the American College of Radiology. Gastroenterology 2008; 134: 1570-1595
231 Engel C. et al. Efficacy of annual colonoscopic surveillance in individuals with hereditary nonpolyposis colorectal cancer. Clin Gastroenterol Hepatol 2010; 8: 174-182
232 Dove-Edwin I. et al. Prevention of colorectal cancer by colonoscopic surveillance in individuals with a family history of colorectal cancer: 16 year, prospective, follow-up study. BMJ 2005; 331: 1047
233 Duncan RE. et al. The challenge of developmentally appropriate care: predictive genetic testing in young people for familial adenomatous polyposis. Fam Cancer 2010; 9: 27-35
234 Douma KF. et al. Psychosocial issues in genetic testing for familial adenomatous polyposis: a review of the literature. Psychooncology 2008; 17: 737-745
235 Douma KF. et al. Psychological distress and use of psychosocial support in familial adenomatous polyposis. Psychooncology 2010; 19: 289-298
236 Vasen HF. et al. The International Collaborative Group on Hereditary Non-Polyposis Colorectal Cancer (ICG-HNPCC). Dis Colon Rectum 1991; 34: 424-425
237 Rodriguez-Bigas MA. et al. A National Cancer Institute Workshop on Hereditary Nonpolyposis Colorectal Cancer Syndrome: meeting highlights and Bethesda guidelines. J Natl Cancer Inst 1997; 89: 1758-1762
238 Schulmann K. et al. Small bowel cancer risk in Lynch syndrome. Gut 2008; 57: 1629-1630
239 ten Kate GL. et al. Is surveillance of the small bowel indicated for Lynch syndrome families?. Gut 2007; 56: 1198-1201
240 Schulmann K. et al. HNPCC-associated small bowel cancer: clinical and molecular characteristics. Gastroenterology 2005; 128: 590-599
241 van der Post RS. et al. Risk of urothelial bladder cancer in Lynch syndrome is increased, in particular among MSH2 mutation carriers. J Med Genet 2010; 47: 464-470
242 Kastrinos F. et al. Risk of pancreatic cancer in families with Lynch syndrome. JAMA 2009; 302: 1790-1795
243 Win AK. et al. Colorectal and Other Cancer Risks for Carriers and Noncarriers From Families With a DNA Mismatch Repair Gene Mutation: A Prospective Cohort Study. J Clin Oncol 2012; 30: 958-964
244 Vasen HF. et al. MSH2 mutation carriers are at higher risk of cancer than MLH1 mutation carriers: a study of hereditary nonpolyposis colorectal cancer families. J Clin Oncol 2001; 19: 4074-4080
245 Aarnio M. et al. Life-time risk of different cancers in hereditary non-polyposis colorectal cancer (HNPCC) syndrome. Int J Cancer 1995; 64: 430-433
246 Vasen HF. et al. The risk of brain tumours in hereditary non-polyposis colorectal cancer (HNPCC). Int J Cancer 1996; 65: 422-425
247 Kruse R. et al. Muir-Torre phenotype has a frequency of DNA mismatch-repair-gene mutations similar to that in hereditary nonpolyposis colorectal cancer families defined by the Amsterdam criteria. Am J Hum Genet 1998; 63: 63-70
248 Umar A. et al. Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst 2004; 96: 261-268
249 Shia J. Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry. J Mol Diagn 2008; 10: 293-300
250 Deng G. et al. BRAF mutation is frequently present in sporadic colorectal cancer with methylated hMLH1, but not in hereditary nonpolyposis colorectal cancer. Clin Cancer Res 2004; 10: 191-195
251 Domingo E. et al. BRAF screening as a low-cost effective strategy for simplifying HNPCC genetic testing. J Med Genet 2004; 41: 664-668
252 Loughrey MB. et al. Incorporation of somatic BRAF mutation testing into an algorithm for the investigation of hereditary non-polyposis colorectal cancer. Fam Cancer 2007; 6: 301-310
253 McGivern A. et al. Promoter hypermethylation frequency and BRAF mutations distinguish hereditary non-polyposis colon cancer from sporadic MSI-H colon cancer. Fam Cancer 2004; 3: 101-107
254 Levine AJ. et al. Cancer risks for the relatives of colorectal cancer cases with a methylated MLH1 promoter region: data from the Colorectal Cancer Family Registry. Cancer Prev Res (Phila) 2012; 5: 328-335
255 Foulkes WD. A tale of four syndromes: familial adenomatous polyposis, Gardner syndrome, attenuated APC and Turcot syndrome. QJM 1995; 88: 853-863
256 Lynch HT. et al. Attenuated familial adenomatous polyposis (AFAP). A phenotypically and genotypically distinctive variant of FAP. Cancer 1995; 76: 2427-2433
257 Lynch HT, Smyrk TC. Classification of familial adenomatous polyposis: a diagnostic nightmare. Am J Hum Genet 1998; 62: 1288-1289
258 Soravia C. et al. Genotype-phenotype correlations in attenuated adenomatous polyposis coli. Am J Hum Genet 1998; 62: 1290-1301
259 Hernegger GS, Moore HG, Guillem JG. Attenuated familial adenomatous polyposis: an evolving and poorly understood entity. Dis Colon Rectum 2002; 45: 127-134 ; discussion 134–136
260 Knudsen AL, Bisgaard ML, Bulow S. Attenuated familial adenomatous polyposis (AFAP). A review of the literature. Fam Cancer 2003; 2: 43-55
261 Al-Tassan N. et al. Inherited variants of MYH associated with somatic G:C-->T:A mutations in colorectal tumors. Nat Genet 2002; 30: 227-232
262 Cao Y. et al. Challenge in the differentiation between attenuated familial adenomatous polyposis and hereditary nonpolyposis colorectal cancer: case report with review of the literature. Am J Gastroenterol 2002; 97: 1822-1827
263 Aretz S. The differential diagnosis and surveillance of hereditary gastrointestinal polyposis syndromes. Dtsch Arztebl Int 2010; 107: 163-173
264 Aretz S, Genuardi M, Hes FJ. Clinical utility gene card for: MUTYH-associated polyposis (MAP), autosomal recessive colorectal adenomatous polyposis. Eur J Hum Genet; 2012
265 Sampson JR, Jones N. MUTYH-associated polyposis. Best Pract Res Clin Gastroenterol 2009; 23: 209-218
266 Morreau H, Riddel R, Aretz S. MUTYH-associated polyposis. In: Bosman FT. et al. Editors WHO Classification of Tumours of the Digestive System. Lyon: IARC/ WHO Press; 2010: 156-159
267 Aretz S. et al. MUTYH-associated polyposis: 70 of 71 patients with biallelic mutations present with an attenuated or atypical phenotype. Int J Cancer 2006; 119: 807-814
268 Lubbe SJ. et al. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol 2009; 27: 3975-3980
269 Cleary SP. et al. Germline MutY human homologue mutations and colorectal cancer: a multisite case-control study. Gastroenterology 2009; 136: 1251-1260
270 Boparai KS. et al. Hyperplastic polyps and sessile serrated adenomas as a phenotypic expression of MYH-associated polyposis. Gastroenterology 2008; 135: 2014-2018
271 Vogt S. et al. Expanded extracolonic tumor spectrum in MUTYH-associated polyposis. Gastroenterology 2009; 137: 1976-1985 e1–10
272 Papadopoulos N, Lindblom A. Molecular basis of HNPCC: mutations of MMR genes. Hum Mut 1997; 10: 89-99
273 Kuiper RP. et al. Recurrence and variability of germline EPCAM deletions in Lynch syndrome. Hum Mutat 2011; 32: 407-414
274 Jarvinen HJ. et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology 2000; 118: 829-834
275 de Vos tot Nederveen Cappel WH. et al. Surveillance for hereditary nonpolyposis colorectal cancer: a long-term study on 114 families. Dis Colon Rectum 2002; 45: 1588-1594
276 Edelstein DL. et al. Rapid development of colorectal neoplasia in patients with Lynch syndrome. Clin Gastroenterol Hepatol 2011; 9: 340-343
277 Renkonen-Sinisalo L. et al. Surveillance improves survival of colorectal cancer in patients with hereditary nonpolyposis colorectal cancer. Cancer Detect Prev 2000; 24: 137-142
278 Huneburg R. et al. Chromocolonoscopy detects more adenomas than white light colonoscopy or narrow band imaging colonoscopy in hereditary nonpolyposis colorectal cancer screening. Endoscopy 2009; 41: 316-322
279 Stoffel EM. et al. Missed adenomas during colonoscopic surveillance in individuals with Lynch Syndrome (hereditary nonpolyposis colorectal cancer). Cancer Prev Res (Phila) 2008; 1: 470-475
280 Hurlstone DP. et al. High magnification chromoscopic colonoscopy or high frequency 20 MHz mini probe endoscopic ultrasound staging for early colorectal neoplasia: a comparative prospective analysis. Gut 2005; 54: 1585-1589
281 Aarnio M. et al. Cancer risk in mutation carriers of DNA-mismatch-repair genes. Int J Cancer 1999; 81: 214-218
282 Dove-Edwin I. et al. The outcome of endometrial carcinoma surveillance by ultrasound scan in women at risk of hereditary nonpolyposis colorectal carcinoma and familial colorectal carcinoma. Cancer 2002; 94: 1708-1712
283 Rijcken FE. et al. Gynecologic screening in hereditary nonpolyposis colorectal cancer. Gynecol Oncol 2003; 91: 74-80
284 Renkonen-Sinisalo L. et al. Surveillance for endometrial cancer in hereditary nonpolyposis colorectal cancer syndrome. Int J Cancer 2007; 120: 821-824
285 Vasen HF. et al. Guidelines for the clinical management of Lynch syndrome (hereditary non-polyposis cancer). J Med Genet 2007; 44: 353-362
286 Goecke T. et al. Genotype-phenotype comparison of German MLH1 and MSH2 mutation carriers clinically affected with Lynch syndrome: a report by the German HNPCC Consortium. J Clin Oncol 2006; 24: 4285-4292
287 Burn J. et al. Effect of aspirin or resistant starch on colorectal neoplasia in the Lynch syndrome. N Engl J Med 2008; 359: 2567-2578
288 Burn J. et al. Long-term effect of aspirin on cancer risk in carriers of hereditary colorectal cancer: an analysis from the CAPP2 randomised controlled trial. Lancet 2011; 378: 2081-2087
289 Natarajan N. et al. Comparison of extended colectomy and limited resection in patients with Lynch syndrome. Dis Colon Rectum 2010; 53: 77-82
290 Kalady MF. et al. Risk of colorectal adenoma and carcinoma after colectomy for colorectal cancer in patients meeting Amsterdam criteria. Ann Surg 2010; 252: 507-511 ; discussion 511–513
291 Parry S. et al. Metachronous colorectal cancer risk for mismatch repair gene mutation carriers: the advantage of more extensive colon surgery. Gut 2011; 60: 950-957
292 Stupart DA. et al. Surgery for colonic cancer in HNPCC: total vs segmental colectomy. Colorectal Dis 2011; 13: 1395-1399
293 Schmeler KM. et al. Prophylactic surgery to reduce the risk of gynecologic cancers in the Lynch syndrome. N Engl J Med 2006; 354: 261-269
294 Church JM. et al. Teenagers with familial adenomatous polyposis: what is their risk for colorectal cancer?. Dis Colon Rectum 2002; 45: 887-889
295 King JE. et al. Care of patients and their families with familial adenomatous polyposis. Mayo Clin Proc 2000; 75: 57-67
296 Bertario L. et al. Causes of death and postsurgical survival in familial adenomatous polyposis: results from the Italian Registry. Italian Registry of Familial Polyposis Writing Committee. Semin Surg Oncol 1994; 10: 225-234
297 Galle TS, Juel K, Bulow S. Causes of death in familial adenomatous polyposis. Scand J Gastroenterol 1999; 34: 808-812
298 Heiskanen I, Luostarinen T, Jarvinen HJ. Impact of screening examinations on survival in familial adenomatous polyposis. Scand J Gastroenterol 2000; 35: 1284-1287
299 Vasen HF. et al. Decision analysis in the surgical treatment of patients with familial adenomatous polyposis: a Dutch-Scandinavian collaborative study including 659 patients. Gut 2001; 49: 231-235
300 Bulow S. Results of national registration of familial adenomatous polyposis. Gut 2003; 52: 742-746
301 Ficari F. et al. APC gene mutations and colorectal adenomatosis in familial adenomatous polyposis. Br J Cancer 2000; 82: 348-353
302 Bulow S. Clinical features in familial polyposis coli. Results of the Danish Polyposis Register. Dis Colon Rectum 1986; 29: 102-107
303 De Cosse JJ. et al. Rectal cancer risk in patients treated for familial adenomatous polyposis. The Leeds Castle Polyposis Group. Br J Surg 1992; 79: 1372-1375
304 Nyam DC. et al. Ileal pouch-anal canal anastomosis for familial adenomatous polyposis: early and late results. Ann Surg 1997; 226: 514-519 ; discussion 519–521
305 Parc YR. et al. Familial adenomatous polyposis: results after ileal pouch-anal anastomosis in teenagers. Dis Colon Rectum 2000; 43: 893-898 ; discussion 898–902
306 Van Duijvendijk P. et al. Quality of life after total colectomy with ileorectal anastomosis or proctocolectomy and ileal pouch-anal anastomosis for familial adenomatous polyposis. Br J Surg 2000; 87: 590-596
307 Church J. et al. Risk of rectal cancer in patients after colectomy and ileorectal anastomosis for familial adenomatous polyposis: a function of available surgical options. Dis Colon Rectum 2003; 46: 1175-1181
308 Will OC. et al. Familial adenomatous polyposis and the small bowel: a loco-regional review and current management strategies. Pathol Res Pract 2008; 204: 449-458
309 Spigelman AD. et al. Upper gastrointestinal cancer in patients with familial adenomatous polyposis. Lancet 1989; 2: 783-785
310 Burke CA. et al. The natural history of untreated duodenal and ampullary adenomas in patients with familial adenomatous polyposis followed in an endoscopic surveillance program. Gastrointest Endosc 1999; 49: 358-364
311 Matsumoto T. et al. Natural history of ampullary adenoma in familial adenomatous polyposis: reconfirmation of benign nature during extended surveillance. Am J Gastroenterol 2000; 95: 1557-1562
312 Moozar KL. et al. Slow progression of periampullary neoplasia in familial adenomatous polyposis. J Gastrointest Surg 2002; 6: 831-837 ; discussion 837
313 Saurin JC. et al. The influence of mutation site and age on the severity of duodenal polyposis in patients with familial adenomatous polyposis. Gastrointest Endosc 2002; 55: 342-347
314 Saurin JC. et al. Surveillance of duodenal adenomas in familial adenomatous polyposis reveals high cumulative risk of advanced disease. J Clin Oncol 2004; 22: 493-498
315 Vasen HF. et al. Decision analysis in the management of duodenal adenomatosis in familial adenomatous polyposis. Gut 1997; 40: 716-719
316 Bulow S. et al. Duodenal adenomatosis in familial adenomatous polyposis. Gut 2004; 53: 381-386
317 Kadmon M, Tandara A, Herfarth C. Duodenal adenomatosis in familial adenomatous polyposis coli. A review of the literature and results from the Heidelberg Polyposis Register. Int J Colorectal Dis 2001; 16: 63-75
318 Norton ID. et al. Safety and outcome of endoscopic snare excision of the major duodenal papilla. Gastrointest Endosc 2002; 56: 239-243
319 Kalady MF. et al. Pancreas-preserving duodenectomy in the management of duodenal familial adenomatous polyposis. J Gastrointest Surg 2002; 6: 82-87
320 Parc Y, Mabrut JY, Shields C. Surgical management of the duodenal manifestations of familial adenomatous polyposis. Br J Surg 2011; 98: 480-484
321 de Vos tot Nederveen Cappel WH. et al. Worldwide survey among polyposis registries of surgical management of severe duodenal adenomatosis in familial adenomatous polyposis. Br J Surg 2003; 90: 705-710
322 Heiskanen I, Kellokumpu I, Jarvinen H. Management of duodenal adenomas in 98 patients with familial adenomatous polyposis. Endoscopy 1999; 31: 412-416
323 Norton ID. et al. Endoscopic surveillance and ablative therapy for periampullary adenomas. Am J Gastroenterol 2001; 96: 101-106
324 Bleau BL, Gostout CJ. Endoscopic treatment of ampullary adenomas in familial adenomatous polyposis. J Clin Gastroenterol 1996; 22: 237-241
325 Soravia C. et al. Desmoid disease in patients with familial adenomatous polyposis. Dis Colon Rectum 2000; 43: 363-369
326 Bertario L. et al. Multiple approach to the exploration of genotype-phenotype correlations in familial adenomatous polyposis. J Clin Oncol 2003; 21: 1698-1707
327 Friedl W. et al. Can APC mutation analysis contribute to therapeutic decisions in familial adenomatous polyposis? Experience from 680 FAP families. Gut 2001; 48: 515-521
328 Janinis J. et al. The pharmacological treatment of aggressive fibromatosis: a systematic review. Ann Oncol 2003; 14: 181-190
329 Tonelli F. et al. Treatment of desmoids and mesenteric fibromatosis in familial adenomatous polyposis with raloxifene. Tumori 2003; 89: 391-396
330 Gega M. et al. Successful chemotherapeutic modality of doxorubicin plus dacarbazine for the treatment of desmoid tumors in association with familial adenomatous polyposis. J Clin Oncol 2006; 24: 102-105
331 Skapek SX. et al. Vinblastine and methotrexate for desmoid fibromatosis in children: results of a Pediatric Oncology Group Phase II Trial. J Clin Oncol 2007; 25: 501-506
332 Latchford AR. et al. A 10-year review of surgery for desmoid disease associated with familial adenomatous polyposis. Br J Surg 2006; 93: 1258-1264
333 Möslein G. Current ideas in desmoid tumours: invited commentary. Fam Cancer 2006; 5: 287-288
334 Clark SK, Phillips RK. Desmoids in familial adenomatous polyposis. Br J Surg 1996; 83: 1494-1504
335 Nieuwenhuis MH. et al. Evaluation of management of desmoid tumours associated with familial adenomatous polyposis in Dutch patients. Br J Cancer 2011; 104: 37-42
336 Huang K. et al. Prognostic factors for extra-abdominal and abdominal wall desmoids: a 20-year experience at a single institution. J Surg Oncol 2009; 100: 563-569
337 Salas S. et al. Prognostic factors influencing progression-free survival determined from a series of sporadic desmoid tumors: a wait-and-see policy according to tumor presentation. J Clin Oncol 2011; 29: 3553-3558
338 Bulow C, Bulow S. Is screening for thyroid carcinoma indicated in familial adenomatous polyposis? The Leeds Castle Polyposis Group. Int J Colorectal Dis 1997; 12: 240-242
339 Jarrar AM. et al. Screening for thyroid cancer in patients with familial adenomatous polyposis. Ann Surg 2011; 253: 515-521
340 Martayan A. et al. Gene variants associated to malignant thyroid disease in familial adenomatous polyposis: a novel APC germline mutation. J Endocrinol Invest 2010; 33: 603-606
341 Herraiz M. et al. Prevalence of thyroid cancer in familial adenomatous polyposis syndrome and the role of screening ultrasound examinations. Clin Gastroenterol Hepatol 2007; 5: 367-373
342 Bell B, Mazzaferri EL. Familial adenomatous polyposis (Gardner’s syndrome) and thyroid carcinoma. A case report and review of the literature. Dig Dis Sci 1993; 38: 185-190
343 Perrier ND. et al. Thyroid cancer in patients with familial adenomatous polyposis. World J Surg 1998; 22: 738-742 ; discussion 743
344 Hughes LJ, Michels VV. Risk of hepatoblastoma in familial adenomatous polyposis. Am J Med Genet 1992; 43: 1023-1025
345 Thomas D. et al. Familial hepatoblastoma and APC gene mutations: renewed call for molecular research. Eur J Cancer 2003; 39: 2200-2204
346 Aretz S. et al. Should children at risk for familial adenomatous polyposis be screened for hepatoblastoma and children with apparently sporadic hepatoblastoma be screened for APC germline mutations?. Pediatr Blood Cancer 2006; 47: 811-818
347 Vasen HF. et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut 2008; 57: 704-713
348 Waddell WR, Loughry RW. Sulindac for polyposis of the colon. J Surg Oncol 1983; 24: 83-87
349 Labayle D. et al. Sulindac causes regression of rectal polyps in familial adenomatous polyposis. Gastroenterology 1991; 101: 635-639
350 Giardiello FM. et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-1316
351 Cruz-Correa M. et al. Long-term treatment with sulindac in familial adenomatous polyposis: a prospective cohort study. Gastroenterology 2002; 122: 641-645
352 Winde G. et al. Complete reversion and prevention of rectal adenomas in colectomized patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Advantages of low-dose nonsteroidal anti-inflammatory drug regimen in reversing adenomas exceeding 33 months. Dis Colon Rectum 1995; 38: 813-830
353 Giardiello FM. et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002; 346: 1054-1059
354 Steinbach G. et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000; 342: 1946-1952
355 Phillips RK. et al. A randomised, double blind, placebo controlled study of celecoxib, a selective cyclooxygenase 2 inhibitor, on duodenal polyposis in familial adenomatous polyposis. Gut 2002; 50: 857-860
356 Solomon SD. et al. Cardiovascular risk of celecoxib in 6 randomized placebo-controlled trials: the cross trial safety analysis. Circulation 2008; 117: 2104-2113
357 Matsuo S. et al. Attenuated familial adenomatous polyposis associated with advanced rectal cancer in a 16-year-old boy: report of a case. Surg Today 2001; 31: 1020-1023
358 Leggett BA. et al. Severe upper gastrointestinal polyposis associated with sparse colonic polyposis in a familial adenomatous polyposis family with an APC mutation at codon 1520. Gut 1997; 41: 518-521
359 Zwick A. et al. Gastric adenocarcinoma and dysplasia in fundic gland polyps of a patient with attenuated adenomatous polyposis coli. Gastroenterology 1997; 113: 659-663
360 Hofgartner WT. et al. Gastric adenocarcinoma associated with fundic gland polyps in a patient with attenuated familial adenomatous polyposis. Am J Gastroenterol 1999; 94: 2275-2281
361 Jones N. et al. Increased colorectal cancer incidence in obligate carriers of heterozygous mutations in MUTYH. Gastroenterology 2009; 137: 489-494, 494 e1 ; quiz 725–726
362 Farrington SM. et al. Germline susceptibility to colorectal cancer due to base-excision repair gene defects. Am J Hum Genet 2005; 77: 112-119
363 Nielsen M. et al. Analysis of MUTYH genotypes and colorectal phenotypes in patients With MUTYH-associated polyposis. Gastroenterology 2009; 136: 471-476
364 Nascimbeni R. et al. Rectum-sparing surgery may be appropriate for biallelic MutYH-associated polyposis. Dis Colon Rectum 2010; 53: 1670-1675
365 Nielsen M. et al. Duodenal carcinoma in MUTYH-associated polyposis. J Clin Pathol 2006; 59: 1212-1215
366 Zbuk M, Eng C. Hamartomatous polyposis syndromes. Nat Clin Pract Gastroenterol Hepatol 2007; 4: 492-502
367 Aretz S. et al. High proportion of large genomic STK11 deletions in Peutz-Jeghers syndrome. Hum Mutat 2005; 26: 513-519
368 Hinds R. et al. Complications of childhood Peutz-Jeghers syndrome: implications for pediatric screening. J Pediatr Gastroenterol Nutr 2004; 39: 219-220
369 Reid JD. Intestinal carcinoma in the Peutz-Jeghers syndrome. Jama 1974; 229: 833-834
370 Burdick D, Prior JT. Peutz-Jeghers syndrome. A clinicopathologic study of a large family with a 27-year follow-up. Cancer 1982; 50: 2139-2146
371 Giardiello FM. et al. Increased risk of cancer in the Peutz-Jeghers syndrome. N Engl J Med 1987; 316: 1511-1514
372 Foley TR, McGarrity TJ, Abt AB. Peutz-Jeghers syndrome: a clinicopathologic survey of the “Harrisburg family” with a 49-year follow-up. Gastroenterology 1988; 95: 1535-1540
373 Spigelman AD, Murday V, Phillips RK. Cancer and the Peutz-Jeghers syndrome. Gut 1989; 30: 1588-1590
374 Hizawa K. et al. Neoplastic transformation arising in Peutz-Jeghers polyposis. Dis Colon Rectum 1993; 36: 953-957
375 Boardman LA. et al. Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med 1998; 128: 896-899
376 Mehenni H. et al. Cancer risks in LKB1 germline mutation carriers. Gut 2006; 55: 984-990
377 Giardiello FM. et al. Very high risk of cancer in familial Peutz-Jeghers syndrome. Gastroenterology 2000; 119: 1447-1453
378 Hearle N. et al. Frequency and spectrum of cancers in the Peutz-Jeghers syndrome. Clin Cancer Res 2006; 12: 3209-3215
379 Sweet K. et al. Molecular classification of patients with unexplained hamartomatous and hyperplastic polyposis. JAMA 2005; 294: 2465-2473
380 Aretz S. et al. High proportion of large genomic deletions and a genotype phenotype update in 80 unrelated families with juvenile polyposis syndrome. J Med Genet 2007; 44: 702-709
381 Gallione CJ. et al. A combined syndrome of juvenile polyposis and hereditary haemorrhagic telangiectasia associated with mutations in MADH4 (SMAD4). Lancet 2004; 363: 852-859
382 Watanabe A. et al. Familial juvenile polyposis of the stomach. Gastroenterology 1979; 77: 148-151
383 Jass JR. et al. Juvenile polyposis--a precancerous condition. Histopathology 1988; 13: 619-630
384 Sassatelli R. et al. Generalized juvenile polyposis with mixed pattern and gastric cancer. Gastroenterology 1993; 104: 910-915
385 Coburn MC. et al. Malignant potential in intestinal juvenile polyposis syndromes. Ann Surg Oncol 1995; 2: 386-391
386 Desai DC. et al. Juvenile polyposis. Br J Surg 1995; 82: 14-17
387 Delnatte C. et al. Contiguous gene deletion within chromosome arm 10q is associated with juvenile polyposis of infancy, reflecting cooperation between the BMPR1A and PTEN tumor-suppressor genes. Am J Hum Genet 2006; 78: 1066-1074
388 Hobert JA, Eng C. PTEN hamartoma tumor syndrome: an overview. Genet Med 2009; 11: 687-694
389 Tan MH. et al. Lifetime cancer risks in individuals with germline PTEN mutations. Clin Cancer Res 2012; 18: 400-407
390 Orloff MS, Eng C. Genetic and phenotypic heterogeneity in the PTEN hamartoma tumour syndrome. Oncogene 2008; 27: 5387-5397
391 Marsh DJ. et al. PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndrome. Hum Mol Genet 1999; 8: 1461-1472
392 Jeevaratnam P. et al. Familial giant hyperplastic polyposis predisposing to colorectal cancer: a new hereditary bowel cancer syndrome. J Pathol 1996; 179: 20-25
393 Leggett BA. et al. Hyperplastic polyposis: association with colorectal cancer. Am J Surg Pathol 2001; 25: 177-184
394 Renaut AJ, Douglas PR, Newstead GL. Hyperplastic polyposis of the colon and rectum. Colorectal Dis 2002; 4: 213-215
395 Jaeger EE. et al. An ancestral Ashkenazi haplotype at the HMPS/CRAC1 locus on 15q13-q14 is associated with hereditary mixed polyposis syndrome. Am J Hum Genet 2003; 72: 1261-1267
396 Rozen P, Samuel Z, Brazowski E. A prospective study of the clinical, genetic, screening, and pathologic features of a family with hereditary mixed polyposis syndrome. Am J Gastroenterol 2003; 98: 2317-2320
397 Beggs AD. et al. Peutz-Jeghers syndrome: a systematic review and recommendations for management. Gut 2010; 59: 975-986
398 Dignass A. et al. Updated German guideline on diagnosis and treatment of ulcerative colitis, 2011. Z Gastroenterol 2011; 49: 1276-1341
399 Collins PD. et al. Strategies for detecting colon cancer and/or dysplasia in patients with inflammatory bowel disease. Cochrane Database Syst Rev 2006;
400 Rutter MD. et al. Thirty-year analysis of a colonoscopic surveillance program for neoplasia in ulcerative colitis. Gastroenterology 2006; 130: 1030-1038
401 Lutgens MW. et al. High frequency of early colorectal cancer in inflammatory bowel disease. Gut 2008; 57: 1246-1251
402 Lim CH. et al. Ten year follow up of ulcerative colitis patients with and without low grade dysplasia. Gut 2003; 52: 1127-1132
403 Connell WR. et al. Factors affecting the outcome of endoscopic surveillance for cancer in ulcerative colitis. Gastroenterology 1994; 107: 934-944
404 Claessen MM. et al. More right-sided IBD-associated colorectal cancer in patients with primary sclerosing cholangitis. Inflamm Bowel Dis 2009; 15: 1331-1336
405 Soetikno RM. et al. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis. Gastrointest Endosc 2002; 56: 48-54
406 Scarpa M. et al. Systematic review of dysplasia after restorative proctocolectomy for ulcerative colitis. Br J Surg 2007; 94: 534-545
407 Hoffmann JC. et al. Clinical practice guideline on diagnosis and treatment of Crohn’s disease. Z Gastroenterol 2008; 46: 1094-1146
408 Javeri K, Williams TR, Bonnett JW. An overview of the method, application, and various findings of computed tomographic colonography in patients after incomplete colonoscopy. Curr Probl Diagn Radiol 2010; 39: 262-274
409 Copel L. et al. CT colonography in 546 patients with incomplete colonoscopy. Radiology 2007; 244: 471-478
410 Neri E. et al. Colorectal cancer: role of CT colonography in preoperative evaluation after incomplete colonoscopy. Radiology 2002; 223: 615-619
411 Morrin MM. et al. Role of virtual computed tomographic colonography in patients with colorectal cancers and obstructing colorectal lesions. Dis Colon Rectum 2000; 43: 303-311
412 Pickhardt PJ. et al. Colorectal cancer: CT colonography and colonoscopy for detection--systematic review and meta-analysis. Radiology 2011; 259: 393-405
413 Corley DA. et al. Adenoma detection rate and risk of colorectal cancer and death. N Engl J Med 2014; 370: 1298-1306
414 Kaminski MF. et al. Quality indicators for colonoscopy and the risk of interval cancer. N Engl J Med 2010; 362: 1795-1803
415 Denzer U. et al. S2k guideline: quality requirements for gastrointestinal endoscopy, AWMF registry no. 021–022. Z Gastroenterol 2015; 53: E1-E227
416 Rembacken B. et al. Quality in screening colonoscopy: position statement of the European Society of Gastrointestinal Endoscopy (ESGE). Endoscopy 2012; 44: 957-968
417 Valori R. et al. European guidelines for quality assurance in colorectal cancer screening and diagnosis. First Edition--Quality assurance in endoscopy in colorectal cancer screening and diagnosis. Endoscopy 2012; 44 (Suppl. 03) e88-e105
418 Rees CJ. et al. UK key performance indicators and quality assurance standards for colonoscopy. Gut 2016; 65: 1923-1929
419 Rex DK. et al. Quality indicators for colonoscopy. Am J Gastroenterol 2006; 101: 873-885
420 Aranda-Hernandez J, Hwang J, Kandel G. Seeing better--Evidence based recommendations on optimizing colonoscopy adenoma detection rate. World J Gastroenterol 2016; 22: 1767-1778
421 Barclay RL. et al. Colonoscopic withdrawal times and adenoma detection during screening colonoscopy. N Engl J Med 2006; 355: 2533-2541
422 Barclay RL, Vicari JJ, Greenlaw RL. Effect of a time-dependent colonoscopic withdrawal protocol on adenoma detection during screening colonoscopy. Clin Gastroenterol Hepatol 2008; 6: 1091-1098
423 Butterly L. et al. Serrated and adenomatous polyp detection increases with longer withdrawal time: results from the New Hampshire Colonoscopy Registry. Am J Gastroenterol 2014; 109: 417-426
424 Sawhney MS. et al. Effect of institution-wide policy of colonoscopy withdrawal time > or = 7 minutes on polyp detection. Gastroenterology 2008; 135: 1892-1898
425 Adler A. et al. Factors determining the quality of screening colonoscopy: a prospective study on adenoma detection rates, from 12134 examinations (Berlin colonoscopy project 3, BECOP-3). Gut 2013; 62: 236-241
426 Gellad ZF. et al. Colonoscopy withdrawal time and risk of neoplasia at 5 years: results from VA Cooperative Studies Program 380. Am J Gastroenterol 2010; 105: 1746-1752
427 Moritz V. et al. Withdrawal time as a quality indicator for colonoscopy – a nationwide analysis. Endoscopy 2012; 44: 476-481
428 Robertson DJ. et al. Colorectal cancer in patients under close colonoscopic surveillance. Gastroenterology 2005; 129: 34-41
429 Pabby A. et al. Analysis of colorectal cancer occurrence during surveillance colonoscopy in the dietary Polyp Prevention Trial. Gastrointest Endosc 2005; 61: 385-391
430 Sawhney MS. et al. Microsatellite instability in interval colon cancers. Gastroenterology 2006; 131: 1700-1705
431 Hosokawa O. et al. Invasive colorectal cancer detected up to 3 years after a colonoscopy negative for cancer. Endoscopy 2003; 35: 506-510
432 Bressler B. et al. Colonoscopic miss rates for right-sided colon cancer: a population-based analysis. Gastroenterology 2004; 127: 452-456
433 Leaper M. et al. Reasons for failure to diagnose colorectal carcinoma at colonoscopy. Endoscopy 2004; 36: 499-503
434 Murthy SK, Ducharme R, Rostom A. et al. Post-Colonoscopy Colorectal Cancer Rates Have Decreased Over Time in Average-Risk Patients Aged 50 to 74: A Population-Based Study from Ontario, Canada. Gastroenterology 2016; 150: 120
435 Plumb AA. et al. Sensitivity and specificity of CT colonography for the detection of colonic neoplasia after positive faecal occult blood testing: systematic review and meta-analysis. Eur Radiol 2014; 24: 1049-1058
436 Lin OS. et al. Preference for colonoscopy versus computerized tomographic colonography: a systematic review and meta-analysis of observational studies. J Gen Intern Med 2012; 27: 1349-1360
437 Zijta FM, Bipat S, Stoker J. Magnetic resonance (MR) colonography in the detection of colorectal lesions: a systematic review of prospective studies. Eur Radiol 2010; 20: 1031-1046
438 Hartmann D. et al. Incomplete conventional colonoscopy: magnetic resonance colonography in the evaluation of the proximal colon. Endoscopy 2005; 37: 816-820
439 Ajaj W. et al. MR colonography in patients with incomplete conventional colonoscopy. Radiology 2005; 234: 452-459
440 Spada C. et al. Clinical indications for computed tomographic colonography: European Society of Gastrointestinal Endoscopy (ESGE) and European Society of Gastrointestinal and Abdominal Radiology (ESGAR) Guideline. Endoscopy 2014; 46: 897-915
441 Spada C. et al. Colon capsule versus CT colonography in patients with incomplete colonoscopy: a prospective, comparative trial. Gut 2015; 64: 272-281
442 Spada C. et al. Accuracy of First- and Second-Generation Colon Capsules in Endoscopic Detection of Colorectal Polyps: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2016; 14: 1533-1543.e8
443 Rex DK. et al. Accuracy of capsule colonoscopy in detecting colorectal polyps in a screening population. Gastroenterology 2015; 148: 948-957 e2
444 Reumkens A. et al. Post-Colonoscopy Complications: A Systematic Review, Time Trends, and Meta-Analysis of Population-Based Studies. Am J Gastroenterol 2016; 111: 1092-1101
445 Boroff ES. et al. Polyp and adenoma detection rates in the proximal and distal colon. Am J Gastroenterol 2013; 108: 993-999
446 Dodou D, de Winter JC. The relationship between distal and proximal colonic neoplasia: a meta-analysis. J Gen Intern Med 2012; 27: 361-370
447 Lin OS. et al. Risk of proximal colon neoplasia with distal hyperplastic polyps: a meta-analysis. Arch Intern Med 2005; 165: 382-390
448 Arora A, Singh P. Colonoscopy in patients 80 years of age and older is safe, with high success rate and diagnostic yield. Gastrointest Endosc 2004; 60: 408-413
449 Karajeh MA, Sanders DS, Hurlstone DP. Colonoscopy in elderly people is a safe procedure with a high diagnostic yield: a prospective comparative study of 2000 patients. Endoscopy 2006; 38: 226-230
450 Jafri SM, Monkemuller K, Lukens FJ. Endoscopy in the elderly: a review of the efficacy and safety of colonoscopy, esophagogastroduodenoscopy, and endoscopic retrograde cholangiopancreatography. J Clin Gastroenterol 2010; 44: 161-166
451 Travis AC, Pievsky D, Saltzman JR. Endoscopy in the elderly. Am J Gastroenterol 2012; 107: 1495-1501 ; quiz 1494, 1502
452 Khan S. et al. Colonoscopy in the octogenarian population: diagnostic and survival outcomes from a large series of patients. Surgeon 2011; 9: 195-199
453 Lim YJ, Hong SJ. What is the best strategy for successful bowel preparation under special conditions?. World J Gastroenterol 2014; 20: 2741-2745
454 Lin OS. Performing colonoscopy in elderly and very elderly patients: Risks, costs and benefits. World J Gastrointest Endosc 2014; 6: 220-226
455 Lin OS. et al. Screening colonoscopy in very elderly patients: prevalence of neoplasia and estimated impact on life expectancy. JAMA 2006; 295: 2357-2365
456 Yano H. et al. Oxygen desaturation during sedation for colonoscopy in elderly patients. Hepatogastroenterology 1998; 45: 2138-2141
457 Schreuders EH. et al. Colorectal cancer screening: a global overview of existing programmes. Gut 2015; 64: 1637-1649
458 Kiesslich R. et al. Methylene blue-aided chromoendoscopy for the detection of intraepithelial neoplasia and colon cancer in ulcerative colitis. Gastroenterology 2003; 124: 880-888
459 Freire P. et al. Surveillance in ulcerative colitis: is chromoendoscopy-guided endomicroscopy always better than conventional colonoscopy? A randomized trial. Inflamm Bowel Dis 2014; 20: 2038-2045
460 Mooiweer E. et al. Chromoendoscopy for Surveillance in Inflammatory Bowel Disease Does Not Increase Neoplasia Detection Compared With Conventional Colonoscopy With Random Biopsies: Results From a Large Retrospective Study. Am J Gastroenterol 2015; 110: 1014-1021
461 Wu L. et al. The diagnostic accuracy of chromoendoscopy for dysplasia in ulcerative colitis: meta-analysis of six randomized controlled trials. Colorectal Dis 2012; 14: 416-420
462 Iannone A. et al. Chromoendoscopy for Surveillance in Ulcerative Colitis and Crohn’s Disease: A Systematic Review of Randomized Trials. Clin Gastroenterol Hepatol 2016; 15: 1684-1697
463 Rahmi G. et al. Impact of chromoscopy on adenoma detection in patients with Lynch syndrome: a prospective, multicenter, blinded, tandem colonoscopy study. Am J Gastroenterol 2015; 110: 288-298
464 Lecomte T. et al. Chromoendoscopic colonoscopy for detecting preneoplastic lesions in hereditary nonpolyposis colorectal cancer syndrome. Clin Gastroenterol Hepatol 2005; 3: 897-902
465 Dinesen L, Chua TJ, Kaffes AJ. Meta-analysis of narrow-band imaging versus conventional colonoscopy for adenoma detection. Gastrointest Endosc 2012; 75: 604-611
466 Omata F. et al. Image-enhanced, chromo, and cap-assisted colonoscopy for improving adenoma/neoplasia detection rate: a systematic review and meta-analysis. Scand J Gastroenterol 2014; 49: 222-237
467 Sabbagh LC. et al. Narrow-band imaging does not improve detection of colorectal polyps when compared to conventional colonoscopy: a randomized controlled trial and meta-analysis of published studies. BMC Gastroenterol 2011; 11: 100
468 Pasha SF. et al. Comparison of the yield and miss rate of narrow band imaging and white light endoscopy in patients undergoing screening or surveillance colonoscopy: a meta-analysis. Am J Gastroenterol 2012; 107: 363-370 ; quiz 371
469 Jin XF. et al. Meta-analysis for evaluating the accuracy of endoscopy with narrow band imaging in detecting colorectal adenomas. J Gastroenterol Hepatol 2012; 27: 882-887
470 Nagorni A, Bjelakovic G, Petrovic B. Narrow band imaging versus conventional white light colonoscopy for the detection of colorectal polyps. Cochrane Database Syst Rev 2012; 1: CD008361
471 Chung SJ. et al. Comparison of detection and miss rates of narrow band imaging, flexible spectral imaging chromoendoscopy and white light at screening colonoscopy: a randomised controlled back-to-back study. Gut 2014; 63: 785-791
472 Hoffman A. et al. High definition plus colonoscopy combined with i-scan tone enhancement vs. high definition colonoscopy for colorectal neoplasia: A randomized trial. Dig Liver Dis 2014; 46: 991-996
473 Hoffman A. et al. High definition colonoscopy combined with i-Scan is superior in the detection of colorectal neoplasias compared with standard video colonoscopy: a prospective randomized controlled trial. Endoscopy 2010; 42: 827-833
474 Hong SN. et al. Prospective, randomized, back-to-back trial evaluating the usefulness of i-SCAN in screening colonoscopy. Gastrointest Endosc 2012; 75: 1011-1021 e2
475 Kudo S. et al. Colonoscopic diagnosis and management of nonpolypoid early colorectal cancer. World J Surg 2000; 24: 1081-1090
476 Kiesslich R. et al. Chromoendoscopy with indigocarmine improves the detection of adenomatous and nonadenomatous lesions in the colon. Endoscopy 2001; 33: 1001-1006
477 Kudo S. et al. Pit pattern in colorectal neoplasia: endoscopic magnifying view. Endoscopy 2001; 33: 367-373
478 Brooker JC. et al. Total colonic dye-spray increases the detection of diminutive adenomas during routine colonoscopy: a randomized controlled trial. Gastrointest Endosc 2002; 56: 333-338
479 Eisen G. et al. High-resolution chromoendoscopy for classifying colonic polyps: a multicenter study. Gastrointest Endosc 2002; 55: 687-694
480 Tsuda S. et al. Flat and depressed colorectal tumours in a southern Swedish population: a prospective chromoendoscopic and histopathological study. Gut 2002; 51: 550-555
481 He Q. et al. Cap-assisted colonoscopy versus conventional colonoscopy: systematic review and meta-analysis. Int J Colorectal Dis 2013; 28: 279-281
482 Morgan JL. et al. Transparent cap colonoscopy versus standard colonoscopy: a systematic review and meta-analysis. Tech Coloproctol 2013; 17: 353-360
483 Ng SC. et al. The efficacy of cap-assisted colonoscopy in polyp detection and cecal intubation: a meta-analysis of randomized controlled trials. Am J Gastroenterol 2012; 107: 1165-1173
484 Westwood DA, Alexakis N, Connor SJ. Transparent cap-assisted colonoscopy versus standard adult colonoscopy: a systematic review and meta-analysis. Dis Colon Rectum 2012; 55: 218-225
485 Biecker E. et al. Novel Endocuff-assisted Colonoscopy Significantly Increases the Polyp Detection Rate: A Randomized Controlled Trial. J Clin Gastroenterol 2014; 49: 413-418
486 Floer M. et al. Higher adenoma detection rates with endocuff-assisted colonoscopy – a randomized controlled multicenter trial. PLoS One 2014; 9: e114267
487 van Doorn SC. et al. Adenoma detection with Endocuff colonoscopy versus conventional colonoscopy: a multicentre randomised controlled trial. Gut 2015; 66: 438-445
488 Ngu WS, Tsiamoulos Z, Bassett P. et al. Improved adenoma detection with endocuff vision – a multicentre randomised controlled trial. UEGW late breaking abstract 2016
489 Halpern Z. et al. Comparison of adenoma detection and miss rates between a novel balloon colonoscope and standard colonoscopy: a randomized tandem study. Endoscopy 2015; 47: 301
490 The Paris endoscopic classification of superficial neoplastic lesions: esophagus, stomach, and colon: November 30 to December 1, 2002. Gastrointest Endosc 2003; 58 (Suppl. 06) S3-S43
491 Abu Dayyeh BK. et al. ASGE Technology Committee systematic review and meta-analysis assessing the ASGE PIVI thresholds for adopting real-time endoscopic assessment of the histology of diminutive colorectal polyps. Gastrointest Endosc 2015; 81: 502.e1-502.e16
492 Hewett DG. et al. Validation of a simple classification system for endoscopic diagnosis of small colorectal polyps using narrow-band imaging. Gastroenterology 2012; 143: 599-607 e1
493 Ignjatovic A. et al. Narrow band imaging for detection of dysplasia in colitis: a randomized controlled trial. Am J Gastroenterol 2012; 107: 885-890
494 Hassan C. et al. Colonic polyps: are we ready to resect and discard?. Gastrointest Endosc Clin N Am 2013; 23: 663-678
495 Hassan C, Pickhardt PJ, Rex DK. A resect and discard strategy would improve cost-effectiveness of colorectal cancer screening. Clin Gastroenterol Hepatol 2010; 8: p. 865-869 e1–3
496 Kessler WR. et al. A quantitative assessment of the risks and cost savings of forgoing histologic examination of diminutive polyps. Endoscopy 2011; 43: 683-691
497 Kiesslich R. et al. Confocal laser endoscopy for diagnosing intraepithelial neoplasias and colorectal cancer in vivo. Gastroenterology 2004; 127: 706-713
498 Gondal G. et al. Biopsy of colorectal polyps is not adequate for grading of neoplasia. Endoscopy 2005; 37: 1193-1197
499 Nivatvongs S. Complications in colonoscopic polypectomy. An experience with 1555 polypectomies. Dis Colon Rectum 1986; 29: 825-830
500 Reiertsen O. et al. Complications of fiberoptic gastrointestinal endoscopy--five years’ experience in a central hospital. Endoscopy 1987; 19 (01) 1-6
501 Waye JD, Lewis BS, Yessayan S. Colonoscopy: a prospective report of complications. J Clin Gastroenterol 1992; 15: 347-351
502 Waye JD, Kahn O, Auerbach ME. Complications of colonoscopy and flexible sigmoidoscopy. Gastrointest Endosc Clin N Am 1996; 6: 343-377
503 Hsieh YH. et al. Is submucosal epinephrine injection necessary before polypectomy? A prospective, comparative study. Hepatogastroenterology 2001; 48: 1379-1382
504 Heitman SJ, Tate DJ, Bourke MJ. Optimizing Resection of Large Colorectal Polyps. Curr Treat Options Gastroenterol 2017; 15: 213-229
505 Imai K. et al. Should laterally spreading tumors granular type be resected en bloc in endoscopic resections?. Surg Endosc 2014; 28: 2167-2173
506 Oka S. et al. Therapeutic strategy for colorectal laterally spreading tumor. Dig Endosc 2009; 21 (Suppl. 01) S43-S46
507 Saito Y. et al. Endoscopic treatment for laterally spreading tumors in the colon. Endoscopy 2001; 33: 682-686
508 Saito Y. et al. Endoscopic submucosal dissection (ESD) for colorectal tumors. Dig Endosc 2009; 21 (Suppl. 01) S7-S12
509 Uraoka T. et al. Endoscopic indications for endoscopic mucosal resection of laterally spreading tumours in the colorectum. Gut 2006; 55: 1592-1597
510 Moss A. et al. Endoscopic mucosal resection outcomes and prediction of submucosal cancer from advanced colonic mucosal neoplasia. Gastroenterology 2011; 140: 1909-1918
511 Rotondano G. et al. The Cooperative Italian FLIN Study Group: prevalence and clinico-pathological features of colorectal laterally spreading tumors. Endoscopy 2011; 43: 856-861
512 Ishiguro A. et al. Correlation of lifting versus non-lifting and microscopic depth of invasion in early colorectal cancer. Gastrointest Endosc 1999; 50: 329-333
513 Uno Y, Munakata A. The non-lifting sign of invasive colon cancer. Gastrointest Endosc 1994; 40: 485-489
514 Kobayashi N. et al. Determining the treatment strategy for colorectal neoplastic lesions: endoscopic assessment or the non-lifting sign for diagnosing invasion depth?. Endoscopy 2007; 39: 701-705
515 Voloyiannis T. et al. Management of the difficult colon polyp referred for resection: resect or rescope?. Dis Colon Rectum 2008; 51: 292-295
516 Aziz Aadam A. et al. Physician assessment and management of complex colon polyps: a multicenter video-based survey study. Am J Gastroenterol 2014; 109: 1312-1324
517 Lipof T. et al. Preoperative colonoscopy decreases the need for laparoscopic management of colonic polyps. Dis Colon Rectum 2005; 48: 1076-1080
518 Church JM. Avoiding surgery in patients with colorectal polyps. Dis Colon Rectum 2003; 46: 1513-1516
519 Buchner AM, Guarner-Argente C, Ginsberg GG. Outcomes of EMR of defiant colorectal lesions directed to an endoscopy referral center. Gastrointest Endosc 2012; 76: 255-263
520 Friedland S. et al. Outcomes of repeat colonoscopy in patients with polyps referred for surgery without biopsy-proven cancer. Gastrointest Endosc 2014; 79: 101-107
521 Efthymiou M. et al. Biopsy forceps is inadequate for the resection of diminutive polyps. Endoscopy 2011; 43: 312-316
522 Deenadayalu VP, Rex DK. Colon polyp retrieval after cold snaring. Gastrointest Endosc 2005; 62: 253-256
523 Repici A. et al. Safety of cold polypectomy for <10mm polyps at colonoscopy: a prospective multicenter study. Endoscopy 2012; 44: 27-31
524 Tappero G. et al. Cold snare excision of small colorectal polyps. Gastrointest Endosc 1992; 38: 310-313
525 Kim JS. et al. Cold snare polypectomy versus cold forceps polypectomy for diminutive and small colorectal polyps: a randomized controlled trial. Gastrointest Endosc 2015; 81: 741-747
526 Lee CK, Shim JJ, Jang JY. Cold snare polypectomy vs. Cold forceps polypectomy using double-biopsy technique for removal of diminutive colorectal polyps: a prospective randomized study. Am J Gastroenterol 2013; 108: 1593-1600
527 Moss A. et al. Long-term adenoma recurrence following wide-field endoscopic mucosal resection (WF-EMR) for advanced colonic mucosal neoplasia is infrequent: results and risk factors in 1000 cases from the Australian Colonic EMR (ACE) study. Gut 2015; 64: 57-65
528 Knabe M. et al. Standardized long-term follow-up after endoscopic resection of large, nonpedunculated colorectal lesions: a prospective two-center study. Am J Gastroenterol 2014; 109: 183-189
529 Seidel J. et al. Complication and local recurrence rate after endoscopic resection of large high-risk colorectal adenomas of >/=3 cm in size. Int J Colorectal Dis 2016; 31: 603-611
530 Cipolletta L. et al. Endoscopic resection for superficial colorectal neoplasia in Italy: a prospective multicentre study. Dig Liver Dis 2014; 46: 146-151
531 Heresbach D. et al. A national survey of endoscopic mucosal resection for superficial gastrointestinal neoplasia. Endoscopy 2010; 42: 806-813
532 Woodward TA. et al. Predictors of complete endoscopic mucosal resection of flat and depressed gastrointestinal neoplasia of the colon. Am J Gastroenterol 2012; 107: 650-654
533 Repici A. et al. Efficacy and safety of endoscopic submucosal dissection for colorectal neoplasia: a systematic review. Endoscopy 2012; 44: 137-150
534 Kim YJ. et al. Comparison of clinical outcomes among different endoscopic resection methods for treating colorectal neoplasia. Dig Dis Sci 2013; 58: 1727-1736
535 Kobayashi N. et al. Matched case-control study comparing endoscopic submucosal dissection and endoscopic mucosal resection for colorectal tumors. J Gastroenterol Hepatol 2012; 27: 728-733
536 Saito Y. et al. Clinical outcome of endoscopic submucosal dissection versus endoscopic mucosal resection of large colorectal tumors as determined by curative resection. Surg Endosc 2010; 24: 343-352
537 Tajika M. et al. Comparison of endoscopic submucosal dissection and endoscopic mucosal resection for large colorectal tumors. Eur J Gastroenterol Hepatol 2011; 23: 1042-1049
538 Terasaki M. et al. Clinical outcomes of endoscopic submucosal dissection and endoscopic mucosal resection for laterally spreading tumors larger than 20 mm. J Gastroenterol Hepatol 2012; 27: 734-740
539 Fujiya M. et al. Efficacy and adverse events of EMR and endoscopic submucosal dissection for the treatment of colon neoplasms: a meta-analysis of studies comparing EMR and endoscopic submucosal dissection. Gastrointest Endosc 2015; 81: 583-595
540 Wang J. et al. Endoscopic submucosal dissection vs endoscopic mucosal resection for colorectal tumors: a meta-analysis. World J Gastroenterol 2014; 20: 8282-8287
541 Sauer M. et al. Endoscopic submucosal dissection for flat or sessile colorectal neoplasia > 20 mm: A European single-center series of 182 cases. Endosc Int Open 2016; 4: E895-E900
542 Probst A. et al. Endoscopic submucosal dissection in large sessile lesions of the rectosigmoid: learning curve in a European center. Endoscopy 2012; 44: 660-667
543 Rahmi G. et al. Endoscopic submucosal dissection for superficial rectal tumors: prospective evaluation in France. Endoscopy 2014; 46: 670-676
544 Repici A. et al. High efficacy of endoscopic submucosal dissection for rectal laterally spreading tumors larger than 3 cm. Gastrointest Endosc 2013; 77: 96-101
545 Probst A. et al. Endoscopic submucosal dissection for early rectal neoplasia: experience from a European center. Endoscopy 2017; 49: 222-232
546 Schmidt AD, Gubier M, Caca C. et al. Endoskopische Vollwandresektion im unteren GI-Trakt mit dem FTRD-System: eine retrospektive Studie. Zeitschrift für Gastroenterologie 2014; 52: 52-56
547 Fisher DA. et al. Complications of colonoscopy. Gastrointest Endosc 2011; 74: 745-752
548 Niv Y. et al. Screening colonoscopy for colorectal cancer in asymptomatic people: a meta-analysis. Dig Dis Sci 2008; 53: 3049-3054
549 Adler A. et al. Data quality of the German screening colonoscopy registry. Endoscopy 2013; 45: 813-818
550 Bokemeyer B. et al. Screening colonoscopy for colorectal cancer prevention: results from a German online registry on 269000 cases. Eur J Gastroenterol Hepatol 2009; 21: 650-655
551 Crispin A. et al. Process quality and incidence of acute complications in a series of more than 230000 outpatient colonoscopies. Endoscopy 2009; 41: 1018-1025
552 Eckardt VF. et al. Complications and adverse effects of colonoscopy with selective sedation. Gastrointest Endosc 1999; 49: 560-565
553 Hagel AF. et al. Colonoscopy-associated perforation: a 7-year survey of in-hospital frequency, treatment and outcome in a German university hospital. Colorectal Dis 2012; 14: 1121-1125
554 Pox CP. et al. Efficacy of a nationwide screening colonoscopy program for colorectal cancer. Gastroenterology 2012; 142: 1460-1467 e2
555 Sieg A, Hachmoeller-Eisenbach U, Eisenbach T. Prospective evaluation of complications in outpatient GI endoscopy: a survey among German gastroenterologists. Gastrointest Endosc 2001; 53: 620-627
556 Stock C. et al. Adverse events requiring hospitalization within 30 days after outpatient screening and nonscreening colonoscopies. Gastrointest Endosc 2013; 77: 419-429
557 Heldwein W. et al. The Munich Polypectomy Study (MUPS): prospective analysis of complications and risk factors in 4000 colonic snare polypectomies. Endoscopy 2005; 37: 1116-1122
558 Bowles CJ. et al. A prospective study of colonoscopy practice in the UK today: are we adequately prepared for national colorectal cancer screening tomorrow?. Gut 2004; 53: 277-283
559 Kang HY. et al. Incidence and management of colonoscopic perforations in Korea. Digestion 2008; 78: 218-223
560 Ko CW. et al. Serious complications within 30 days of screening and surveillance colonoscopy are uncommon. Clin Gastroenterol Hepatol 2010; 8: 166-173
561 Nelson DB. et al. Procedural success and complications of large-scale screening colonoscopy. Gastrointest Endosc 2002; 55: 307-314
562 Niv Y. et al. Complications in colonoscopy: analysis of 7-year physician-reported adverse events. Eur J Gastroenterol Hepatol 2011; 23: 492-498
563 Rabeneck L. et al. Bleeding and perforation after outpatient colonoscopy and their risk factors in usual clinical practice. Gastroenterology 2008; 135: 1899-1906 e1
564 Singh H. et al. Colonoscopy and its complications across a Canadian regional health authority. Gastrointest Endosc 2009; 69: 665-671
565 Warren JL. et al. Adverse events after outpatient colonoscopy in the Medicare population. Ann Intern Med 2009; 150: 849-857, W152
566 Zubarik R. et al. Prospective analysis of complications 30 days after outpatient colonoscopy. Gastrointest Endosc 1999; 50: 322-328
567 Zubarik R. et al. Procedure-related abdominal discomfort in patients undergoing colorectal cancer screening: a comparison of colonoscopy and flexible sigmoidoscopy. Am J Gastroenterol 2002; 97: 3056-3061
568 Hamilton SR, Aaltonen LA. Pathology and Genetics of Tumours of the Digestive System. World Health Organization Classifecation of Tumours, ed Lyon: IARC Press; 2000
569 Jass JR. Classification of colorectal cancer based on correlation of clinical, morphological and molecular features. Histopathology 2007; 50: 113-130
570 Makinen MJ. Colorectal serrated adenocarcinoma. Histopathology 2007; 50: 131-150
571 Chetty R. Traditional serrated adenoma (TSA): morphological questions, queries and quandaries. J Clin Pathol 2016; 69: 6-11
572 Gibson JA, Odze RD. Pathology of premalignant colorectal neoplasia. Dig Endosc 2016; 28: 312-323
573 Bosman FT, Hruban RH, Theise ND. WHO Classification of Tumours of the Digestive System. 4 ed. World Health Organisation; 2010
574 Gao Q. et al. Serrated polyps and the risk of synchronous colorectal advanced neoplasia: a systematic review and meta-analysis. Am J Gastroenterol 2015; 110: 501-509 ; quiz 510
575 Holme O. et al. Long-term risk of colorectal cancer in individuals with serrated polyps. Gut 2015; 64: 929-936
576 Erichsen R. et al. Increased Risk of Colorectal Cancer Development Among Patients With Serrated Polyps. Gastroenterology 2016; 150: 895-902 e5
577 Hassan C. et al. New paradigms for colonoscopic management of diminutive colorectal polyps: predict, resect, and discard or do not resect?. Clin Endosc 2013; 46: 130-137
578 Baretton GB, Tannapfel A, Schmitt W. Standardized and structured histopathological evaluation of colorectal polyps: a practical checklist against the background of the new WHO classification. Pathologe 2011; 32: 289-296
579 Wada H. et al. Systematic review and meta-analysis of histopathological predictive factors for lymph node metastasis in T1 colorectal cancer. J Gastroenterol 2015; 50: 727-734
580 Kawachi H. et al. A three-tier classification system based on the depth of submucosal invasion and budding/sprouting can improve the treatment strategy for T1 colorectal cancer: a retrospective multicenter study. Mod Pathol 2015; 28: 872-879
581 Mou S. et al. Pathologic predictive factors for lymph node metastasis in submucosal invasive (T1) colorectal cancer: a systematic review and meta-analysis. Surg Endosc 2013; 27: 2692-703
582 Beaton C. et al. Systematic review and meta-analysis of histopathological factors influencing the risk of lymph node metastasis in early colorectal cancer. Colorectal Dis 2013; 15: 788-797
583 Bosch SL. et al. Predicting lymph node metastasis in pT1 colorectal cancer: a systematic review of risk factors providing rationale for therapy decisions. Endoscopy 2013; 45 (10) 827-834
584 Choi JY. et al. Meta-analysis of predictive clinicopathologic factors for lymph node metastasis in patients with early colorectal carcinoma. J Korean Med Sci 2015; 30: 398-406
585 Ueno H. et al. Risk factors for an adverse outcome in early invasive colorectal carcinoma. Gastroenterology 2004; 127: 385-394
586 Hassan C. et al. Histologic risk factors and clinical outcome in colorectal malignant polyp: a pooled-data analysis. Dis Colon Rectum 2005; 48: 1588-1596
587 Blackstock W. et al. ACR Appropriateness Criteria: local excision in early-stage rectal cancer. Curr Probl Cancer 2010; 34: 193-200
588 Russo S. et al. ACR Appropriateness Criteria(R) Local Excision in Early Stage Rectal Cancer. Am J Clin Oncol 2015; 38: 520-525
589 Kikuchi R. et al. Management of early invasive colorectal cancer. Risk of recurrence and clinical guidelines. Dis Colon Rectum 1995; 38 (12) 1286-1295
590 Di Gregorio C. et al. Clinical outcome of low- and high-risk malignant colorectal polyps: results of a population-based study and meta-analysis of the available literature. Intern Emerg Med 2014; 9: 151-160
591 Fischer J. et al. Management of malignant colorectal polyps in New Zealand. ANZ J Surg 2016; 87: 350-355
592 Wu XR, Liang J, Church JM. Management of sessile malignant polyps: is colonoscopic polypectomy enough?. Surg Endosc 2015; 29 (10) 2947-2952
593 Hassan C. et al. Endoscopic follow-up after colorectal cancer resection: an Italian multicentre study. Dig Liver Dis 2006; 38: 45-50
594 Seitz U. et al. Is endoscopic polypectomy an adequate therapy for malignant colorectal adenomas? Presentation of 114 patients and review of the literature. Dis Colon Rectum 2004; 47: 1789-1796 ; discussion 1796–1797
595 Meining A. et al. Risk factors for unfavorable outcomes after endoscopic removal of submucosal invasive colorectal tumors. Clin Gastroenterol Hepatol 2011; 9: 590-594
596 Nascimbeni R. et al. Risk of lymph node metastasis in T1 carcinoma of the colon and rectum. Dis Colon Rectum 2002; 45: 200-206
597 Ramirez M. et al. Management of the malignant polyp. Clin Colon Rectal Surg 2008; 21: 286-290
598 Matsuda T. et al. Risk of lymph node metastasis in patients with pedunculated type early invasive colorectal cancer: a retrospective multicenter study. Cancer Sci 2011; 102: 1693-1697
599 Kitajima K. et al. Correlations between lymph node metastasis and depth of submucosal invasion in submucosal invasive colorectal carcinoma: a Japanese collaborative study. J Gastroenterol 2004; 39: 534-543
600 Suh JH. et al. Predictors for lymph node metastasis in T1 colorectal cancer. Endoscopy 2012; 44: 590-595
601 Okabe S. et al. Lymph node metastasis in T1 adenocarcinoma of the colon and rectum. J Gastrointest Surg 2004; 8: 1032-1039 ; discussion 1039–1040
602 Nakadoi K. et al. Management of T1 colorectal carcinoma with special reference to criteria for curative endoscopic resection. J Gastroenterol Hepatol 2012; 27: 1057-1062
603 Ikematsu H. et al. Long-term outcomes after resection for submucosal invasive colorectal cancers. Gastroenterology 2013; 144: 551-559 ; quiz e14
604 Cooper GS. et al. Management of malignant colonic polyps: a population-based analysis of colonoscopic polypectomy versus surgery. Cancer 2012; 118: 651-659
605 Provenzale D. et al. Risk for colon adenomas in patients with rectosigmoid hyperplastic polyps. Ann Intern Med 1990; 113: 760-763
606 Rex DK. et al. Distal colonic hyperplastic polyps do not predict proximal adenomas in asymptomatic average-risk subjects. Gastroenterology 1992; 102: 317-319
607 Sciallero S. et al. Distal hyperplastic polyps do not predict proximal adenomas: results from a multicentric study of colorectal adenomas. Gastrointest Endosc 1997; 46: 124-130
608 Koide N. et al. A case of hyperplastic polyposis of the colon with adenocarcinomas in hyperplastic polyps after long-term follow-up. Endoscopy 2002; 34: 499-502
609 Cottet V. et al. Long-term risk of colorectal cancer after adenoma removal: a population-based cohort study. Gut 2012; 61: 1180-1186
610 Loberg M. et al. Long-term colorectal-cancer mortality after adenoma removal. N Engl J Med 2014; 371: 799-807
611 Winawer SJ. et al. Randomized comparison of surveillance intervals after colonoscopic removal of newly diagnosed adenomatous polyps. The National Polyp Study Workgroup. N Engl J Med 1993; 328 (13) 901-906
612 Higaki S. et al. Long-term follow-up of large flat colorectal tumors resected endoscopically. Endoscopy 2003; 35 (10) 845-849
613 Regula J. et al. Argon plasma coagulation after piecemeal polypectomy of sessile colorectal adenomas: long-term follow-up study. Endoscopy 2003; 35: 212-218
614 Seitz U. et al. Long-term results of endoscopic removal of large colorectal adenomas. Endoscopy 2003; 35: S41-S44
615 Hurlstone DP. et al. A prospective analysis of extended endoscopic mucosal resection for large rectal villous adenomas: an alternative technique to transanal endoscopic microsurgery. Colorectal Dis 2005; 7: 339-344
616 Boix J. et al. Endoscopic removal of large sessile colorectal adenomas: is it safe and effective?. Dig Dis Sci 2007; 52: 840-844
617 Pereyra L. et al. Risk of Metachronous Advanced Neoplastic Lesions in Patients with Sporadic Sessile Serrated Adenomas Undergoing Colonoscopic Surveillance. Am J Gastroenterol 2016; 111: 871-878
618 Macaron C. et al. Risk of Metachronous Polyps in Individuals With Serrated Polyps. Dis Colon Rectum 2015; 58: 762-768
619 Martinez ME. et al. A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy. Gastroenterology 2009; 136: 832-841
620 Lieberman DA. et al. Utilization of colonoscopy in the United States: results from a national consortium. Gastrointest Endosc 2005; 62: 875-883
621 Pickhardt PJ. et al. Computed tomographic virtual colonoscopy to screen for colorectal neoplasia in asymptomatic adults. N Engl J Med 2003; 349: 2191-2200
622 Vemulapalli KC, Rex DK. Risk of advanced lesions at first follow-up colonoscopy in high-risk groups as defined by the United Kingdom post-polypectomy surveillance guideline: data from a single US center. Gastrointest Endosc 2014; 80: 299-306
623 Park HW. et al. Probability of high-risk colorectal neoplasm recurrence based on the results of two previous colonoscopies. Dig Dis Sci 2015; 60: 226-233
624 Suh KH. et al. Risk of adenomas with high-risk characteristics based on two previous colonoscopy. J Gastroenterol Hepatol 2014; 29 (12) 1985-1990
625 Laiyemo AO. et al. Utilization and yield of surveillance colonoscopy in the continued follow-up study of the polyp prevention trial. Clin Gastroenterol Hepatol 2009; 7: 562-567 ; quiz 497
626 Robertson D. Estimated Risk of Advanced and Multiple Adenomas Based On the Results of Two Prior Colonoscopies. Ann Intern Med 2009; 151: 103-109
627 Robertson DJ. et al. Colorectal cancers soon after colonoscopy: a pooled multicohort analysis. Gut 2014; 63: 949-956
628 Ferlitsch M. et al. Colorectal polypectomy and endoscopic mucosal resection (EMR): European Society of Gastrointestinal Endoscopy (ESGE) Clinical Guideline. Endoscopy 2017; 49: 270-297
629 Baron JA. et al. A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med 2003; 348: 891-899
630 Benamouzig R. et al. Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology 2003; 125: 328-336
631 Weingarten MA, Zalmanovici A, Yaphe J. Dietary calcium supplementation for preventing colorectal cancer and adenomatous polyps. Cochrane Database Syst Rev 2005;
632 Imperiale TF. Aspirin and the prevention of colorectal cancer. N Engl J Med 2003; 348: 879-880
633 Bresalier RS. et al. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med 2005; 352: 1092-1102
634 Solomon SD. et al. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med 2005; 352: 1071-1080
635 Psaty BM, Potter JD. Risks and benefits of celecoxib to prevent recurrent adenomas. N Engl J Med 2006; 355: 950-852
636 Fielding LP. et al. Clinicopathological staging for colorectal cancer: an International Documentation System (IDS) and an International Comprehensive Anatomical Terminology (ICAT). J Gastroenterol Hepatol 1991; 6: 325-344
637 Soreide O. et al. International standardization and documentation of the treatment of rectal cancer. In: Soreide O, Norstein J. Editors Rectal cancer surgery. Optimisation – standardization – documentation. Berlin Heidelberg New York.: Springer; 1997: 405-445
638 UICC, TNM Classification of Malignant Tumours. 6th Edition ed. ed. L.H. Sobin and C. Wittekind New York: John Wiley & Sons; 2002
639 NIH consensus conference. Adjuvant therapy for patients with colon and rectal cancer. Jama 1990; 264: 1444-1450
640 Nelson H. et al. Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst 2001; 93: 583-596
641 Pilipshen SJ. et al. Patterns of pelvic recurrence following definitive resections of rectal cancer. Cancer 1984; 53: 1354-1362
642 Burton S. et al. MRI directed multidisciplinary team preoperative treatment strategy: the way to eliminate positive circumferential margins?. Br J Cancer 2006; 94: 351-357
643 Segelman J. et al. Differences in multidisciplinary team assessment and treatment between patients with stage IV colon and rectal cancer. Colorectal Dis 2009; 11: 768-774
644 MacDermid E. et al. Improving patient survival with the colorectal cancer multi-disciplinary team. Colorectal Dis 2009; 11: 291-295
645 Barillari P. et al. Effect of preoperative colonoscopy on the incidence of synchronous and metachronous neoplasms. Acta Chir Scand 1990; 156: 163-166
646 Faivre J. Endoscopic monitoring after excision of colorectal cancer. J Chir (Paris) 1997; 134: 283-285
647 Chen HS, Sheen-Chen SM. Synchronous and “early” metachronous colorectal adenocarcinoma: analysis of prognosis and current trends. Dis Colon Rectum 2000; 43: 1093-1099
648 Floriani I. et al. Performance of imaging modalities in diagnosis of liver metastases from colorectal cancer: a systematic review and meta-analysis. J Magn Reson Imaging 2010; 31: 19-31
649 Rafaelsen SR, Jakobsen A. Contrast-enhanced ultrasound vs multidetector-computed tomography for detecting liver metastases in colorectal cancer: a prospective, blinded, patient-by-patient analysis. Colorectal Dis 2011; 13: 420-425
650 Quaia E. et al. Comparison of contrast-enhanced ultrasonography versus baseline ultrasound and contrast-enhanced computed tomography in metastatic disease of the liver: diagnostic performance and confidence. Eur Radiol 2006; 16: 1599-1609
651 Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology 2010; 257: 674-684
652 Mainenti P. et al. Detection of colo-rectal liver metastases: prospective comparison of contrast enhanced US, multidetector CT, PET/CT, and 1.5 Tesla MR with extracellular and reticulo-endothelial cell specific contrast agents. Abdom Imaging 2010; 35: 511-521
653 McAndrew MR, Saba AK. Efficacy of routine preoperative computed tomography scans in colon cancer. Am Surg 1999; 65: 205-208
654 Barton JB. et al. The utility of routine preoperative computed tomography scanning in the management of veterans with colon cancer. Am J Surg 2002; 183: 499-503
655 Dighe S. et al. Diagnostic precision of CT in local staging of colon cancers: a meta-analysis. Clin Radiol 2010; 65: 708-719
656 Abdel-Nabi H. et al. Staging of primary colorectal carcinomas with fluorine-18 fluorodeoxyglucose whole-body PET: correlation with histopathologic and CT findings. Radiology 1998; 206: 755-760
657 Akiyoshi T. et al. Comparison of preoperative whole-body positron emission tomography with MDCT in patients with primary colorectal cancer. Colorectal Dis 2009; 11: 464-469
658 Furukawa H. et al. Positron emission tomography scanning is not superior to whole body multidetector helical computed tomography in the preoperative staging of colorectal cancer. Gut 2006; 55: 1007-1011
659 Kam MH. et al. Comparison of magnetic resonance imaging-fluorodeoxy- glucose positron emission tomography fusion with pathological staging in rectal cancer. Br J Surg 2010; 97: 266-268
660 Kinner S. et al. Whole-body PET/CT-colonography: a possible new concept for colorectal cancer staging. Abdom Imaging 2007; 32: 606-612
661 Llamas-Elvira JM. et al. Fluorine-18 fluorodeoxyglucose PET in the preoperative staging of colorectal cancer. Eur J Nucl Med Mol Imaging 2007; 34: 859-867
662 Ono K. et al. Comparison of diffusion-weighted MRI and 2-[fluorine-18]-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) for detecting primary colorectal cancer and regional lymph node metastases. J Magn Reson Imaging 2009; 29: 336-340
663 Tateishi U. et al. Non-enhanced CT versus contrast-enhanced CT in integrated PET/CT studies for nodal staging of rectal cancer. Eur J Nucl Med Mol Imaging 2007; 34: 1627-1634
664 Veit-Haibach P. et al. Diagnostic accuracy of colorectal cancer staging with whole-body PET/CT colonography. JAMA 2006; 296: 2590-2600
665 Bassi MC. et al. FDG-PET/CT imaging for staging and target volume delineation in preoperative conformal radiotherapy of rectal cancer. Int J Radiat Oncol Biol Phys 2008; 70: 1423-1426
666 Davey K. et al. The impact of 18-fluorodeoxyglucose positron emission tomography-computed tomography on the staging and management of primary rectal cancer. Dis Colon Rectum 2008; 51: 997-1003
667 Gearhart SL. et al. Improved staging with pretreatment positron emission tomography/computed tomography in low rectal cancer. Ann Surg Oncol 2006; 13: 397-404
668 Kantorova I. et al. Routine (18)F-FDG PET preoperative staging of colorectal cancer: comparison with conventional staging and its impact on treatment decision making. J Nucl Med 2003; 44: 1784-1788
669 Nagata K. et al. PET/CT colonography for the preoperative evaluation of the colon proximal to the obstructive colorectal cancer. Dis Colon Rectum 2008; 51: 882-890
670 Park IJ. et al. Efficacy of PET/CT in the accurate evaluation of primary colorectal carcinoma. Eur J Surg Oncol 2006; 32: 941-947
671 Paskeviciute B. et al. Impact of (18)F-FDG-PET/CT on staging and irradiation of patients with locally advanced rectal cancer. Strahlenther Onkol 2009; 185: 260-265
672 Ruers TJ. et al. Improved selection of patients for hepatic surgery of colorectal liver metastases with (18)F-FDG PET: a randomized study. J Nucl Med 2009; 50: 1036-1041
673 Moulton CA. An Ontario Clinical Oncology Group (OCOG) randomized controlled trial (RCT) assessing FDG PET/CT in resectable liver colorectal adenocarcinoma metastases (CAM). J Clin Oncol 2011 (suppl): abstr 3520
674 Glazer ES. et al. Effectiveness of positron emission tomography for predicting chemotherapy response in colorectal cancer liver metastases. Arch Surg 2010; 145: 340-345 ; discussion 345
675 Lubezky N. et al. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg 2007; 11: 472-478
676 Spatz J. et al. Neoadjuvant chemotherapy affects staging of colorectal liver metastasis--a comparison of PET, CT and intraoperative ultrasound. Int J Colorectal Dis 2011; 26: 165-171
677 IQWIG. Positronenemissionstomographie (PET und PET/CT) bei rezidivierendem kolorektalen Karzinom – Vorbericht (vorläufige Nutzenbewertung). 2011
678 Patel S. et al. Positron emission tomography/computed tomographic scans compared to computed tomographic scans for detecting colorectal liver metastases: a systematic review. Ann Surg 2011; 253: 666-671
679 Taylor RA, Tuorto SJ, Akhurst TJ. et al. Evaluation with positron emission tomography before hepatic resection for metastatic colorectal cancer improves survival in patients with a high clinical risk score. 2007 Gastrointestinal Cancers Symposium, Abstract No: 240. 2007
680 Adie S. et al. Resection of liver metastases from colorectal cancer: does preoperative chemotherapy affect the accuracy of PET in preoperative planning?. ANZ J Surg 2009; 79: 358-361
681 Levy M. et al. Tumor markers in staging and prognosis of colorectal carcinoma. Neoplasma 2008; 55: 138-142
682 Lewis MR. et al. Metastatic colorectal adenocarcinoma involving the ovary with elevated serum CA125: a potential diagnostic pitfall. Gynecol Oncol 2007; 105: 395-398
683 Chen CC. et al. Is it reasonable to add preoperative serum level of CEA and CA19-9 to staging for colorectal cancer?. J Surg Res 2005; 124: 169-174
684 Merkel S. et al. The prognostic inhomogeneity in pT3 rectal carcinomas. Int J Colorectal Dis 2001; 16: 298-304
685 Nagtegaal ID, Quirke P. What is the role for the circumferential margin in the modern treatment of rectal cancer?. J Clin Oncol 2008; 26: 303-312
686 Bipat S. et al. Rectal cancer: local staging and assessment of lymph node involvement with endoluminal US, CT, and MR imaging--a meta-analysis. Radiology 2004; 232: 773-783
687 Puli SR. et al. Accuracy of endoscopic ultrasound to diagnose nodal invasion by rectal cancers: a meta-analysis and systematic review. Ann Surg Oncol 2009; 16: 1255-1265
688 Ahmetoglu A. et al. MDCT with multiplanar reconstruction in the preoperative local staging of rectal tumor. Abdom Imaging 2011; 36: 31-37
689 Kim CK. et al. Preoperative staging of rectal cancer: accuracy of 3-Tesla magnetic resonance imaging. Eur Radiol 2006; 16: 972-980
690 Kim YW. et al. A prospective comparison study for predicting circumferential resection margin between preoperative MRI and whole mount sections in mid-rectal cancer: significance of different scan planes. Eur J Surg Oncol 2008; 34: 648-654
691 Kim YW. et al. Factors related to preoperative assessment of the circumferential resection margin and the extent of mesorectal invasion by magnetic resonance imaging in rectal cancer: a prospective comparison study. World J Surg 2009; 33: 1952-1960
692 Matsuoka H. et al. MRI diagnosis of mesorectal lymph node metastasis in patients with rectal carcinoma. What is the optimal criterion?. Anticancer Res 2004; 24: 4097-4101
693 Wolberink SV. et al. Multislice CT as a primary screening tool for the prediction of an involved mesorectal fascia and distant metastases in primary rectal cancer: a multicenter study. Dis Colon Rectum 2009; 52: 928-934
694 Purkayastha S. et al. Magnetic resonance colonography vs computed tomography colonography for the diagnosis of colorectal cancer: an indirect comparison. Colorectal Dis 2007; 9: 100-111
695 Torzilli G. et al. Contrast-enhanced intraoperative ultrasonography during hepatectomies for colorectal cancer liver metastases. J Gastrointest Surg 2005; 9: 1148-1153 ; discussion 1153–1154
696 Zirngibl H, Husemann B, Hermanek P. Intraoperative spillage of tumor cells in surgery for rectal cancer. Dis Colon Rectum 1990; 33: 610-614
697 Cahill RA, Leroy J, Marescaux J. Could lymphatic mapping and sentinel node biopsy provide oncological providence for local resectional techniques for colon cancer? A review of the literature. BMC Surg 2008; 8: 17
698 Wiese D. et al. Ultrastaging of sentinel lymph nodes (SLNs) vs. non-SLNs in colorectal cancer-do we need both?. Am J Surg 2010; 199: 354-358 ; discussion 358
699 Goligher JC. Incidence and pathology of carcinoma of the colon and rectum, in Surgery of the anus, rectum and colon. London: Balliére Tindall; 1984: S.445
700 Toyota S, Ohta H, Anazawa S. Rationale for extent of lymph node dissection for right colon cancer. Dis Colon Rectum 1995; 38: 705-711
701 Tan KY. et al. Distribution of the first metastatic lymph node in colon cancer and its clinical significance. Colorectal Dis 2010; 12: 44-47
702 Lan YT. et al. Significance of lymph node retrieval from the terminal ileum for patients with cecal and ascending colonic cancers. Ann Surg Oncol 2011; 18: 146-152
703 Chang GJ. et al. Lymph node evaluation and survival after curative resection of colon cancer: systematic review. J Natl Cancer Inst 2007; 99: 433-441
704 Le Voyer TE. et al. Colon cancer survival is associated with increasing number of lymph nodes analyzed: a secondary survey of intergroup trial INT-0089. J Clin Oncol 2003; 21: 2912-2919
705 Van Damme JP. Vascular anatomy in abdominal surgery. Stuttgart: Thieme; 1990
706 Kanemitsu Y. et al. Survival benefit of high ligation of the inferior mesenteric artery in sigmoid colon or rectal cancer surgery. Br J Surg 2006; 93: 609-615
707 Chin CC. et al. Carcinoma obstruction of the proximal colon cancer and long-term prognosis--obstruction is a predictor of worse outcome in TNM stage II tumor. Int J Colorectal Dis 2010; 25: 817-822
708 Hohenberger W. et al. Standardized surgery for colonic cancer: complete mesocolic excision and central ligation--technical notes and outcome. Colorectal Dis 2009; 11: 354-364 ; discussion 364–365
709 West NP. et al. Multicentre experience with extralevator abdominoperineal excision for low rectal cancer. Br J Surg 2010; 97: 588-599
710 Bertelsen CA. et al. Can the quality of colonic surgery be improved by standardization of surgical technique with complete mesocolic excision?. Colorectal Dis 2011; 13: 1123-1129
711 (NICE), N.I.f.C.E. Radiofrequency ablation for the treatment of colorectal metastases in the liver. London: 2011
712 Kim KH. et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc 2011; 81: 25-34
713 Mulier S. et al. Radiofrequency ablation versus resection for resectable colorectal liver metastases: time for a randomized trial?. Ann Surg Oncol 2008; 15: 144-157
714 (NICE), N.I.f.C.E. Selective internal radiation therapy for colorectal metastases in the liver. London: 2011
715 Townsend A, Price T, Karapetis C. Selective internal radiation therapy for liver metastases from colorectal cancer. Cochrane Database Syst Rev 2009;
716 Christophi C. et al. Long-term survival of patients with unresectable colorectal liver metastases treated by percutaneous interstitial laser thermotherapy. World J Surg 2004; 28: 987-994
717 Wietzke-Braun P. et al. Quality of life and outcome of ultrasound-guided laser interstitial thermo-therapy for non-resectable liver metastases of colorectal cancer. Eur J Gastroenterol Hepatol 2004; 16: 389-395
718 Abcarian H, Pearl RK. Simple technique for high ligation of the inferior mesenteric artery and vein. Dis Colon Rectum 1991; 34: 1138
719 Buunen M. et al. Level of arterial ligation in total mesorectal excision (TME): an anatomical study. Int J Colorectal Dis 2009; 24: 1317-1320
720 Pezim ME, Nicholls RJ. Survival after high or low ligation of the inferior mesenteric artery during curative surgery for rectal cancer. Ann Surg 1984; 200: 729-733
721 Surtees P, Ritchie JK, Phillips RK. High versus low ligation of the inferior mesenteric artery in rectal cancer. Br J Surg 1990; 77: 618-621
722 Slanetz Jr CA, Grimson R. Effect of high and intermediate ligation on survival and recurrence rates following curative resection of colorectal cancer. Dis Colon Rectum 1997; 40: 1205-1218 ; discussion 1218–1219
723 Lange MM. et al. Level of arterial ligation in rectal cancer surgery: low tie preferred over high tie. A review. Dis Colon Rectum 2008; 51: 1139-1145
724 Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery-the clue to pelvic recurrence?. Br J Surg 1982; 69: 613-616
725 Bokey EL. et al. Local recurrence after curative excision of the rectum for cancer without adjuvant therapy: role of total anatomical dissection. Br J Surg 1999; 86: 1164-1170
726 Hermanek PJ. Multiviszerale Resektion beim kolorektalen Karzinom. Erfahrungen der SGKRK-Studie. Langenbecks Arch Surg; 1992 Kongressband: 95–100
727 Havenga K. et al. Male and female sexual and urinary function after total mesorectal excision with autonomic nerve preservation for carcinoma of the rectum. J Am Coll Surg 1996; 182: 495-502
728 Enker WE. et al. Abdominoperineal resection via total mesorectal excision and autonomic nerve preservation for low rectal cancer. World J Surg 1997; 21: 715-720
729 Georgiou P. et al. Extended lymphadenectomy versus conventional surgery for rectal cancer: a meta-analysis. Lancet Oncol 2009; 10: 1053-1062
730 Gohl J, Hohenberger W, Merkel S. Lymph node dissection in rectal carcinoma: TME and what else?. Onkologie 2009; 32: 57-61
731 Mortenson MM. et al. Total mesorectal excision and pelvic node dissection for rectal cancer: an appraisal. Surg Oncol Clin N Am 2007; 16: 177-197
732 Koch M. et al. Is the lateral lymph node compartment relevant?. Recent Results Cancer Res 2005; 165: 40-45
733 Scott N. et al. Total mesorectal excision and local recurrence: a study of tumour spread in the mesorectum distal to rectal cancer. Br J Surg 1995; 82: 1031-1033
734 Reynolds JV. et al. Pathological evidence in support of total mesorectal excision in the management of rectal cancer. Br J Surg 1996; 83: 1112-1115
735 Hida J. et al. Lymph node metastases detected in the mesorectum distal to carcinoma of the rectum by the clearing method: justification of total mesorectal excision. J Am Coll Surg 1997; 184: 584-588
736 Zaheer S. et al. Surgical treatment of adenocarcinoma of the rectum. Ann Surg 1998; 227: 800-811
737 Leong AF. Selective total mesorectal excision for rectal cancer. Dis Colon Rectum 2000; 43: 1237-1240
738 Heald RJ, Karanjia ND. Results of radical surgery for rectal cancer. World J Surg 1992; 16: 848-857
739 Enker WE. Total mesorectal excision--the new golden standard of surgery for rectal cancer. Ann Med 1997; 29: 127-133
740 Lazorthes F. et al. Distal intramural spread of carcinoma of the rectum correlated with lymph nodal involvement. Surg Gynecol Obstet 1990; 170: 45-48
741 Kwok SP. et al. Prospective analysis of the distal margin of clearance in anterior resection for rectal carcinoma. Br J Surg 1996; 83: 969-972
742 Andreola S. et al. Distal intramural spread in adenocarcinoma of the lower third of the rectum treated with total rectal resection and coloanal anastomosis. Dis Colon Rectum 1997; 40: 25-29
743 Goldstein NS, Soman A, Sacksner J. Disparate surgical margin lengths of colorectal resection specimens between in vivo and in vitro measurements. The effects of surgical resection and formalin fixation on organ shrinkage. Am J Clin Pathol 1999; 111: 349-351
744 Kiran RP, Lian L, Lavery IC. Does a subcentimeter distal resection margin adversely influence oncologic outcomes in patients with rectal cancer undergoing restorative proctectomy?. Dis Colon Rectum 2011; 54: 157-163
745 Rutkowski A. et al. Distal bowel surgical margin shorter than 1 cm after preoperative radiation for rectal cancer: is it safe?. Ann Surg Oncol 2008; 15: 3124-3131
746 Brown CJ, Fenech DS, McLeod RS. Reconstructive techniques after rectal resection for rectal cancer. Cochrane Database Syst Rev 2008;
747 Fazio VW. et al. A randomized multicenter trial to compare long-term functional outcome, quality of life, and complications of surgical procedures for low rectal cancers. Ann Surg 2007; 246: 481-488 ; discussion 488–490
748 Liao C. et al. Meta-analysis of the colon J-pouch vs transverse coloplasty pouch after anterior resection for rectal cancer. Colorectal Dis 2010; 12: 624-631
749 Siddiqui MR. et al. A meta-analysis comparing side to end with colonic J-pouch formation after anterior resection for rectal cancer. Tech Coloproctol 2010; 14: 113-123
750 Hida J. et al. Functional outcome after low anterior resection with low anastomosis for rectal cancer using the colonic J-pouch. Prospective randomized study for determination of optimum pouch size. Dis Colon Rectum 1996; 39: 986-991
751 Hohenberger W. et al. Neoadjuvant radiochemotherapy for rectal cancer. Chirurg 2009; 80: 294-302
752 Artioukh DY. Controversial aspects of rectal cancer surgery following preoperative chemoradiation. Colorectal Dis 2010; 12 (Suppl. 02) 25-29
753 Habr-Gama A. et al. Operative versus nonoperative treatment for stage 0 distal rectal cancer following chemoradiation therapy: long-term results. Ann Surg 2004; 240: 711-717 ; discussion 717–718
754 Tekkis PP. et al. Comparison of circumferential margin involvement between restorative and nonrestorative resections for rectal cancer. Colorectal Dis 2005; 7: 369-374
755 Nagtegaal ID. et al. Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol 2005; 23: 9257-9264
756 Nisar J, Scott HJ. Myocutaneous flap reconstruction of the pelvis after abdominoperineal excision. Colorectal Dis 2009; 11: 806-816
757 Montedori A. et al. Covering ileo- or colostomy in anterior resection for rectal carcinoma. Cochrane Database Syst Rev 2010;
758 Lindgren R. et al. What is the risk for a permanent stoma after low anterior resection of the rectum for cancer? A six-year follow-up of a multicenter trial. Dis Colon Rectum 2011; 54: 41-47
759 Klink CD. et al. Protective ileostoma versus protective transverse stoma. What evidence is available?. Chirurg 2010; 81: 974-977
760 Rondelli F. et al. Loop ileostomy versus loop colostomy for fecal diversion after colorectal or coloanal anastomosis: a meta-analysis. Int J Colorectal Dis 2009; 24: 479-488
761 Bass EM. et al. Does preoperative stoma marking and education by the enterostomal therapist affect outcome?. Dis Colon Rectum 1997; 40: 440-442
762 Millan M. et al. Preoperative stoma siting and education by stomatherapists of colorectal cancer patients: a descriptive study in twelve Spanish colorectal surgical units. Colorectal Dis 2010; 12: e88-e92
763 Chaudhri S. et al. Preoperative intensive, community-based vs. traditional stoma education: a randomized, controlled trial. Dis Colon Rectum 2005; 48: 504-509
764 Hermanek P, Marzoli GP. Lokale Therapie des Rektumkarzinoms. Verfahren in kurativer Intention. Berlin Heidelberg Ney York Tokyo: Springer; 1994
765 Winde G. et al. Surgical cure for early rectal carcinomas (T1). Transanal endoscopic microsurgery vs. anterior resection. Dis Colon Rectum 1996; 39: 969-976
766 Sengupta S, Tjandra JJ. Local excision of rectal cancer: what is the evidence?. Dis Colon Rectum 2001; 44: 1345-1361
767 Matzel KE, Merkel S, Hohenberger W. Lokale Therapieprinzipien beim Rektumkarzinom. Chirurg 2003; 74: 897-904
768 Ptok H. et al. Oncological outcome of local vs radical resection of low-risk pT1 rectal cancer. Arch Surg 2007; 142: 649-655 ; discussion 656
769 You YN. et al. Is the increasing rate of local excision for stage I rectal cancer in the United States justified?: a nationwide cohort study from the National Cancer Database. Ann Surg 2007; 245: 726-733
770 Moore JS. et al. Transanal endoscopic microsurgery is more effective than traditional transanal excision for resection of rectal masses. Dis Colon Rectum 2008; 51: 1026-1030 ; discussion 1030–1031
771 Sgourakis G. et al. Transanal endoscopic microsurgery for T1 and T2 rectal cancers: a meta-analysis and meta-regression analysis of outcomes. Am Surg 2011; 77: 761-772
772 Bach SP. et al. A predictive model for local recurrence after transanal endoscopic microsurgery for rectal cancer. Br J Surg 2009; 96: 280-290
773 Glimelius B, Pahlman L, Cervantes A. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2010; 21 (Suppl. 05) v82-v86
774 Suppiah A. et al. Transanal endoscopic microsurgery in early rectal cancer: time for a trial?. Colorectal Dis 2008; 10: 314-327 ; discussion 327–329
775 Valentini V. et al. Multidisciplinary Rectal Cancer Management: 2nd European Rectal Cancer Consensus Conference (EURECA-CC2). Radiother Oncol 2009; 92: 148-163
776 Hahnloser D. et al. Immediate radical resection after local excision of rectal cancer: an oncologic compromise?. Dis Colon Rectum 2005; 48: 429-437
777 Schwenk W. et al. Short term benefits for laparoscopic colorectal resection. Cochrane Database Syst Rev 2005;
778 Liang Y. et al. Laparoscopic versus open colorectal resection for cancer: a meta-analysis of results of randomized controlled trials on recurrence. Eur J Surg Oncol 2008; 34: 1217-1224
779 Kuhry E. et al. Long-term results of laparoscopic colorectal cancer resection. Cochrane Database Syst Rev 2008;
780 Guillou PJ. et al. Short-term endpoints of conventional versus laparoscopic-assisted surgery in patients with colorectal cancer (MRC CLASICC trial): multicentre, randomised controlled trial. Lancet 2005; 365: 1718-1726
781 Jayne DG. et al. Five-year follow-up of the Medical Research Council CLASICC trial of laparoscopically assisted versus open surgery for colorectal cancer. Br J Surg 2010; 97: 1638-1645
782 Kwak JM. et al. Robotic vs laparoscopic resection of rectal cancer: short-term outcomes of a case-control study. Dis Colon Rectum 2011; 54: 151-156
783 Pigazzi A. et al. Multicentric study on robotic tumor-specific mesorectal excision for the treatment of rectal cancer. Ann Surg Oncol 2010; 17: 1614-1620
784 Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. Cancer Treat Res 1996; 82: 359-374
785 Verwaal VJ. et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21: 3737-3743
786 Verwaal VJ. et al. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15: 2426-2432
787 Cao C. et al. A systematic review and meta-analysis of cytoreductive surgery with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis of colorectal origin. Ann Surg Oncol 2009; 16: 2152-2165
788 Khot UP. et al. Systematic review of the efficacy and safety of colorectal stents. Br J Surg 2002; 89: 1096-1102
789 Stillwell AP, Buettner PG, Ho YH. Meta-analysis of survival of patients with stage IV colorectal cancer managed with surgical resection versus chemotherapy alone. World J Surg 2010; 34: 797-807
790 Poultsides GA. et al. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009; 27: 3379-3384
791 Hermanek P, Guggenmoos-Holzmann I, Gall FP. Prognostic factors in rectal carcinoma. A contribution to the further development of tumor classification. Dis Colon Rectum 1989; 32: 593-599
792 Hermanek P, Hohenberger W. The importance of volume in colorectal cancer surgery. Eur J Surg Oncol 1996; 22: 213-215
793 Compton CC. Pathology report in colon cancer: what is prognostically important?. Dig Dis 1999; 17: 67-79
794 Wong JH. et al. Number of nodes examined and staging accuracy in colorectal carcinoma. J Clin Oncol 1999; 17: 2896-2900
795 Compton C. et al. American Joint Committee on Cancer Prognostic Factors Consensus Conference: Colorectal Working Group. Cancer 2000; 88: 1739-1757
796 Compton CC. Updated protocol for the examination of specimens from patients with carcinomas of the colon and rectum, excluding carcinoid tumors, lymphomas, sarcomas, and tumors of the vermiform appendix: a basis for checklists. Cancer Committee. Arch Pathol Lab Med 2000; 124: 1016-1025
797 Hermanek P. Methodik der histopathologischen Untersuchung von Resektionen kolorektaler Karzinome. Chir Gastroenterol 2000; 16: 255-259
798 Hermanek P. Lymph nodes and malignant tumors. Zentralbl Chir 2000; 125: 790-795
799 Junginger T, Hermanek P, Klimpfinger M. Klassifikation maligner Tumoren des Gastrointestinaltraktes I. Berlin Heidelberg New York: Springer Verlag; 2002
800 Wittekind C. et al. TNM residual tumor classification revisited. Cancer 2002; 94: 2511-2516
801 Leibl S, Tsybrovskyy O, Denk H. How many lymph nodes are necessary to stage early and advanced adenocarcinoma of the sigmoid colon and upper rectum?. Virchows Arch 2003; 443: 133-138
802 Sobin LH. TNM, sixth edition: new developments in general concepts and rules. Semin Surg Oncol 2003; 21: 19-22
803 Dworak O, Keilholz L, Hoffmann A. Pathological features of rectal cancer after preoperative radiochemotherapy. Int J Colorectal Dis 1997; 12: 19-23
804 Wright CM. et al. Prognostic significance of extensive microsatellite instability in sporadic clinicopathological stage C colorectal cancer. Br J Surg 2000; 87: 1197-1202
805 Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 2005; 23: 609-618
806 Benatti P. et al. Microsatellite instability and colorectal cancer prognosis. Clin Cancer Res 2005; 11: 8332-8340
807 Malesci A. et al. Reduced likelihood of metastases in patients with microsatellite-unstable colorectal cancer. Clin Cancer Res 2007; 13: 3831-3839
808 Leopoldo S. et al. Two subtypes of mucinous adenocarcinoma of the colorectum: clinicopathological and genetic features. Ann Surg Oncol 2008; 15: 1429-1439
809 Lanza G. et al. Medullary-type poorly differentiated adenocarcinoma of the large bowel: a distinct clinicopathologic entity characterized by microsatellite instability and improved survival. J Clin Oncol 1999; 17: 2429-2438
810 Parc Y. et al. Prognostic significance of microsatellite instability determined by immunohistochemical staining of MSH2 and MLH1 in sporadic T3N0M0 colon cancer. Gut 2004; 53: 371-375
811 Gafa R. et al. Sporadic colorectal adenocarcinomas with high-frequency microsatellite instability. Cancer 2000; 89: 2025-2037
812 Lanza G. et al. Immunohistochemical pattern of MLH1 / MSH2 expression is related to clinical and pathological features in colorectal adenocarcinomas with microsatellite instability. Mod Pathol 2002; 15: 741-749
813 Lindor NM. et al. Immunohistochemistry versus microsatellite instability testing in phenotyping colorectal tumors. J Clin Oncol 2002; 20: 1043-1048
814 Overbeek LI. et al. Interpretation of immunohistochemistry for mismatch repair proteins is only reliable in a specialized setting. Am J Surg Pathol 2008; 32: 1246-1251
815 Prandi M. et al. Prognostic evaluation of stage B colon cancer patients is improved by an adequate lymphadenectomy: results of a secondary analysis of a large scale adjuvant trial. Ann Surg 2002; 235: 458-463
816 Ogino S. et al. Negative lymph node count is associated with survival of colorectal cancer patients, independent of tumoral molecular alterations and lymphocytic reaction. Am J Gastroenterol 2010; 105: 420-433
817 Swanson RS. et al. The prognosis of T3N0 colon cancer is dependent on the number of lymph nodes examined. Ann Surg Oncol 2003; 10: 65-71
818 Carloss H. et al. The impact of number of lymph nodes removed on five-year survival in stage II colon and rectal cancer. J Ky Med Assoc 2004; 102: 345-347
819 Fazio L. et al. Association between colonic screening, subject characteristics, and stage of colorectal cancer. Am J Gastroenterol 2005; 100: 2531-2539
820 Wong SL. et al. Hospital lymph node examination rates and survival after resection for colon cancer. JAMA 2007; 298: 2149-2154
821 Qiu HB. et al. Ratio of metastatic to resected lymph nodes enhances to predict survival in patients with stage III colorectal cancer. Ann Surg Oncol 2011; 18: 1568-1574
822 Wang J. et al. Should total number of lymph nodes be used as a quality of care measure for stage III colon cancer?. Ann Surg 2009; 249: 559-563
823 Chen SL. et al. Lymph node ratio as a quality and prognostic indicator in stage III colon cancer. Ann Surg 2011; 253: 82-87
824 Ha YH. et al. Influence of preoperative chemoradiotherapy on the number of lymph nodes retrieved in rectal cancer. Ann Surg 2010; 252: 336-340
825 West NP. et al. Complete mesocolic excision with central vascular ligation produces an oncologically superior specimen compared with standard surgery for carcinoma of the colon. J Clin Oncol 2010; 28: 272-278
826 West NP. et al. Pathology grading of colon cancer surgical resection and its association with survival: a retrospective observational study. Lancet Oncol 2008; 9: 857-865
827 Quirke P. et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG CO16 randomised clinical trial. Lancet 2009; 373: 821-828
828 Tilney HS. et al. The influence of circumferential resection margins on long-term outcomes following rectal cancer surgery. Dis Colon Rectum 2009; 52: 1723-1729
829 Bernstein TE. et al. Circumferential resection margin as a prognostic factor in rectal cancer. Br J Surg 2009; 96: 1348-1357
830 West NP. et al. Evidence of the oncologic superiority of cylindrical abdominoperineal excision for low rectal cancer. J Clin Oncol 2008; 26: 3517-3522
831 Leite JS. et al. Clinical significance of macroscopic completeness of mesorectal resection in rectal cancer. Colorectal Dis 2011; 13: 381-386
832 Kreienberg R. et al. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms. Informationszentrum für Standards in der Onkologie (ISTO), Deutsche Krebsgesellschaft e.V; 2008 1. Aktualisierung
833 Edwards AG, Hailey S, Maxwell M. Psychological interventions for women with metastatic breast cancer. Cochrane Database Syst Rev 2004;
834 Sheard T, Maguire P. The effect of psychological interventions on anxiety and depression in cancer patients: results of two meta-analyses. Br J Cancer 1999; 80: 1770-1780
835 Keller M. et al. Recognition of distress and psychiatric morbidity in cancer patients: a multi-method approach. Ann Oncol 2004; 15: 1243-1249
836 Sharpe M. et al. Major depression in outpatients attending a regional cancer centre: screening and unmet treatment needs. Br J Cancer 2004; 90: 314-320
837 Singer S, Das-Munshi J, Brahler E. Prevalence of mental health conditions in cancer patients in acute care--a meta-analysis. Ann Oncol 2010; 21: 925-930
838 Zabora J. et al. The prevalence of psychological distress by cancer site. Psychooncology 2001; 10: 19-28
839 Jansen L. et al. Health-related quality of life during the 10 years after diagnosis of colorectal cancer: a population-based study. J Clin Oncol 2011; 29: 3263-3269
840 Lynch BM. et al. Describing and predicting psychological distress after colorectal cancer. Cancer 2008; 112: 1363-1370
841 Miovic M, Block S. Psychiatric disorders in advanced cancer. Cancer 2007; 110: 1665-1676
842 Ramsey SD. et al. Quality of life in survivors of colorectal carcinoma. Cancer 2000; 88: 1294-1303
843 Zettl S, Hartlapp J. eds Sexualstörungen durch Krankheit und Therapie. Heidelberg: Springer; 1997: S.59
844 Fallowfield L. et al. Psychiatric morbidity and its recognition by doctors in patients with cancer. Br J Cancer 2001; 84: 1011-1015
845 Sollner W. et al. How successful are oncologists in identifying patient distress, perceived social support, and need for psychosocial counselling?. Br J Cancer 2001; 84: 179-185
846 Ell K. et al. Randomized controlled trial of collaborative care management of depression among low-income patients with cancer. J Clin Oncol 2008; 26: 4488-4496
847 Strong V. et al. Management of depression for people with cancer (SMaRT oncology 1): a randomised trial. Lancet 2008; 372: 40-48
848 Herschbach P, Weis J. eds Screeningverfahren in der Psychoonkologie. Berlin: Deutsche Krebsgesellschaft; 2008
849 NHMRC. Clinical practice guidelines for the psychosocial care of adults with cancer. 2003: 1-237
850 Turner J. et al. Clinical practice guidelines for the psychosocial care of adults with cancer. Psychooncology 2005; 14: 159-173
851 Weis J. et al. Psychoonkologie: Konzepte und Aufgaben einer jungen Fachdisziplin. Onkologe 2007; 13: 185-194
852 Edwards AG, Hulbert-Williams N, Neal RD. Psychological interventions for women with metastatic breast cancer. Cochrane Database Syst Rev 2008;
853 Faller H. et al. Effects of psychooncological interventions on emotional distress and quality of life in adult cancer patients: systematic review and meta-analysis. Nat J Cancer in press.
854 Goedendorp MM. et al. Psychosocial interventions for reducing fatigue during cancer treatment in adults. Cochrane Database Syst Rev 2009;
855 Jacobsen PB, Jim HS. Psychosocial interventions for anxiety and depression in adult cancer patients: achievements and challenges. CA Cancer J Clin 2008; 58: 214-230
856 Luebbert K, Dahme B, Hasenbring M. The effectiveness of relaxation training in reducing treatment-related symptoms and improving emotional adjustment in acute non-surgical cancer treatment: a meta-analytical review. Psychooncology 2001; 10: 490-502
857 Osborn RL, Demoncada AC, Feuerstein M. Psychosocial interventions for depression, anxiety, and quality of life in cancer survivors: meta-analyses. Int J Psychiatry Med 2006; 36: 13-34
858 Rehse B, Pukrop R. Effects of psychosocial interventions on quality of life in adult cancer patients: meta analysis of 37 published controlled outcome studies. Patient Educ Couns 2003; 50: 179-186
859 Uitterhoeve RJ. et al. Psychosocial interventions for patients with advanced cancer – a systematic review of the literature. Br J Cancer 2004; 91: 1050-1062
860 Williams S, Dale J. The effectiveness of treatment for depression/depressive symptoms in adults with cancer: a systematic review. Br J Cancer 2006; 94: 372-390
861 Merkel S. et al. Prognosis of patients with colonic carcinoma before, during and after implementation of complete mesocolic excision. Br J Surg 2016; 103: 1220-1229
862 Booth CM. et al. Use and Effectiveness of Adjuvant Chemotherapy for Stage III Colon Cancer: A Population-Based Study. J Natl Compr Canc Netw 2016; 14: 47-56
863 Tournigand C. et al. Adjuvant therapy with fluorouracil and oxaliplatin in stage II and elderly patients (between ages 70 and 75 years) with colon cancer: subgroup analyses of the Multicenter International Study of Oxaliplatin, Fluorouracil, and Leucovorin in the Adjuvant Treatment of Colon Cancer trial. J Clin Oncol 2012; 30: 3353-3360
864 Haller DG. et al. Impact of age and medical comorbidity on adjuvant treatment outcomes for stage III colon cancer: a pooled analysis of individual patient data from four randomized, controlled trials. Ann Oncol 2015; 26: 715-724
865 Schmoll HJ. et al. Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. J Clin Oncol 2015; 33: 3733-3740
866 McCleary NJ. et al. Impact of age on the efficacy of newer adjuvant therapies in patients with stage II/III colon cancer: findings from the ACCENT database. J Clin Oncol 2013; 31: 2600-2606
867 Fata F. et al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colon carcinoma: a 10-year experience of the Geisinger Medical Center. Cancer 2002; 94: 1931-1938
868 Biagi JJ. et al. Association between time to initiation of adjuvant chemotherapy and survival in colorectal cancer: a systematic review and meta-analysis. JAMA 2011; 305: 2335-2342
869 Des Guetz G. et al. Does delaying adjuvant chemotherapy after curative surgery for colorectal cancer impair survival? A meta-analysis. Eur J Cancer 2010; 46: 1049-1055
870 Bos AC. et al. Timing of adjuvant chemotherapy and its relation to survival among patients with stage III colon cancer. Eur J Cancer 2015; 51: 2553-2561
871 Bayraktar UD. et al. Does delay of adjuvant chemotherapy impact survival in patients with resected stage II and III colon adenocarcinoma?. Cancer 2011; 117: 2364-2370
872 Lima IS. et al. Association between receipt and timing of adjuvant chemotherapy and survival for patients with stage III colon cancer in Alberta, Canada. Cancer 2011; 117: 3833-3840
873 Nachiappan S. et al. Initiation of adjuvant chemotherapy within 8 weeks of elective colorectal resection improves overall survival regardless of reoperation. Colorectal Dis 2016; 18: 1041-1049
874 Dube S, Heyen F, Jenicek M. Adjuvant chemotherapy in colorectal carcinoma: results of a meta-analysis. Dis Colon Rectum 1997; 40: 35-41
875 Gill S. et al. Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?. J Clin Oncol 2004; 22: 1797-1806
876 Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. International Multicentre Pooled Analysis of Colon Cancer Trials (IMPACT) investigators. Lancet 1995; 345: 939-944
877 Sargent DJ. et al. A pooled analysis of adjuvant chemotherapy for resected colon cancer in elderly patients. N Engl J Med 2001; 345: 1091-1097
878 Francini G. et al. Folinic acid and 5-fluorouracil as adjuvant chemotherapy in colon cancer. Gastroenterology 1994; 106: 899-906
879 O’Connell MJ. et al. Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 1997; 15: 246-250
880 Figueredo A. et al. Adjuvant therapy for stage II colon cancer after complete resection. Provincial Gastrointestinal Disease Site Group. Cancer Prev Control 1997; 1: 379-392
881 Efficacy of adjuvant fluorouracil and folinic acid in B2 colon cancer. International Multicentre Pooled Analysis of B2 Colon Cancer Trials (IMPACT B2) Investigators. J Clin Oncol 1999; 17: 1356-1363
882 Mamounas E. et al. Comparative efficacy of adjuvant chemotherapy in patients with Dukes’ B versus Dukes’ C colon cancer: results from four National Surgical Adjuvant Breast and Bowel Project adjuvant studies (C-01, C-02, C-03, and C-04). J Clin Oncol 1999; 17: 1349-1355
883 Benson 3rd AB. et al. American Society of Clinical Oncology recommendations on adjuvant chemotherapy for stage II colon cancer. J Clin Oncol 2004; 22: 3408-3419
884 Quasar Collaborative G. et al. Adjuvant chemotherapy versus observation in patients with colorectal cancer: a randomised study. Lancet 2007; 370: 2020-2029
885 O’Connor ES. et al. Adjuvant chemotherapy for stage II colon cancer with poor prognostic features. J Clin Oncol 2011; 29: 3381-3388
886 Andre T. et al. Adjuvant Fluorouracil, Leucovorin, and Oxaliplatin in Stage II to III Colon Cancer: Updated 10-Year Survival and Outcomes According to BRAF Mutation and Mismatch Repair Status of the MOSAIC Study. J Clin Oncol 2015; 33: 4176-4187
887 Moertel CG. et al. Intergroup study of fluorouracil plus levamisole as adjuvant therapy for stage II/Dukes’ B2 colon cancer. J Clin Oncol 1995; 13 (12) 2936-2943
888 Taal BG, Van Tinteren H, Zoetmulder FA. Adjuvant 5FU plus levamisole in colonic or rectal cancer: improved survival in stage II and III. Br J Cancer 2001; 85: 1437-1443
889 Schrag D. et al. Adjuvant chemotherapy use for Medicare beneficiaries with stage II colon cancer. J Clin Oncol 2002; 20: 3999-4005
890 Caplin S. et al. For patients with Dukes’ B (TNM Stage II) colorectal carcinoma, examination of six or fewer lymph nodes is related to poor prognosis. Cancer 1998; 83: 666-672
891 Merkel S. et al. High-risk groups of patients with Stage II colon carcinoma. Cancer 2001; 92: 1435-1443
892 Petersen VC. et al. Identification of objective pathological prognostic determinants and models of prognosis in Dukes’ B colon cancer. Gut 2002; 51: 65-69
893 Morris M. et al. Population-based study of prognostic factors in stage II colonic cancer. Br J Surg 2006; 93: 866-871
894 Burdy G. et al. Identifying patients with T3-T4 node-negative colon cancer at high risk of recurrence. Dis Colon Rectum 2001; 44: 1682-1688
895 Jestin P. et al. Emergency surgery for colonic cancer in a defined population. Br J Surg 2005; 92: 94-100
896 McArdle CS, McMillan DC, Hole DJ. The impact of blood loss, obstruction and perforation on survival in patients undergoing curative resection for colon cancer. Br J Surg 2006; 93: 483-488
897 George S. et al. Will Rogers revisited: prospective observational study of survival of 3592 patients with colorectal cancer according to number of nodes examined by pathologists. Br J Cancer 2006; 95: 841-847
898 Chen SL, Bilchik AJ. More extensive nodal dissection improves survival for stages I to III of colon cancer: a population-based study. Ann Surg 2006; 244: 602-610
899 Ribic CM. et al. Tumor microsatellite-instability status as a predictor of benefit from fluorouracil-based adjuvant chemotherapy for colon cancer. N Engl J Med 2003; 349: 247-257
900 Sargent DJ. et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol 2010; 28: 3219-3226
901 Jover R. et al. Mismatch repair status in the prediction of benefit from adjuvant fluorouracil chemotherapy in colorectal cancer. Gut 2006; 55: 848-855
902 Kim JE. et al. Defective Mismatch Repair Status was not Associated with DFS and OS in Stage II Colon Cancer Treated with Adjuvant Chemotherapy. Ann Surg Oncol 2015; 22 (Suppl. 03) 630-637
903 Moertel CG. et al. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma. N Engl J Med 1990; 322: 352-358
904 Hermanek P, Hutter RV, Sobin LH. Prognostic grouping: the next step in tumor classification. J Cancer Res Clin Oncol 1990; 116: 513-516
905 Martinez-Lopez E. et al. Allelic loss on chromosome 18q as a prognostic marker in stage II colorectal cancer. Gastroenterology 1998; 114: 1180-1187
906 Ogunbiyi OA. et al. Confirmation that chromosome 18q allelic loss in colon cancer is a prognostic indicator. J Clin Oncol 1998; 16: 427-433
907 Jernvall P. et al. Loss of heterozygosity at 18q21 is indicative of recurrence and therefore poor prognosis in a subset of colorectal cancers. Br J Cancer 1999; 79: 903-908
908 Font A. et al. Prognostic value of K-ras mutations and allelic imbalance on chromosome 18q in patients with resected colorectal cancer. Dis Colon Rectum 2001; 44: 549-557
909 Diep CB. et al. Genetic tumor markers with prognostic impact in Dukes’ stages B and C colorectal cancer patients. J Clin Oncol 2003; 21: 820-829
910 Carethers JM. et al. Prognostic significance of allelic lost at chromosome 18q21 for stage II colorectal cancer. Gastroenterology 1998; 114: 1188-1195
911 Araujo SE. et al. DNA ploidy status and prognosis in colorectal cancer: a meta-analysis of published data. Dis Colon Rectum 2007; 50: 1800-1810
912 Klingbiel D. et al. Prognosis of stage II and III colon cancer treated with adjuvant 5-fluorouracil or FOLFIRI in relation to microsatellite status: results of the PETACC-3 trial. Ann Oncol 2015; 26: 126-132
913 Lanza G. et al. Immunohistochemical test for MLH1 and MSH2 expression predicts clinical outcome in stage II and III colorectal cancer patients. J Clin Oncol 2006; 24: 2359-2367
914 Sinicrope FA. et al. Prognostic impact of microsatellite instability and DNA ploidy in human colon carcinoma patients. Gastroenterology 2006; 131: 729-737
915 Elsaleh H, Iacopetta B. Microsatellite instability is a predictive marker for survival benefit from adjuvant chemotherapy in a population-based series of stage III colorectal carcinoma. Clin Colorectal Cancer 2001; 1: 104-109
916 Thomas ML. et al. Clinicopathological predictors of benefit from adjuvant chemotherapy for stage C colorectal cancer: Microsatellite unstable cases benefit. Asia Pac J Clin Oncol 2015; 11: 343-351
917 Dalerba P. et al. CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer. N Engl J Med 2016; 374: 211-222
918 Tie J. et al. Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med 2016; 8: 346ra92
919 Turner N. et al. Analysis of local chronic inflammatory cell infiltrate combined with systemic inflammation improves prognostication in stage II colon cancer independent of standard clinicopathologic criteria. Int J Cancer 2016; 138: 671-678
920 Andre T. et al. Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med 2004; 350: 2343-2351
921 Kuebler JP. et al. Oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: results from NSABP C-07. J Clin Oncol 2007; 25: 2198-2204
922 Kidwell KM. et al. Long-term neurotoxicity effects of oxaliplatin added to fluorouracil and leucovorin as adjuvant therapy for colon cancer: results from National Surgical Adjuvant Breast and Bowel Project trials C-07 and LTS-01. Cancer 2012; 118: 5614-5622
923 de Gramont A, Boni C, Navarro M. et al. Oxaliplatin/5FU/LV in adjuvant colon cancer: Updated efficacy results of the MOSAIC trial, including survival, with a median follow-up of six years. Journal of Clinical Oncology, 2007 ASCO Annual Meeting Proceedings (Post-Meeting Edition) Vol 25, No 18S (June 20 Supplement). 2007 4007. 2007
924 Schmoll HJ. et al. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. Lancet Oncol 2014; 15: 1481-1492
925 Shi Q, Sobrero AF, Shields AF. et al. Prospective pooled analysis of six phase III trials investigating duration of adjuvant (adjuv) oxaliplatin-based therapy (3 vs 6 months) for patients (pts) with stage III colon cancer (CC): The IDEA (International Duration Evaluation of Adjuvant chemotherapy) collaboration. J Clin Oncol 2017 35.
926 Andre T. et al. Three versus six months adjuvant oxaliplatin-based chemotherapy for patients with stage III colon cancer: The French participation to the International Duration Evaluation of Adjuvant chemotherapy (IDEA) project. J Clin Oncol 2017 35. (suppl; abstr 3500)
927 Sobrero AF. et al. FOLFOX4/XELOX in stage II–III colon cancer: Efficacy results of the Italian three or six colon adjuvant (TOSCA) trial. J Clin Oncol 2017 35. (suppl; abstr 3501)
928 Iveson T. et al. Final DFS results of the SCOT study: An international phase III randomised (1:1) non-inferiority trial comparing 3 versus 6 months of oxaliplatin based adjuvant chemotherapy for colorectal cancer. J Clin Oncol 2017 35. (suppl; abstr 3502)
929 Hwang IG. et al. Association between timing and duration of adjuvant chemotherapy and survival for colorectal cancer in korea, 2011–2014: A nationwide study based on the database of quality assessment and the health insurance. J Clin Oncol 2017 35. (suppl; abstr 3605)
930 Sanoff HK. et al. Effect of adjuvant chemotherapy on survival of patients with stage III colon cancer diagnosed after age 75 years. J Clin Oncol 2012; 30: 2624-2634
931 Yothers G. et al. Oxaliplatin as adjuvant therapy for colon cancer: updated results of NSABP C-07 trial, including survival and subset analyses. J Clin Oncol 2011; 29: 3768-3774
932 Lund CM. et al. Efficacy and toxicity of adjuvant chemotherapy in elderly patients with colorectal cancer: the ACCORE study. ESMO Open 2016; 1: e000087
933 Kim CA. et al. Efficacy and safety of single agent or combination adjuvant chemotherapy in elderly patients with colon cancer: a Canadian cancer institute experience. Clin Colorectal Cancer 2014; 13: 199-206
934 Twelves C. et al. Capecitabine as adjuvant treatment for stage III colon cancer. N Engl J Med 2005; 352: 2696-2704
935 Andre T, Quinaux E, Louvet C. et al. Updated results at 6 year of the GERCOR C96.1 phase III study comparing LV5FU2 to monthly 5FU-leucovorin (mFufol) as adjuvant treatment for Dukes B2 and C colon cancer patients. Journal of Clinical Oncology, 2005 ASCO Annual Meeting Proceedings. Vol 23, No 16S (June 1 Supplement). 2005 3522. 2005
936 Carrato A, Köhne C, Bedenne L. et al. Folinic acid modulated bolus 5-FU or infusional 5-FU for adjuvant treatment of patients of UICC stage III colon cancer: Preliminary analysis of the PETACC-2-study. Journal of Clinical Oncology, 2006 ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 24, No 18S (June 20 Supplement). 2006: 3563
937 Andre T. et al. Semimonthly versus monthly regimen of fluorouracil and leucovorin administered for 24 or 36 weeks as adjuvant therapy in stage II and III colon cancer: results of a randomized trial. J Clin Oncol 2003; 21: 2896-2903
938 Arkenau HT, Rettig K, Porschen R. Adjuvant chemotherapy in curative resected colon carcinoma: 5-fluorouracil/leucovorin versus high-dose 5-fluorouracil 24-h infusion/leucovorin versus high-dose 5-fluorouracil 24-h infusion. Int J Colorectal Dis 2005; 20: 258-261
939 Chau I. et al. A randomised comparison between 6 months of bolus fluorouracil/leucovorin and 12 weeks of protracted venous infusion fluorouracil as adjuvant treatment in colorectal cancer. Ann Oncol 2005; 16: 549-557
940 Lembersky BC. et al. Oral uracil and tegafur plus leucovorin compared with intravenous fluorouracil and leucovorin in stage II and III carcinoma of the colon: results from National Surgical Adjuvant Breast and Bowel Project Protocol C-06. J Clin Oncol 2006; 24: 2059-2064
941 Sakamoto J. et al. Efficacy of oral adjuvant therapy after resection of colorectal cancer: 5-year results from three randomized trials. J Clin Oncol 2004; 22: 484-492
942 Poplin EA. et al. Phase III Southwest Oncology Group 9415/Intergroup 0153 randomized trial of fluorouracil, leucovorin, and levamisole versus fluorouracil continuous infusion and levamisole for adjuvant treatment of stage III and high-risk stage II colon cancer. J Clin Oncol 2005; 23: 1819-1825
943 O’Connell MJ. et al. Prospectively randomized trial of postoperative adjuvant chemotherapy in patients with high-risk colon cancer. J Clin Oncol 1998; 16: 295-300
944 Haller DG. et al. Phase III study of fluorouracil, leucovorin, and levamisole in high-risk stage II and III colon cancer: final report of Intergroup 0089. J Clin Oncol 2005; 23: 8671-8678
945 Van Cutsem E. et al. Randomized phase III trial comparing biweekly infusional fluorouracil/leucovorin alone or with irinotecan in the adjuvant treatment of stage III colon cancer: PETACC-3. J Clin Oncol 2009; 27: 3117-3125
946 Ychou M. et al. A phase III randomised trial of LV5FU2 + irinotecan versus LV5FU2 alone in adjuvant high-risk colon cancer (FNCLCC Accord02 / FFCD9802). Ann Oncol 2009; 20: 674-680
947 Saltz LB. et al. Irinotecan fluorouracil plus leucovorin is not superior to fluorouracil plus leucovorin alone as adjuvant treatment for stage III colon cancer: results of CALGB 89803. J Clin Oncol 2007; 25: 3456-3461
948 Alberts SR. et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA 2012; 307: 1383-1393
949 Taieb J. et al. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol 2014; 15: 862-873
950 Allegra CJ. et al. Bevacizumab in stage II-III colon cancer: 5-year update of the National Surgical Adjuvant Breast and Bowel Project C-08 trial. J Clin Oncol 2013; 31: 359-364
951 de Gramont A. et al. Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 2012; 13: 1225-1233
952 Kerr RS. et al. Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet Oncol 2016; 17: 1543-1557
953 Amlani A. et al. Compliance with adjuvant capecitabine in patients with stage II and III colon cancer: comparison of administrative versus medical record data. Cancer Med 2016; 5: 1776-1782
954 van Gijn W. et al. Preoperative radiotherapy combined with total mesorectal excision for resectable rectal cancer: 12-year follow-up of the multicentre, randomised controlled TME trial. Lancet Oncol 2011; 12: 575-582
955 Sebag-Montefiore D. et al. Preoperative radiotherapy versus selective postoperative chemoradiotherapy in patients with rectal cancer (MRC CR07 and NCIC-CTG C016): a multicentre, randomised trial. Lancet 2009; 373: 811-820
956 Sauer R. et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-1740
957 Sauer R. et al. Preoperative versus postoperative chemoradiotherapy for locally advanced rectal cancer: results of the German CAO/ARO/AIO-94 randomized phase III trial after a median follow-up of 11 years. J Clin Oncol 2012; 30: 1926-1933
958 Bosset JF. et al. Chemotherapy with preoperative radiotherapy in rectal cancer. N Engl J Med 2006; 355: 1114-1123
959 Bosset JF. et al. Fluorouracil-based adjuvant chemotherapy after preoperative chemoradiotherapy in rectal cancer: long-term results of the EORTC 22921 randomised study. Lancet Oncol 2014; 15: 184-190
960 Gerard JP. et al. Preoperative radiotherapy with or without concurrent fluorouracil and leucovorin in T3–4 rectal cancers: results of FFCD 9203. J Clin Oncol 2006; 24: 4620-4625
961 Folkesson J. et al. Swedish Rectal Cancer Trial: long lasting benefits from radiotherapy on survival and local recurrence rate. J Clin Oncol 2005; 23: 5644-5650
962 Marijnen CA. Organ preservation in rectal cancer: have all questions been answered?. Lancet Oncol 2015; 16: e13-e22
963 Lezoche E. et al. Randomized clinical trial of endoluminal locoregional resection versus laparoscopic total mesorectal excision for T2 rectal cancer after neoadjuvant therapy. Br J Surg 2012; 99: 1211-1218
964 Bujko K. et al. Preoperative radiotherapy and local excision of rectal cancer with immediate radical re-operation for poor responders: a prospective multicentre study. Radiother Oncol 2013; 106: 198-205
965 Verseveld M. et al. Chemoradiation therapy for rectal cancer in the distal rectum followed by organ-sparing transanal endoscopic microsurgery (CARTS study). Br J Surg 2015; 102: 853-860
966 Garcia-Aguilar J. et al. Organ preservation for clinical T2N0 distal rectal cancer using neoadjuvant chemoradiotherapy and local excision (ACOSOG Z6041): results of an open-label, single-arm, multi-institutional, phase 2 trial. Lancet Oncol 2015; 16: 1537-1546
967 Wong RK. et al. Pre-operative radiotherapy and curative surgery for the management of localized rectal carcinoma. Cochrane Database Syst Rev 2007;
968 Fiorica F. et al. Can chemotherapy concomitantly delivered with radiotherapy improve survival of patients with resectable rectal cancer? A meta-analysis of literature data. Cancer Treat Rev 2010; 36: 539-549
969 Ceelen WP, Van Nieuwenhove Y, Fierens K. Preoperative chemoradiation versus radiation alone for stage II and III resectable rectal cancer. Cochrane Database Syst Rev 2009;
970 Camma C. et al. Preoperative radiotherapy for resectable rectal cancer: A meta-analysis. Jama 2000; 284: 1008-1015
971 Adjuvant radiotherapy for rectal cancer: a systematic overview of 8507 patients from 22 randomised trials. Lancet 2001; 358: 1291-1304
972 FL G. et al. AJCC Cancer Staging Atlas. New York.: Springer; 2006
973 Rodel C. et al. Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial. Lancet Oncol 2015; 16: 979-989
974 Kreis ME. et al. Use of Preoperative Magnetic Resonance Imaging to Select Patients with Rectal Cancer for Neoadjuvant Chemoradiation--Interim Analysis of the German OCUM Trial (NCT01325649). J Gastrointest Surg 2016; 20: 25-32 ; discussion 32–33
975 Bonnetain F. et al. What is the clinical benefit of preoperative chemoradiotherapy with 5FU/leucovorin for T3–4 rectal cancer in a pooled analysis of EORTC 22921 and FFCD 9203 trials: surrogacy in question?. Eur J Cancer 2012; 48 (12) 1781-1790
976 Wiltink LM. et al. Health-related quality of life 14 years after preoperative short-term radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomised trial. Eur J Cancer 2014; 50: 2390-2398
977 Birgisson H. et al. Adverse effects of preoperative radiation therapy for rectal cancer: long-term follow-up of the Swedish Rectal Cancer Trial. J Clin Oncol 2005; 23: 8697-8705
978 Chen TY. et al. Bowel function 14 years after preoperative short-course radiotherapy and total mesorectal excision for rectal cancer: report of a multicenter randomized trial. Clin Colorectal Cancer 2015; 14: 106-114
979 Wiltink LM. et al. A comprehensive longitudinal overview of health-related quality of life and symptoms after treatment for rectal cancer in the TME trial. Acta Oncol 2016; 55: 502-508
980 Li XT. et al. Evaluating local lymph node metastasis with magnetic resonance imaging, endoluminal ultrasound and computed tomography in rectal cancer: a meta-analysis. Colorectal Dis 2015; 17: O129-O135
981 Merkel S. et al. Prognostic subdivision of ypT3 rectal tumours according to extension beyond the muscularis propria. Br J Surg 2014; 101: 566-572
982 Taylor FG. et al. Preoperative high-resolution magnetic resonance imaging can identify good prognosis stage I, II, and III rectal cancer best managed by surgery alone: a prospective, multicenter, European study. Ann Surg 2011; 253: 711-719
983 Taylor FG. et al. Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. J Clin Oncol 2014; 32: 34-43
984 Peeters KC. et al. The TME trial after a median follow-up of 6 years: increased local control but no survival benefit in irradiated patients with resectable rectal carcinoma. Ann Surg 2007; 246: 693-701
985 Krook JE. et al. Effective surgical adjuvant therapy for high-risk rectal carcinoma. N Engl J Med 1991; 324: 709-715
986 Smalley SR. et al. Phase III trial of fluorouracil-based chemotherapy regimens plus radiotherapy in postoperative adjuvant rectal cancer: GI INT 0144. J Clin Oncol 2006; 24: 3542-3547
987 Ngan SY. et al. Randomized trial of short-course radiotherapy versus long-course chemoradiation comparing rates of local recurrence in patients with T3 rectal cancer: Trans-Tasman Radiation Oncology Group trial 01.04. J Clin Oncol 2012; 30: 3827-3833
988 Bujko K. et al. Sphincter preservation following preoperative radiotherapy for rectal cancer: report of a randomised trial comparing short-term radiotherapy vs. conventionally fractionated radiochemotherapy. Radiother Oncol 2004; 72: 15-24
989 Bujko K. et al. Long-term results of a randomized trial comparing preoperative short-course radiotherapy with preoperative conventionally fractionated chemoradiation for rectal cancer. Br J Surg 2006; 93: 1215-1223
990 Pietrzak L. et al. Quality of life, anorectal and sexual functions after preoperative radiotherapy for rectal cancer: report of a randomised trial. Radiother Oncol 2007; 84: 217-225
991 McLachlan SA. et al. The impact on health-related quality of life in the first 12 months: A randomised comparison of preoperative short-course radiation versus long-course chemoradiation for T3 rectal cancer (Trans-Tasman Radiation Oncology Group Trial 01.04). Eur J Cancer 2016; 55: 15-26
992 Pettersson D. et al. Interim analysis of the Stockholm III trial of preoperative radiotherapy regimens for rectal cancer. Br J Surg 2010; 97: 580-587
993 Pettersson D. et al. Tumour regression in the randomized Stockholm III Trial of radiotherapy regimens for rectal cancer. Br J Surg 2015; 102: 972-978 ; discussion 978
994 Bujko K. et al. Long-course oxaliplatin-based preoperative chemoradiation versus 5 × 5 Gy and consolidation chemotherapy for cT4 or fixed cT3 rectal cancer: results of a randomized phase III study. Ann Oncol 2016; 27: 834-842
995 Ansari N. et al. Acute Adverse Events and Postoperative Complications in a Randomized Trial of Preoperative Short-course Radiotherapy Versus Long-course Chemoradiotherapy for T3 Adenocarcinoma of the Rectum: Trans-Tasman Radiation Oncology Group Trial (TROG 01.04). Ann Surg 2017; 265: 882-888
996 Nilsson PJ. et al. Short-course radiotherapy followed by neo-adjuvant chemotherapy in locally advanced rectal cancer--the RAPIDO trial. BMC Cancer 2013; 13: 279
997 Hofheinz RD. et al. Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial. Lancet Oncol 2012; 13: 579-588
998 O’Connell MJ. et al. Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04. J Clin Oncol 2014; 32: 1927-1934
999 Allegra CJ. et al. Neoadjuvant 5-FU or Capecitabine Plus Radiation With or Without Oxaliplatin in Rectal Cancer Patients: A Phase III Randomized Clinical Trial. J Natl Cancer Inst 2015 107.
1000 Rodel C, Hofheinz R, Liersch T. Rectal cancer: state of the art in 2012. Curr Opin Oncol 2012; 24: 441-447
1001 Aschele C. et al. Primary tumor response to preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer: pathologic results of the STAR-01 randomized phase III trial. J Clin Oncol 2011; 29: 2773-2780
1002 Aschele C. et al. Final results of STAR-01: A randomized phase III trial comparing preoperative chemoradiation with or without oxaliplatin in locally advanced rectal cancer. J Clin Oncol 2016 34. (suppl; abstr 3521)
1003 Gerard JP. et al. Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer. J Clin Oncol 2012; 30: 4558-4565
1004 Francois E. et al. ACCORD12/0405-Prodige 2 phase III trial neoadjuvant treatment in rectal cancer: Results after 5 years of follow-up. J Clin Oncol 2016 34. (supp 4S; abstr 490
1005 Schmoll H. et al. Preoperative chemoradiotherapy and postoperative chemothrapy with capecitabine and oxaliplatin versus capecitabine alone in locally advanced rectal cancer: disease-free survial at interim analysis. Proc Am Soc Clin Oncol 2014 32. (abstract 3501)
1006 Jiao D. et al. Fluorouracil-based preoperative chemoradiotherapy with or without oxaliplatin for stage II/III rectal cancer: a 3-year follow-up study. Chin J Cancer Res 2015; 27: 588-596
1007 Deng Y. et al. Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Trial. J Clin Oncol 2016; 34: 3300-3307
1008 An X. et al. Short term results of neoadjuvant chemoradiotherapy with fluoropyrimidine alone or in combination with oxaliplatin in locally advanced rectal cancer: a meta analysis. Eur J Cancer 2013; 49: 843-851
1009 Yang YJ. et al. Fluorouracil-based neoadjuvant chemoradiotherapy with or without oxaliplatin for treatment of locally advanced rectal cancer: An updated systematic review and meta-analysis. Oncotarget 2016; 7: 45513-45524
1010 Lefevre JH. et al. Effect of Interval (7 or 11 weeks) Between Neoadjuvant Radiochemotherapy and Surgery on Complete Pathologic Response in Rectal Cancer: A Multicenter, Randomized, Controlled Trial (GRECCAR-6). J Clin Oncol; 2016
1011 Wang XJ. et al. Effect of Interval between Neoadjuvant Chemoradiotherapy and Surgery on Oncological Outcome for Rectal Cancer: A Systematic Review and Meta-Analysis. Gastroenterol Res Pract 2016; 2016: 6756859
1012 Petrelli F. et al. Increasing the Interval Between Neoadjuvant Chemoradiotherapy and Surgery in Rectal Cancer: A Meta-analysis of Published Studies. Ann Surg 2016; 263: 458-464
1013 Foster JD. et al. Timing of surgery after long-course neoadjuvant chemoradiotherapy for rectal cancer: a systematic review of the literature. Dis Colon Rectum 2013; 56: 921-930
1014 van den Broek CB. et al. Impact of the interval between short-course radiotherapy and surgery on outcomes of rectal cancer patients. Eur J Cancer 2013; 49: 3131-3139
1015 Erlandsson J. et al. Optimal fractionation of preoperative radiotherapy and timing to surgery for rectal cancer (Stockholm III): a multicentre, randomised, non-blinded, phase 3, non-inferiority trial. Lancet Oncol 2017; 18: 336-346
1016 Pach R. et al. Randomized clinical trial on preoperative radiotherapy 25 Gy in rectal cancer--treatment results at 5-year follow-up. Langenbecks Arch Surg 2012; 397: 801-807
1017 Bujko K, Partycki M, Pietrzak L. Neoadjuvant radiotherapy (5 × 5 Gy): immediate versus delayed surgery. Recent Results Cancer Res 2014; 203: 171-187
1018 Fernandez-Martos C. et al. Phase II, randomized study of concomitant chemoradiotherapy followed by surgery and adjuvant capecitabine plus oxaliplatin (CAPOX) compared with induction CAPOX followed by concomitant chemoradiotherapy and surgery in magnetic resonance imaging-defined, locally advanced rectal cancer: Grupo cancer de recto 3 study. J Clin Oncol 2010; 28: 859-865
1019 Fernandez-Martos C. et al. Chemoradiation, surgery and adjuvant chemotherapy versus induction chemotherapy followed by chemoradiation and surgery: long-term results of the Spanish GCR-3 phase II randomized trialdagger. Ann Oncol 2015; 26: 1722-1728
1020 Garcia-Aguilar J. et al. Effect of adding mFOLFOX6 after neoadjuvant chemoradiation in locally advanced rectal cancer: a multicentre, phase 2 trial. Lancet Oncol 2015; 16: 957-966
1021 Smith JJ. et al. Organ Preservation in Rectal Adenocarcinoma: a phase II randomized controlled trial evaluating 3-year disease-free survival in patients with locally advanced rectal cancer treated with chemoradiation plus induction or consolidation chemotherapy, and total mesorectal excision or nonoperative management. BMC Cancer 2015; 15: 767
1022 Schrag D. et al. Neoadjuvant chemotherapy without routine use of radiation therapy for patients with locally advanced rectal cancer: a pilot trial. J Clin Oncol 2014; 32: 513-518
1023 Fernandez-Martos C. et al. Preoperative chemotherapy in patients with intermediate-risk rectal adenocarcinoma selected by high-resolution magnetic resonance imaging: the GEMCAD 0801 Phase II Multicenter Trial. Oncologist 2014; 19: 1042-1043
1024 van Dijk TH. et al. Evaluation of short-course radiotherapy followed by neoadjuvant bevacizumab, capecitabine, and oxaliplatin and subsequent radical surgical treatment in primary stage IV rectal cancer. Ann Oncol 2013; 24: 1762-1769
1025 Rodel CR. Sauer, Radiotherapy and concurrent radiochemotherapy for rectal cancer. Surg Oncol 2004; 13: 93-101
1026 Gunderson LL. et al. Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. J Clin Oncol 2004; 22: 1785-1796
1027 Valentini V. et al. EURECCA consensus conference highlights about rectal cancer clinical management: the radiation oncologist’s expert review. Radiother Oncol 2014; 110: 195-198
1028 Petersen SH. et al. Postoperative adjuvant chemotherapy in rectal cancer operated for cure. Cochrane Database Syst Rev 2012;
1029 Akasu T. et al. Adjuvant chemotherapy with uracil-tegafur for pathological stage III rectal cancer after mesorectal excision with selective lateral pelvic lymphadenectomy: a multicenter randomized controlled trial. Jpn J Clin Oncol 2006; 36: 237-244
1030 Hamaguchi T. et al. Final results of randomized trials by the National Surgical Adjuvant Study of Colorectal Cancer (NSAS-CC). Cancer Chemother Pharmacol 2011; 67: 587-596
1031 Sainato A. et al. No benefit of adjuvant Fluorouracil Leucovorin chemotherapy after neoadjuvant chemoradiotherapy in locally advanced cancer of the rectum (LARC): Long term results of a randomized trial (I-CNR-RT). Radiother Oncol 2014; 113: 223-229
1032 Glynne-Jones R. et al. Chronicle: results of a randomised phase III trial in locally advanced rectal cancer after neoadjuvant chemoradiation randomising postoperative adjuvant capecitabine plus oxaliplatin (XELOX) versus control. Ann Oncol 2014; 25: 1356-1362
1033 Breugom AJ. et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial. Ann Oncol 2015; 26: 696-701
1034 Breugom AJ. et al. Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015; 16: 200-207
1035 Petrelli F. et al. A systematic review and meta-analysis of adjuvant chemotherapy after neoadjuvant treatment and surgery for rectal cancer. Int J Colorectal Dis 2015; 30: 447-457
1036 Maas M. et al. Adjuvant chemotherapy in rectal cancer: defining subgroups who may benefit after neoadjuvant chemoradiation and resection: a pooled analysis of 3.313 patients. Int J Cancer 2015; 137: 212-220
1037 Hong YS. et al. Oxaliplatin, fluorouracil, and leucovorin versus fluorouracil and leucovorin as adjuvant chemotherapy for locally advanced rectal cancer after preoperative chemoradiotherapy (ADORE): an open-label, multicentre, phase 2, randomised controlled trial. Lancet Oncol 2014; 15: 1245-1253
1038 Modest DP. et al. Impact of Subsequent Therapies on Outcome of the FIRE-3/AIO KRK0306 Trial: First-Line Therapy With FOLFIRI Plus Cetuximab or Bevacizumab in Patients With KRAS Wild-Type Tumors in Metastatic Colorectal Cancer. J Clin Oncol 2015; 33: 3718-3726
1039 Abrams TA. et al. Chemotherapy usage patterns in a US-wide cohort of patients with metastatic colorectal cancer. J Natl Cancer Inst 2014; 106: djt371
1040 Sorich MJ. et al. Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials. Ann Oncol 2015; 26: 13-21
1041 Douillard JY. et al. Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer. N Engl J Med 2013; 369: 1023-1034
1042 Van Cutsem E. et al. Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer. J Clin Oncol 2015; 33: 692-700
1043 Stintzing S. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer (FIRE-3): a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial. Lancet Oncol 2016; 17: 1426-1434
1044 Frattini M. et al. PTEN loss of expression predicts cetuximab efficacy in metastatic colorectal cancer patients. Br J Cancer 2007; 97: 1139-1145
1045 Bokemeyer C. et al. FOLFOX4 plus cetuximab treatment and RAS mutations in colorectal cancer. Eur J Cancer 2015; 51: 1243-1252
1046 Peeters M. et al. Final results from a randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line treatment of metastatic colorectal cancer. Ann Oncol 2014; 25: 107-116
1047 Karapetis CS. et al. K-ras mutations and benefit from cetuximab in advanced colorectal cancer. N Engl J Med 2008; 359: 1757-1765
1048 Van Cutsem E. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27: 1386-1422
1049 Knijn N. et al. KRAS mutation analysis: a comparison between primary tumours and matched liver metastases in 305 colorectal cancer patients. Br J Cancer 2011; 104: 1020-1026
1050 Loes IM. et al. Impact of KRAS, BRAF, PIK3CA, TP53 status and intraindividual mutation heterogeneity on outcome after liver resec-tion for colorectal cancer metastases. Int J Cancer 2016; 139: 647-656
1051 Holch JW. et al. The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. Eur J Cancer 2017; 70: 87-98
1052 Arnold D. et al. Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomised trials. Ann Oncol 2017; 28: 1713-1729
1053 Tejpar S. et al. Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials. JAMA Oncol; 2016
1054 Loupakis F. et al. Primary tumor location as a prognostic factor in metastatic colorectal cancer. J Natl Cancer Inst 2015 107.
1055 Tran B. et al. Impact of BRAF mutation and microsatellite instability on the pattern of metastatic spread and prognosis in metastatic colorectal cancer. Cancer 2011; 117: 4623-4632
1056 Tveit KM. et al. Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin (Nordic FLOX) versus FLOX alone in first-line treatment of metastatic colorectal cancer: the NORDIC-VII study. J Clin Oncol 2012; 30: 1755-1762
1057 Pietrantonio F. et al. Predictive role of BRAF mutations in patients with advanced colorectal cancer receiving cetuximab and panitumumab: a meta-analysis. Eur J Cancer 2015; 51: 587-594
1058 Venderbosch S. et al. Mismatch repair status and BRAF mutation status in metastatic colorectal cancer patients: a pooled analysis of the CAIRO, CAIRO2, COIN, and FOCUS studies. Clin Cancer Res 2014; 20: 5322-5330
1059 Domingo E. et al. BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes. Oncogene 2005; 24: 3995-3998
1060 Cremolini C. et al. BRAF codons 594 and 596 mutations identify a new molecular subtype of metastatic colorectal cancer at favorable prognosis. Ann Oncol 2015; 26: 2092-2097
1061 Goldstein DA, Shaib WL, Flowers CR. Costs and effectiveness of genomic testing in the management of colorectal cancer. Oncology (Williston Park) 2015; 29: 175-183
1062 Liu X. et al. Association of UGT1A1*28 polymorphisms with irinotecan-induced toxicities in colorectal cancer: a meta-analysis in Caucasians. Pharmacogenomics J 2014; 14: 120-129
1063 Perera MA, Innocenti F, Ratain MJ. Pharmacogenetic testing for uridine diphosphate glucuronosyltransferase 1A1 polymorphisms: are we there yet?. Pharmacotherapy 2008; 28: 755-768
1064 Deenen MJ. et al. Upfront Genotyping of DPYD*2A to Individualize Fluoropyrimidine Therapy: A Safety and Cost Analysis. J Clin Oncol 2016; 34: 227-234
1065 Meulendijks D. et al. Clinical relevance of DPYD variants c.1679T>G, c.1236G>A/HapB3, and c.1601G>A as predictors of severe fluoropyrimidine-associated toxicity: a systematic review and meta-analysis of individual patient data. Lancet Oncol 2015; 16: 1639-1650
1066 Le DT. et al. PD-1 Blockade in Tumors with Mismatch-Repair Deficiency. N Engl J Med 2015; 372: 2509-2520
1067 The Cancer Genome Atlas. Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012; 487: 330-337
1068 Funkhouser Jr WK. et al. Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. J Mol Diagn 2012; 14: 91-103
1069 Valtorta E. et al. Assessment of a HER2 scoring system for colorectal cancer: results from a validation study. Mod Pathol 2015; 28: 1481-1491
1070 Bertotti A. et al. A molecularly annotated platform of patient-derived xenografts (“xenopatients”) identifies HER2 as an effective therapeutic target in cetuximab-resistant colorectal cancer. Cancer Discov 2011; 1: 508-523
1071 Bertotti A. et al. The genomic landscape of response to EGFR blockade in colorectal cancer. Nature 2015; 526: 263-267
1072 Sartore-Bianchi A. et al. Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial. Lancet Oncol 2016; 17: 738-746
1073 Schmiegel W. et al. Blood-based detection of RAS mutations to guide anti-EGFR therapy in colorectal cancer patients: concordance of results from circulating tumor DNA and tissue-based RAS testing. Mol Oncol 2017; 11: 208-219
1074 Diaz Jr LA. et al. The molecular evolution of acquired resistance to targeted EGFR blockade in colorectal cancers. Nature 2012; 486: 537-540
1075 Misale S. et al. Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature 2012; 486: 532-536
1076 Misale S. et al. Vertical suppression of the EGFR pathway prevents onset of resistance in colorectal cancers. Nat Commun 2015; 6: 8305
1077 Mekenkamp LJ. et al. Clinicopathological features and outcome in advanced colorectal cancer patients with synchronous vs metachronous metastases. Br J Cancer 2010; 103: 159-164
1078 van der Pool AE. et al. ‘Staged’ liver resection in synchronous and metachronous colorectal hepatic metastases: differences in clinicopathological features and outcome. Colorectal Dis 2010; 12 (10) e229-e235
1079 Slesser AA. et al. The tumour biology of synchronous and metachronous colorectal liver metastases: a systematic review. Clin Exp Metastasis 2013; 30: 457-570
1080 Fong Y, Sun RL, Brennan MF. et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. Ann Surg 1999; 230: 309-318 ; discussion 318–321
1081 de Gramont A. et al. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20800 patient ACCENT data set. J Clin Oncol 2010; 28: 460-465
1082 Van Loon K, Venook AP. Curable patient with metastatic colorectal cancer: balancing effective therapies and toxicities. J Clin Oncol 2014; 32: 991-996
1083 Nigri G. Neoadjuvant chemotherapy for resectable colorectal liver metastases: What ist the evidence? Results of a systematic review of comparative studies. The Surgeon 2014; 13/2015: 83-90
1084 Nordlinger B. et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomised controlled trial. Lancet 2008; 371: 1007-1016
1085 Nordlinger B. et al. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial. Lancet Oncol 2013; 14: 1208-1215
1086 Ono T. et al. Outcome in disappearing colorectal cancer liver metastases during oxaliplatin-based chemotherapy. Oncol Lett 2012; 4: 905-909
1087 Ferrero A. et al. Intraoperative detection of disappearing colorectal liver metastases as a predictor of residual disease. J Gastrointest Surg 2012; 16: 806-814
1088 van Vledder MG. et al. Disappearing colorectal liver metastases after chemotherapy: should we be concerned?. J Gastrointest Surg 2010; 14: 1691-1700
1089 Auer RC. et al. Predictors of a true complete response among disappearing liver metastases from colorectal cancer after chemotherapy. Cancer 2010; 116: 1502-1509
1090 Tanaka K. et al. Importance of complete pathologic response to prehepatectomy chemotherapy in treating colorectal cancer metastases. Ann Surg 2009; 250: 935-942
1091 Fiorentini G. et al. Complete response of colorectal liver metastases after intra-arterial chemotherapy. Tumori 2008; 94: 489-492
1092 Elias D. et al. Outcome of posthepatectomy-missing colorectal liver metastases after complete response to chemotherapy: impact of adjuvant intra-arterial hepatic oxaliplatin. Ann Surg Oncol 2007; 14: 3188-3194
1093 Benoist S. et al. Complete response of colorectal liver metastases after chemotherapy: does it mean cure?. J Clin Oncol 2006; 24: 3939-3945
1094 Elias D. et al. Evolution of missing colorectal liver metastases following inductive chemotherapy and hepatectomy. J Surg Oncol 2004; 86: 4-9
1095 Kim HJ. et al. Incremental value of liver MR imaging in patients with potentially curable colorectal hepatic metastasis detected at CT: a prospective comparison of diffusion-weighted imaging, gadoxetic acid-enhanced MR imaging, and a combination of both MR techniques. Radiology 2015; 274: 712-722
1096 Westwood M. et al. Contrast-enhanced ultrasound using SonoVue(R) (sulphur hexafluoride microbubbles) compared with contrast-enhanced computed tomography and contrast-enhanced magnetic resonance imaging for the characterisation of focal liver lesions and detection of liver metastases: a systematic review and cost-effectiveness analysis. Health Technol Assess 2013; 17: 1-243
1097 Ciliberto D. Role of systemic chemothreapy in the management of rsected or resectable colorectal liver metastases: A systematic review and meta-analysis of randomized controlled trials. Oncology Reports 2012; 27: 1849-1856
1098 Zhu GQ. Systematic Review with network Meta-Analysis. Medicine (Baltimore) 2015 94.
1099 Mitry E. Adjuvant Chemotherapy after potentially curative Resection of metastases from colorectal cancer: A pooled analysis of two randomized trials. Journal of clinical oncology 2008; 26: 4906-4911
1100 Kobayashi H. Impact of adjuvant chemotherapy in patients with curatively resected stage IV colorectal cancer. Medicine 2015; 94: 1-6
1101 Nakai T. The clinical risk score predicts the effectiveness of adjuvant chemotherapy for colorectal liver metastasis. World J Surg 2015; 39: 1527-1536
1102 Rahbari N. Adjuvant thrapy after resection of colorectal liver metastases: the predictive value of the MSKCC clinical risk score in the era of modern chemotherapy. BMC Cancer 2014; 14: 174
1103 Hirokawa F. Reconsideration of the indications for adjuvant chemotherapy for liver metastases from colorectal cancer after initial hepatectomy. Ann Surg Oncol 2014; 21: 139-146
1104 Brandi G. Adjuvant systemic chemotherapy after putative curative resection of colorectal liver and lung metastases. Clinical Colorectal Cancer 2013; 12: 188-194
1105 Faron M. Impact of preoperative and postoperative FOLFOX chemotherapies in patients with resectable colorectal liver metastasis. J Gastrointest Cancer 2014; 45: 298-306
1106 Heinemann V. et al. A study-level meta-analysis of efficacy data from head-to-head first-line trials of epidermal growth factor receptor inhibitors versus bevacizumab in patients with RAS wild-type metastatic colorectal cancer. Eur J Cancer 2016; 67: 11-20
1107 Schwartzberg LS. et al. PEAK: a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer. J Clin Oncol 2014; 32: 2240-2247
1108 Lenz HJ, Innocenti F. et al. CALGB/SWOG 80405: phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with expanded RAS analyses untreated metastatic adenocarcinoma of the colon or rectum (mCRC). Ann Oncol 2014 25. Suppl 05
1109 Cremolini C. et al. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study. Lancet Oncol 2015; 16: 1306-1315
1110 Loupakis F. et al. Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. N Engl J Med 2014; 371: 1609-1618
1111 Yamauchi M. et al. Assessment of colorectal cancer molecular features along bowel subsites challenges the conception of distinct dichotomy of proximal versus distal colorectum. Gut 2012; 61: 847-854
1112 von Einem JC. et al. Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trial. J Cancer Res Clin Oncol 2014; 140: 1607-1614
1113 Missiaglia E. et al. Distal and proximal colon cancers differ in terms of molecular, pathological, and clinical features. Ann Oncol 2014; 25: 1995-2001
1114 Guinney J. et al. The consensus molecular subtypes of colorectal cancer. Nat Med 2015; 21: 1350-1356
1115 Stintzing S. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer-subgroup analysis of patients with KRAS: mutated tumours in the randomised German AIO study KRK-0306. Ann Oncol 2012; 23: 1693-1699
1116 Kubicka S. et al. Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings. Ann Oncol 2013; 24: 2342-2349
1117 Loupakis F. et al. FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer. Eur J Cancer 2014; 50: 57-63
1118 Samowitz WS. et al. Association of smoking, CpG island methylator phenotype, and V600E BRAF mutations in colon cancer. J Natl Cancer Inst 2006; 98: 1731-1738
1119 Rowland A. et al. Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer. Br J Cancer 2015; 112: 1888-1894
1120 Stintzing S, Jung L, Rossius DP. et al. Mutations within the EGFR signaling pathway: Influence on efficacy in FIRE-3: A randomized phase III study of FOLFIRI plus cetuximab or bevacizumab as first-line treatment for wild-type (WT) KRAS (exon 2) metastatic colorectal cancer (mCRC) patients. J Clin Oncol 2014 32. Suppl 03; abstract 445
1121 Kopetz S. et al. Phase II Pilot Study of Vemurafenib in Patients With Metastatic BRAF-Mutated Colorectal Cancer. J Clin Oncol 2015; 33: 4032-4038
1122 Young J. et al. Features of colorectal cancers with high-level microsatellite instability occurring in familial and sporadic settings: parallel pathways of tumorigenesis. Am J Pathol 2001; 159: 2107-2116
1123 Kabbinavar FF. et al. Addition of bevacizumab to bolus fluorouracil and leucovorin in first-line metastatic colorectal cancer: results of a randomized phase II trial. J Clin Oncol 2005; 23: 3697-3705
1124 Cunningham D. et al. Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer (AVEX): an open-label, randomised phase 3 trial. Lancet Oncol 2013; 14: 1077-1085
1125 Souglakos J. et al. FOLFOXIRI (folinic acid, 5-fluorouracil, oxaliplatin and irinotecan) vs FOLFIRI (folinic acid, 5-fluorouracil and irinotecan) as first-line treatment in metastatic colorectal cancer (MCC): a multicentre randomised phase III trial from the Hellenic Oncology Research Group (HORG). Br J Cancer 2006; 94: 798-805
1126 Falcone A. et al. Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) compared with infusional fluorouracil, leucovorin, and irinotecan (FOLFIRI) as first-line treatment for metastatic colorectal cancer: the Gruppo Oncologico Nord Ovest. J Clin Oncol 2007; 25: 1670-1676
1127 Montagnani F. A systematic review of FOLFOXIRI chemotherapy for the firstline treatment of metastatic colorectal cancer: improved efficacy at the cost of increased toxicity. Colorectal Disease 2011; 13: 846-854
1128 Gruenberger T. et al. Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer: the OLIVIA multinational randomised phase II trial. Ann Oncol 2015; 26: 702-708
1129 Maughan TS. et al. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet 2011; 377: 2103-2114
1130 Heinemann V. et al. FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 2014; 15: 1065-1075
1131 Venook AP, Lenz HJ. et al. CALGB/SWOG 80405: Phase III trial of irinotecan/5-FU/leucovorin (FOLFIRI) or oxaliplatin/5-FU/leucovorin (mFOLFOX6) with bevacizumab (BV) or cetuximab (CET) for patients (pts) with KRAS wild-type (wt) untreated metastatic adenocarcinoma of the colon or rectum (MCRC). J Clin Oncol 2014; 32: 5s
1132 Douillard JY. et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 2010; 28: 4697-4705
1133 Van Cutsem E. et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011; 29: 2011-2019
1134 Ye LC. et al. Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases. J Clin Oncol 2013; 31: 1931-1938
1135 Bokemeyer C. et al. Fluorouracil, leucovorin, and oxaliplatin with and without cetuximab in the first-line treatment of metastatic colorectal cancer. J Clin Oncol 2009; 27: 663-671
1136 Hurwitz H. et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350: 2335-2342
1137 Stathopoulos GP. et al. Treatment of colorectal cancer with and without bevacizumab: a phase III study. Oncology 2010; 78: 376-381
1138 Guan ZZ. et al. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer 2011; 30: 682-689
1139 Saltz LB. et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol 2008; 26: 2013-2019
1140 Passardi A. et al. Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer: final results for first-line treatment from the ITACa randomized clinical trial. Ann Oncol 2015; 26: 1201-1207
1141 Kabbinavar F. et al. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU)/leucovorin (LV) with FU/LV alone in patients with metastatic colorectal cancer. J Clin Oncol 2003; 21: 60-65
1142 Tebbutt NC. et al. Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer: results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study. J Clin Oncol 2010; 28: 3191-3198
1143 Tol J. et al. Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. N Engl J Med 2009; 360: 563-572
1144 Hecht JR. et al. A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol 2009; 27: 672-680
1145 Saltz L. et al. Phase III trial of cetuximab, bevacizumab, and 5-fluorouracil/leucovorin vs. FOLFOX-bevacizumab in colorectal cancer. Clin Colorectal Cancer 2012; 11: 101-111
1146 Diaz-Rubio E. et al. Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study. PLoS One 2012; 7: e47345
1147 Simkens LH. et al. Maintenance treatment in metastatic colorectal cancer. Lancet Oncol 2015; 16: e582-e583
1148 Hegewisch-Becker S. et al. Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer (AIO 0207): a randomised, non-inferiority, open-label, phase 3 trial. Lancet Oncol 2015; 16: 1355-1369
1149 Zhao L. et al. Meta-analysis comparing maintenance strategies with continuous therapy and complete chemotherapy-free interval strategies in the treatment of metastatic colorectal cancer. Oncotarget 2016; 7: 33418-33428
1150 Pereira AA. et al. The impact of complete chemotherapy stop on the overall survival of patients with advanced colorectal cancer in first-line setting: A meta-analysis of randomized trials. Acta Oncol 2015; 54: 1737-1746
1151 Berry SR. et al. Continuous versus intermittent chemotherapy strategies in metastatic colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2015; 26: 477-485
1152 Esin E, Yalcin S. Maintenance strategy in metastatic colorectal cancer: A systematic review. Cancer Treat Rev 2016; 42: 82-90
1153 Simkens LH. et al. Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group. Lancet 2015; 385: 1843-1852
1154 Quidde J. et al. Quality of life assessment in patients with metastatic colorectal cancer receiving maintenance therapy after first-line induction treatment: a preplanned analysis of the phase III AIO KRK 0207 trial. Ann Oncol 2016; 27: 2203-2210
1155 Rothenberg ML. et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21: 2059-2069
1156 Rougier P. et al. Randomised trial of irinotecan versus fluorouracil by continuous infusion after fluorouracil failure in patients with metastatic colorectal cancer. Lancet 1998; 352: 1407-1412
1157 Cunningham D. et al. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet 1998; 352: 1413-1418
1158 Tournigand C. et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22: 229-237
1159 Van Cutsem E. et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol 2012; 30: 3499-3506
1160 Tabernero J. et al. Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine (RAISE): a randomised, double-blind, multicentre, phase 3 study. Lancet Oncol 2015; 16: 499-508
1161 Sobrero AF, Rivera F. et al. Phase III trial of Cetuximab plus Irinotecan after Fluoropyrimidine and Oxaliplatin Failure in Patients with Metastatic Colorectal Cancer. J Clin Oncol 2008; 26: 2311-2319
1162 Peeters M. et al. Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 2010; 28: 4706-1713
1163 Giantonio BJ. et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol 2007; 25: 1539-1544
1164 Bennouna J. et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial. Lancet Oncol 2013; 14: 29-37
1165 Masi G. et al. Continuation or reintroduction of bevacizumab beyond progression to first-line therapy in metastatic colorectal cancer: final results of the randomized BEBYP trial. Ann Oncol 2015; 26: 724-730
1166 Cao R. et al. A multi-center randomized phase II clinical study of bevacizumab plus irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) compared with FOLFIRI alone as second-line treatment for Chinese patients with metastatic colorectal cancer. Med Oncol 2015; 32: 325
1167 Ciardiello F. et al. Cetuximab continuation after first progression in metastatic colorectal cancer (CAPRI-GOIM): a randomized phase II trial of FOLFOX plus cetuximab versus FOLFOX. Ann Oncol 2016; 27: 1055-1061
1168 Derangere V. et al. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer?. Oncotarget 2016; 7: 9309-9321
1169 Wainberg ZA, Drakaki A. The importance of optimal drug sequencing in metastatic colorectal cancer: biological rationales for the observed survival benefit conferred by first-line treatment with EGFR inhibitors. Expert Opin Biol Ther 2015; 15: 1205-1220
1170 Zaniboni A, Formica V. The Best. First. Anti-EGFR before anti-VEGF, in the first-line treatment of RAS wild-type metastatic colorectal cancer: from bench to bedside. Cancer Chemother Pharmacol 2016; 78: 233-244
1171 Hecht JR, Dakhil SR. et al. SPIRITT (study 20060141): A randomized phase II study of FOLFIRI with either panitumumab (pmab) or bevacizumab (bev) as second-line treatment (tx) in patients (pts) with wild-type (WT) KRAS metastatic colorectal cancer (mCRC). Journal of Clinical Oncology 2013; 31 (Suppl. 04) 454-454
1172 Hiret S, Bertaut A. et al. Bevacizumab or cetuximab plus chemotherapy after progression with bevacizumab plus chemotherapy in patients with wtKRAS metastatic colorectal cancer: A randomized phase II study (Prodige 18 –UNICANCER GI). J Clin Oncol 2016 34. suppl; abstr 3514
1173 Peeters M. et al. Analysis of KRAS/NRAS Mutations in a Phase III Study of Panitumumab with FOLFIRI Compared with FOLFIRI Alone as Second-line Treatment for Metastatic Colorectal Cancer. Clin Cancer Res 2015; 21: 5469-5479
1174 Van Cutsem E. et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25: 1658-1664
1175 Jonker DJ, O’Callaghan CJ, Karapetis CS. et al. Cetuximab for the Treatment of Colorectal Cancer. N Engl J Med 2007; 357: 2040 , Original Article, 2007
1176 Price TJ. et al. Panitumumab versus cetuximab in patients with chemotherapy-refractory wild-type KRAS exon 2 metastatic colorectal cancer (ASPECCT): a randomised, multicentre, open-label, non-inferiority phase 3 study. Lancet Oncol 2014; 15: 569-579
1177 Mayer RJ. et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372: 1909-1919
1178 Yoshino T. et al. TAS-102 monotherapy for pretreated metastatic colorectal cancer: a double-blind, randomised, placebo-controlled phase 2 trial. Lancet Oncol 2012; 13: 993-1001
1179 Li J. et al. Regorafenib plus best supportive care versus placebo plus best supportive care in Asian patients with previously treated metastatic colorectal cancer (CONCUR): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 2015; 16: 619-629
1180 Grothey A. et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381: 303-312
1181 Santini D. et al. Cetuximab rechallenge in metastatic colorectal cancer patients: how to come away from acquired resistance?. Ann Oncol 2012; 23: 2313-2318
1182 Agcaoglu O. et al. Complementary use of resection and radiofrequency ablation for the treatment of colorectal liver metastases: an analysis of 395 patients. World J Surg 2013; 37: 1333-1339
1183 Sasaki K. et al. Combined resection and RFA in colorectal liver metastases: stratification of long-term outcomes. J Surg Res 2016; 206: 182-189
1184 van Amerongen MJ. et al. Short term and long term results of patients with colorectal liver metastases undergoing surgery with or without radiofrequency ablation. Eur J Surg Oncol 2016; 42: 523-530
1185 Ruers T. et al. Local Treatment of Unresectable Colorectal Liver Metastases: Results of a Randomized Phase II Trial. J Natl Cancer Inst 2017 109.
1186 Gillams AR, Lees WR. Five-year survival in 309 patients with colorectal liver metastases treated with radiofrequency ablation. Eur Radiol 2009; 19: 1206-1213
1187 Wybranski CG, Ricke AJ. Hepatisch metastasiertes kolorektales Karzinom. Der Onkologe 2015; 21: 69-82
1188 Van Tilborg AA. et al. Long-term results of radiofrequency ablation for unresectable colorectal liver metastases: a potentially curative intervention. Br J Radiol 2011; 84: 556-565
1189 Otto G. et al. Radiofrequency ablation as first-line treatment in patients with early colorectal liver metastases amenable to surgery. Ann Surg 2010; 251: 796-803
1190 Saxena A. et al. Impact of treatment modality and number of lesions on recurrence and survival outcomes after treatment of colorectal cancer liver metastases. J Gastrointest Oncol 2014; 5: 46-56
1191 Gillams A. et al. Thermal ablation of colorectal liver metastases: a position paper by an international panel of ablation experts, The Interventional Oncology Sans Frontieres meeting 2013. Eur Radiol 2015; 25: 3438-3454
1192 Tanis E. et al. Local recurrence rates after radiofrequency ablation or resection of colorectal liver metastases. Analysis of the European Organisation for Research and Treatment of Cancer #40004 and #40983. Eur J Cancer 2014; 50: 912-919
1193 Wang DS, Davalos EA, Hwang GL. et al. Superselective transhepatic arterial chemoembolization for hepatocellular carcinoma in high risk patients as a bridge towards liver transplantation – Abstract No. 30. Journal of Vascular and Interventional Radiology 2012; 23: S16
1194 Solbiati L. et al. Small liver colorectal metastases treated with percutaneous radiofrequency ablation: local response rate and long-term survival with up to 10-year follow-up. Radiology 2012; 265: 958-968
1195 Correa-Gallego C. et al. A retrospective comparison of microwave ablation vs. radiofrequency ablation for colorectal cancer hepatic metastases. Ann Surg Oncol 2014; 21: 4278-4283
1196 Ruers T. et al. Radiofrequency ablation (RFA) combined with chemotherapy for unresectable colorectal liver metastases (CRC LM): Long-term survival results of a randomized phase II study of the EORTC-NCRI CCSG-ALM Intergroup 40004 (CLOCC). J Clin Oncol 2015 33. (suppl; abstr 3501)
1197 Petersen CG. Möglichkeiten der lokal-ablativen Bestrahlung (SBRT) bei metastasiertem kolorektalem Karzinom. Der Onkologe 2016; 22: 115-120
1198 Herfarth KK, Debus J, Wannenmacher M. Stereotactic radiation therapy of liver metastases: update of the initial phase-I/II trial. Front Radiat Ther Oncol 2004; 38: 100-105
1199 van der Pool AE. et al. Stereotactic body radiation therapy for colorectal liver metastases. Br J Surg 2010; 97: 377-382
1200 Ricke J. et al. Local response and impact on survival after local ablation of liver metastases from colorectal carcinoma by computed tomography-guided high-dose-rate brachytherapy. Int J Radiat Oncol Biol Phys 2010; 78: 479-485
1201 de Baere T. et al. Radiofrequency ablation is a valid treatment option for lung metastases: experience in 566 patients with 1037 metastases. Ann Oncol 2015; 26: 987-991
1202 Vogl TJ. et al. Thermal Ablation of Colorectal Lung Metastases: Retrospective Comparison Among Laser-Induced Thermotherapy, Radiofrequency Ablation, and Microwave Ablation. Am J Roentgenol 2016; 207: 1340-1349
1203 Hendlisz A. et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with yttrium-90 resin microspheres radioembolization for liver-limited metastatic colorectal cancer refractory to standard chemotherapy. J Clin Oncol 2010; 28: 3687-3694
1204 Van Hazel G. et al. Randomised phase 2 trial of SIR-Spheres plus fluorouracil/leucovorin chemotherapy versus fluorouracil/leucovorin chemotherapy alone in advanced colorectal cancer. J Surg Oncol 2004; 88: 78-85
1205 Sharma RA. et al. Radioembolization of liver metastases from colorectal cancer using yttrium-90 microspheres with concomitant systemic oxaliplatin, fluorouracil, and leucovorin chemotherapy. J Clin Oncol 2007; 25: 1099-1106
1206 van Hazel GA. et al. SIRFLOX: Randomized Phase III Trial Comparing First-Line mFOLFOX6 (Plus or Minus Bevacizumab) Versus mFOLFOX6 (Plus or Minus Bevacizumab) Plus Selective Internal Radiation Therapy in Patients With Metastatic Colorectal Cancer. J Clin Oncol 2016; 34: 1723-1731
1207 Sharma RA, van Hazel GA. et al. Overall survival analysis of the FOXFIRE prospective randomized studies of first-line selective internal radiotherapy (SIRT) in patients with liver metastases from colorectal cancer. J Clin Oncol 2017 35. (suppl; abstr3507)
1208 Garlipp B, Van Hazel GA. et al. REsect: Blinded assessment of amenability to potentially curative treatment of previously unresectable colorectal cancer liver metastases (CRC LM) after chemotherapy 6 RadioEmbolization (SIRT) in the randomized SIRFLOX trial. J Clin Oncol 2017 35. (suppl. Abstract 3532)
1209 Kemeny NE. The re-birth of hepatic arterial infusion for colorectal liver metastases. J Gastrointest Oncol 2013; 4: 118-120
1210 D’Angelica MI. et al. Phase II trial of hepatic artery infusional and systemic chemotherapy for patients with unresectable hepatic metastases from colorectal cancer: conversion to resection and long-term outcomes. Ann Surg 2015; 261: 353-360
1211 Levi FA. et al. Conversion to resection of liver metastases from colorectal cancer with hepatic artery infusion of combined chemotherapy and systemic cetuximab in multicenter trial OPTILIV. Ann Oncol 2016; 27: 267-274
1212 Fiorentini G. et al. Intra-arterial infusion of irinotecan-loaded drug-eluting beads (DEBIRI) versus intravenous therapy (FOLFIRI) for hepatic metastases from colorectal cancer: final results of a phase III study. Anticancer Res 2012; 32: 1387-1395
1213 Martin 2nd RC. et al. Randomized controlled trial of irinotecan drug-eluting beads with simultaneous FOLFOX and bevacizumab for patients with unresectable colorectal liver-limited metastasis. Cancer 2015; 121: 3649-3658
1214 Turaga K. et al. Consensus guidelines from The American Society of Peritoneal Surface Malignancies on standardizing the delivery of hyperthermic intraperitoneal chemotherapy (HIPEC) in colorectal cancer patients in the United States. Ann Surg Oncol 2014; 21: 1501-1505
1215 Elias D. et al. Modified selection criteria for complete cytoreductive surgery plus HIPEC based on peritoneal cancer index and small bowel involvement for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 2014; 40: 1467-1473
1216 van Oudheusden TR. et al. Incidence and treatment of recurrent disease after cytoreductive surgery and intraperitoneal chemotherapy for peritoneally metastasized colorectal cancer: A systematic review. Eur J Surg Oncol 2015; 41: 1269-1277
1217 Petrelli F. et al. FOLFIRI-bevacizumab as first-line chemotherapy in 3500 patients with advanced colorectal cancer: a pooled analysis of 29 published trials. Clin Colorectal Cancer 2013; 12: 145-151
1218 Wulaningsih W. et al. Irinotecan chemotherapy combined with fluoropyrimidines versus irinotecan alone for overall survival and progression-free survival in patients with advanced and/or metastatic colorectal cancer. Cochrane Database Syst Rev 2016; 2: CD008593
1219 Rosmarin D. et al. Genetic markers of toxicity from capecitabine and other fluorouracil-based regimens: investigation in the QUASAR2 study, systematic review, and meta-analysis. J Clin Oncol 2014; 32: 1031-1039
1220 Basch E. et al. Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial. J Clin Oncol 2016; 34: 557-565
1221 Molassiotis A. et al. Effectiveness of a home care nursing program in the symptom management of patients with colorectal and breast cancer receiving oral chemotherapy: a randomized, controlled trial. J Clin Oncol 2009; 27: 6191-6198
1222 Neugut AI. et al. Duration of adjuvant chemotherapy for colon cancer and survival among the elderly. J Clin Oncol 2006; 24: 2368-2375
1223 de Raaf PJ. et al. Systematic monitoring and treatment of physical symptoms to alleviate fatigue in patients with advanced cancer: a randomized controlled trial. J Clin Oncol 2013; 31: 716-723
1224 Enblad P. et al. The risk of subsequent primary malignant diseases after cancers of the colon and rectum. A nationwide cohort study. Cancer 1990; 65: 2091-2100
1225 Cali RL. et al. Cumulative incidence of metachronous colorectal cancer. Dis Colon Rectum 1993; 36: 388-393
1226 Hermanek PJr. et al. Long-term results of surgical therapy of colon cancer. Results of the Colorectal Cancer Study Group. Chirurg 1994; 65: 287-297
1227 Yamazaki T. et al. What is the risk factor for metachronous colorectal carcinoma?. Dis Colon Rectum 1997; 40: 935-938
1228 Hemminki K, Li X, Dong C. Second primary cancers after sporadic and familial colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001; 10: 793-798
1229 Green RJ. et al. Surveillance for second primary colorectal cancer after adjuvant chemotherapy: an analysis of Intergroup 0089. Ann Intern Med 2002; 136: 261-269
1230 Harris GJ. et al. Factors affecting local recurrence of colonic adenocarcinoma. Dis Colon Rectum 2002; 45: 1029-1034
1231 Merkel S. et al. Late locoregional recurrence in rectal carcinoma. Eur J Surg Oncol 2002; 28: 716-722
1232 Poulin EC. et al. Local recurrence and survival after laparoscopic mesorectal resection forrectal adenocarcinoma. Surg Endosc 2002; 16: 989-995
1233 Bulow S. et al. Recurrence and survival after mesorectal excision for rectal cancer. Br J Surg 2003; 90: 974-980
1234 Secco GB. et al. Factors influencing incidence and extension of metachronous liver metastases of colorectal adenocarcinoma. A multivariate analysis. Hepatogastroenterology 1997; 44: 1057-1062
1235 Pietra N. et al. Risk factors of local recurrence of colorectal cancer: a multivariate study. Hepatogastroenterology 1998; 45: 1573-1578
1236 Scholmerich J. Sense and nonsense in after-care of colorectal carcinoma. Med Klin (Munich) 1996; 91: 420-427
1237 Kievit J. Colorectal cancer follow-up: a reassessment of empirical evidence on effectiveness. Eur J Surg Oncol 2000; 26: 322-328
1238 Kievit J. Follow-up of patients with colorectal cancer: numbers needed to test and treat. Eur J Cancer 2002; 38: 986-999
1239 Wichmann MW. et al. Results of long-term follow-up after curative resection of Dukes A colorectal cancer. World J Surg 2002; 26: 732-736
1240 Yamamoto S. et al. Postsurgical surveillance for recurrence of UICC stage I colorectal carcinoma: is follow-up by CEA justified?. Hepatogastroenterology 2005; 52: 444-449
1241 Korner H. et al. Systematic follow-up after curative surgery for colorectal cancer in Norway: a population-based audit of effectiveness, costs, and compliance. J Gastrointest Surg 2005; 9: 320-328
1242 Talbot IC. et al. The clinical significance of invasion of veins by rectal cancer. Br J Surg 1980; 67: 439-442
1243 Minsky BD. et al. Resectable adenocarcinoma of the rectosigmoid and rectum. II. The influence of blood vessel invasion. Cancer 1988; 61: 1417-1424
1244 Krasna MJ. et al. Vascular and neural invasion in colorectal carcinoma. Incidence and prognostic significance. Cancer 1988; 61: 1018-1023
1245 Inoue T. et al. Vascular invasion of colorectal carcinoma readily visible with certain stains. Dis Colon Rectum 1992; 35: 34-39
1246 Bruinvels DJ. et al. Follow-up of patients with colorectal cancer. A meta-analysis. Ann Surg 1994; 219: 174-182
1247 Rosen M. et al. Follow-up of colorectal cancer: a meta-analysis. Dis Colon Rectum 1998; 41: 1116-1126
1248 Jeffery GM, Hickey BE, Hider P. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2002;
1249 Renehan AG. et al. Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials. Bmj 2002; 324: 813
1250 Makela JT, Laitinen SO, Kairaluoma MI. Five-year follow-up after radical surgery for colorectal cancer. Results of a prospective randomized trial. Arch Surg 1995; 130: 1062-1067
1251 Ohlsson B. et al. Follow-up after curative surgery for colorectal carcinoma. Randomized comparison with no follow-up. Dis Colon Rectum 1995; 38: 619-626
1252 Kjeldsen BJ. et al. A prospective randomized study of follow-up after radical surgery for colorectal cancer. Br J Surg 1997; 84: 666-669
1253 Pietra N. et al. Role of follow-up in management of local recurrences of colorectal cancer: a prospective, randomized study. Dis Colon Rectum 1998; 41: 1127-1133
1254 Schoemaker D. et al. Yearly colonoscopy, liver CT, and chest radiography do not influence 5-year survival of colorectal cancer patients. Gastroenterology 1998; 114: 7-14
1255 Secco GB. et al. Efficacy and cost of risk-adapted follow-up in patients after colorectal cancer surgery: a prospective, randomized and controlled trial. Eur J Surg Oncol 2002; 28: 418-423
1256 Jeffery M, Hickey BE, Hider PN. Follow-up strategies for patients treated for non-metastatic colorectal cancer. Cochrane Database Syst Rev 2007;
1257 Wattchow DA. et al. General practice vs surgical-based follow-up for patients with colon cancer: randomised controlled trial. Br J Cancer 2006; 94: 1116-1121
1258 Rodriguez-Moranta F. et al. Postoperative surveillance in patients with colorectal cancer who have undergone curative resection: a prospective, multicenter, randomized, controlled trial. J Clin Oncol 2006; 24: 386-393
1259 Laubert T. et al. Intensified surveillance after surgery for colorectal cancer significantly improves survival. Eur J Med Res 2010; 15: 25-30
1260 Papagrigoriadis SB. Heyman, Patients’ views on follow up of colorectal cancer: implications for risk communication and decision making. Postgrad Med J 2003; 79: 403-407
1261 Cooper GS, Kou TD, Reynolds Jr HL. Receipt of guideline-recommended follow-up in older colorectal cancer survivors: a population-based analysis. Cancer 2008; 113: 2029-2037
1262 Rocklin MS, Slomski CA, Watne AL. Postoperative surveillance of patients with carcinoma of the colon and rectum. Am Surg 1990; 56: 22-27
1263 Benson 3rd AB. et al. 2000 update of American Society of Clinical Oncology colorectal cancer surveillance guidelines. J Clin Oncol 2000; 18: 3586-3588
1264 Berman JM, Cheung RJ, Weinberg DS. Surveillance after colorectal cancer resection. Lancet 2000; 355: 395-359
1265 Desch CE. et al. Recommended colorectal cancer surveillance guidelines by the American Society of Clinical Oncology. J Clin Oncol 1999; 17: 1312
1266 Macdonald JS. Carcinoembryonic antigen screening: pros and cons. Semin Oncol 1999; 26: 556-560
1267 Duffy MJ. et al. Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines. Eur J Cancer 2003; 39: 718-727
1268 Duffy MJ. Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?. Clin Chem 2001; 47: 624-630
1269 Moertel CG. et al. An evaluation of the carcinoembryonic antigen (CEA) test for monitoring patients with resected colon cancer. Jama 1993; 270: 943-947
1270 Safi F, Beyer HG. The value of follow-up after curative surgery of colorectal carcinoma. Cancer Detect Prev 1993; 17: 417-424
1271 Zeng Z, Cohen AM, Urmacher C. Usefulness of carcinoembryonic antigen monitoring despite normal preoperative values in node-positive colon cancer patients. Dis Colon Rectum 1993; 36: 1063-1068
1272 Huebner RH. et al. A meta-analysis of the literature for whole-body FDG PET detection of recurrent colorectal cancer. J Nucl Med 2000; 41: 1177-1189
1273 Annovazzi A. et al. 18-fluorodeoxyglucose positron emission tomography in nonendocrine neoplastic disorders of the gastrointestinal tract. Gastroenterology 2003; 125: 1235-1245
1274 Ahlquist DA. et al. Accuracy of fecal occult blood screening for colorectal neoplasia. A prospective study using Hemoccult and HemoQuant tests. Jama 1993; 269: 1262-1267
1275 Hunerbein M. et al. The role of transrectal ultrasound-guided biopsy in the postoperative follow-up of patients with rectal cancer. Surgery 2001; 129: 164-169
1276 Mitry E. et al. Epidemiology, management and prognosis of colorectal cancer with lung metastases: a 30-year population-based study. Gut 2010; 59: 1383-1388
1277 Desch CE. et al. Colorectal cancer surveillance: 2005 update of an American Society of Clinical Oncology practice guideline. J Clin Oncol 2005; 23: 8512-8519
1278 Chau I. et al. The value of routine serum carcino-embryonic antigen measurement and computed tomography in the surveillance of patients after adjuvant chemotherapy for colorectal cancer. J Clin Oncol 2004; 22: 1420-1429
1279 Sugarbaker PH. et al. A simplified plan for follow-up of patients with colon and rectal cancer supported by prospective studies of laboratory and radiologic test results. Surgery 1987; 102: 79-87
1280 Wang T. et al. The role of postoperative colonoscopic surveillance after radical surgery for colorectal cancer: a prospective, randomized clinical study. Gastrointest Endosc 2009; 69: 609-615
1281 Rulyak SJ. et al. Outcome of follow-up colon examination among a population-based cohort of colorectal cancer patients. Clin Gastroenterol Hepatol 2007; 5: 470-476 ; quiz 407
1282 Rex DK. et al. Guidelines for colonoscopy surveillance after cancer resection: a consensus update by the American Cancer Society and the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology 2006; 130: 1865-1871
1283 Bouvier AM. et al. The lifelong risk of metachronous colorectal cancer justifies long-term colonoscopic follow-up. Eur J Cancer 2008; 44: 522-527
1284 Sobhani I. et al. Early detection of recurrence by 18FDG-PET in the follow-up of patients with colorectal cancer. Br J Cancer 2008; 98: 875-880
1285 Selvaggi F. et al. FGD-PET in the follow-up of recurrent colorectal cancer. Colorectal Dis 2003; 5: 496-500
1286 Eckardt VF, Bernhard G. Nachsorge beim kolorektalen Karzinom. Eine Analyse von Effektivität und Kosten. Deutsches Ärzteblatt 1997; 94: A456-A462
1287 Schwibbe G. Changes in quality of life in oncological patients in the course of an inpatient after-care program. Rehabilitation (Stuttg) 1991; 30: 55-62
1288 Gartner U. et al. Physical complaints, stress and quality of life of oncologic patients. Effects and patient assessment in inpatient rehabilitation]. Med Klin (Munich) 1996; 91: 501-508
1289 Etzioni DA, El-Khoueiry AB, Beart Jr RW. Rates and predictors of chemotherapy use for stage III colon cancer: a systematic review. Cancer 2008; 113: 3279-3289
1290 Grothey A, Kellermann L, Schmoll HJ. Deficits in management of patients with colorectal carcinoma in Germany. Results of multicenter documentation of therapy algorithms. Med Klin (Munich) 2002; 97: 270-277
1291 von der Schulenburg JM, Prenzler A, Schurer W. Cancer management and reimbursement aspects in Germany: an overview demonstrated by the case of colorectal cancer. Eur J Health Econ 2010; 10 (Suppl. 01) S21-S26
1292 Adler GT. Seufferlein, Hope and disappointment in cancer medicine. Z Arztl Fortbild Qualitatssich 2007; 101: 287-292
1293 Harrison JD. et al. What are the unmet supportive care needs of people with cancer? A systematic review. Support Care Cancer 2009; 17: 1117-1128
1294 Lewis R. et al. Nurse-led vs. conventional physician-led follow-up for patients with cancer: systematic review. J Adv Nurs 2009; 65: 706-723
1295 Howell DM. et al. A mixed-method evaluation of nurse-led community-based supportive cancer care. Support Care Cancer 2008; 16: 1343-1352
1296 Ouwens M. et al. Implementation of integrated care for patients with cancer: a systematic review of interventions and effects. Int J Qual Health Care 2009; 21: 137-144
1297 Jahn P. et al. Reduction of chemotherapy-induced anorexia, nausea, and emesis through a structured nursing intervention: a cluster-randomized multicenter trial. Support Care Cancer 2009; 17: 1543-1552
1298 Jahn P. et al. Improvement of pain related self management for oncologic patients through a trans institutional modular nursing intervention: protocol of a cluster randomized multicenter trial. Trials 2010; 11: 29
1299 Chen RC. et al. Patient-reported acute gastrointestinal symptoms during concurrent chemoradiation treatment for rectal cancer. Cancer 2010; 116: 1879-1886
1300 Meyerhardt JA. et al. Impact of body mass index and weight change after treatment on cancer recurrence and survival in patients with stage III colon cancer: findings from Cancer and Leukemia Group B 89803. J Clin Oncol 2008; 26: 4109-4115
1301 Meyerhardt JA. et al. Physical activity and survival after colorectal cancer diagnosis. J Clin Oncol 2006; 24: 3527-3534
1302 Meyerhardt JA. et al. Impact of physical activity on cancer recurrence and survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol 2006; 24: 3535-3541
1303 Ng K. et al. Multivitamin use is not associated with cancer recurrence or survival in patients with stage III colon cancer: findings from CALGB 89803. J Clin Oncol 2010; 28: 4354-4563
1304 Stumpf C. et al. Retrospektive Untersuchung zur Therapie mit Mistelextrakten bei Patienten mit kolorektalem Karzinom. Dtsch Zschr Onkol 2007; 39: 12-22
1305 Friedel W. et al. Fermented Europaen mistletoe (Viscum album L.) extract in supportive care in patients with primary non-metastatic colorectal cancer. In: Scheer R. et al. Editors Die Mistel in der Tumortherapie. Essen: KVC Verlag; 2009: 563-576
1306 Kienle GS, Kiene H. Review article: Influence of Viscum album L (European mistletoe) extracts on quality of life in cancer patients: a systematic review of controlled clinical studies. Integr Cancer Ther 2010; 9: 142-157
1307 Shimizu M. et al. (-)-Epigallocatechin gallate suppresses azoxymethane-induced colonic premalignant lesions in male C57BL/KsJ-db/db mice. Cancer Prev Res (Phila) 2008; 1: 298-304
1308 Hoensch H. et al. Prospective cohort comparison of flavonoid treatment in patients with resected colorectal cancer to prevent recurrence. World J Gastroenterol 2008; 14: 2187-2193
1309 Ito K. et al. Long-term effect of 5-fluorouracil enhanced by intermittent administration of polysaccharide K after curative resection of colon cancer. A randomized controlled trial for 7-year follow-up. Int J Colorectal Dis 2004; 19: 157-164
1310 Sakamoto J. et al. Efficacy of adjuvant immunochemotherapy with polysaccharide K for patients with curatively resected colorectal cancer: a meta-analysis of centrally randomized controlled clinical trials. Cancer Immunol Immunother 2006; 55: 404-411
1311 Kassab S. et al. Homeopathic medicines for adverse effects of cancer treatments. Cochrane Database Syst Rev 2009;
1312 Ärztliches Zentrum für Qualität in der Medizin (ÄZQ), Gramsch E, Hoppe JD, Jonitz G, Köhler A, Ollenschläger G et al. Kompendium Q-M-A. Qualitätsmanagement in der ambulanten Versorgung. 3rd. Köln: Dt. Ärzte-Verl.; 2008
1313 Leitlinienprogramm Onkologie (Deutsche Krebsgesellschaft (DKG), D.K.D. Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF)), Entwicklung von Leitlinien basierten Qualitätsindikatoren. Methodenpapier für das Leitlinienprogramm Onkologie. Berlin: 2017 Version 2.0. 2017.
1314 Vasen HF. et al. New clinical criteria for hereditary nonpolyposis colorectal cancer (HNPCC, Lynch syndrome) proposed by the International Collaborative group on HNPCC. Gastroenterology 1999; 116: 1453-1456